

EXHIBIT 3

Michael Karram, M.D.

Page 1

IN THE UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF WEST VIRGINIA
CHARLESTON DIVISION

IN RE: ETHICON, INC.,
PELVIC REPAIR SYSTEM
PRODUCTS LIABILITY
LITIGATION

Master File No. 2:12-MD-02327
MDL No. 2327

THIS DOCUMENT RELATES TO:

Angela Daugherty and
Jimmy Daugherty v.
Ethicon, Inc., et al.

JOSEPH R. GOODWIN
U.S. DISTRICT JUDGE

Case No. 2:12-cv-02076

(General Prolift)

The Video Deposition of MICHAEL KARRAM, M.D.,
taken by the Plaintiff, pursuant to Notice and Subpoena,
before Teresa A. Moore, a Registered Professional and
Certified Realtime Reporter, at the offices of Frost
Brown Todd LLC, 301 East Fourth Street, Great American
Tower, Suite 3300, Cincinnati, Ohio 45202, on Tuesday,
June 28, 2016, at 6:49 p.m.

GOLKOW TECHNOLOGIES, INC.

877.370.3377 ph | 917.591.5672 fax

deps@golkow.com

Michael Karram, M.D.

<p style="text-align: right;">Page 2</p> <p>1 APPEARANCES:</p> <p>2 On behalf of the Plaintiff:</p> <p>3 GREGORY D. BENTLEY, ESQ.</p> <p>4 of</p> <p>5 ZONIES LAW LLC</p> <p>6 1900 Wazee Street, Suite 203</p> <p>7 Denver, Colorado 80202</p> <p>8 Phone: 720-464-5300</p> <p>9 Email: gbentley@zonieslaw.com</p> <p>10 On behalf of the Defendants</p> <p>11 JORDAN N. WALKER, ESQ.</p> <p>12 of</p> <p>13 BUTLER SNOW LLP</p> <p>14 1020 Highland Colony Parkway, Suite 1400</p> <p>15 Ridgeland, Mississippi 39157</p> <p>16 Phone: 601-948-5711</p> <p>17 Email: jordan.walker@butlersnow.com</p> <p>18 ---</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>	<p style="text-align: right;">Page 4</p> <p>1 MICHAEL KARRAM, M.D.,</p> <p>2 of lawful age, a Witness herein, after having been first</p> <p>3 duly sworn, was examined and deposed as follows:</p> <p>4 EXAMINATION</p> <p>5 BY MR. BENTLEY:</p> <p>6 Q. Doctor, my name is Greg Bentley. I'm an</p> <p>7 attorney representing the plaintiffs in this litigation.</p> <p>8 And we're here today for your general deposition</p> <p>9 regarding Prolift. Do you understand that?</p> <p>10 A. I do.</p> <p>11 (Exhibit 1 marked for identification.)</p> <p>12 BY MR. BENTLEY:</p> <p>13 Q. I'm going to hand you what's being marked as</p> <p>14 Exhibit 1, which I believe is a clean copy of your</p> <p>15 general causation report regarding Prolift.</p> <p>16 Does that look correct to you?</p> <p>17 A. Yes, it does.</p> <p>18 (Exhibit 2 marked for identification.)</p> <p>19 BY MR. BENTLEY:</p> <p>20 Q. Okay. I'm going to hand you, for your</p> <p>21 reference, a clean copy of your reliance list that was</p> <p>22 previously discussed in the TVT-O deposition. For</p> <p>23 purposes of this deposition, we're going to mark the</p> <p>24 reliance list as Exhibit 2. Okay?</p>
<p style="text-align: right;">Page 3</p> <p>1 INDEX</p> <p>2 Page</p> <p>3 MICHAEL KARRAM, M.D.</p> <p>4 Examination By Mr. Walker121</p> <p>5 Further Examination By Mr. Bentley142</p> <p>6</p> <p>7 EXHIBITS</p> <p>8 Page</p> <p>9 Exhibit 1 General Causation Report re:4</p> <p>10 Prolift</p> <p>11 Exhibit 2 Reliance List4</p> <p>12 Exhibit 3 21 CFR 801, Section 10959</p> <p>13 Exhibit 4 Arnaud Clavé, "Polypropylene as60</p> <p>14 a reinforcement in pelvic surgery is not</p> <p>15 inert: comparative analysis of 100 explants"</p> <p>16 Exhibit 5 Vladimir Iakovlev, "Degradation65</p> <p>17 of polypropylene in vivo: A microscopic</p> <p>18 analysis of meshes explanted from patients"</p> <p>19 Exhibit 6 ACOG AUGS Position Statement71</p> <p>20 Exhibit 7 2016 Maher Cochrane Review95</p> <p>21 Exhibit 8 Surgeon's Resource Monograph for123</p> <p>22 Prolift</p> <p>23 ---</p> <p>24</p>	<p style="text-align: right;">Page 5</p> <p>1 A. Okay.</p> <p>2 Q. All right. Doctor, when you began practicing</p> <p>3 medicine, were you treating women who suffered from</p> <p>4 prolapse?</p> <p>5 A. Yes.</p> <p>6 Q. How did you treat women, initially, who</p> <p>7 suffered from prolapse?</p> <p>8 A. It would depend on the type of prolapse they</p> <p>9 had and the symptoms that they had.</p> <p>10 Q. Okay. And what were your available options,</p> <p>11 when you began practicing, to treat women who suffered</p> <p>12 from prolapse?</p> <p>13 A. They were do nothing.</p> <p>14 Q. Okay.</p> <p>15 A. They were nonsurgical options, such as</p> <p>16 pessaries or other obstructive devices or support</p> <p>17 devices that you could use to correct their pelvic organ</p> <p>18 prolapse. There were surgical procedures. And that's</p> <p>19 it.</p> <p>20 Q. Okay. And those three options still exist</p> <p>21 today; isn't that correct?</p> <p>22 A. They do.</p> <p>23 Q. Okay. And with respect to the surgical</p> <p>24 options that were available when you began your career,</p>

Michael Karram, M.D.

Page 6	Page 8
<p>1 what surgical options did you employ to treat women who</p> <p>2 suffered from prolapse?</p> <p>3 A. I used traditional repairs. I used</p> <p>4 obliterative repairs. I used sacrocolpopexies. I used</p> <p>5 native tissue repairs and some augmented repairs with --</p> <p>6 let me think back -- when did I start practice, '84 --</p> <p>7 mostly with porcine, bovine, or other biologic materials</p> <p>8 to augment repairs.</p> <p>9 Q. Okay. And then, today, the Prolift is no</p> <p>10 longer available; is that correct?</p> <p>11 A. That's correct.</p> <p>12 Q. Okay. So, in your practice today, what</p> <p>13 surgical procedures do you use to treat women who suffer</p> <p>14 from prolapse?</p> <p>15 A. The same procedures that I just described.</p> <p>16 Q. Do you still employ all --</p> <p>17 A. Plus --</p> <p>18 Q. I'm sorry.</p> <p>19 A. Plus, I use augmented synthetic mesh</p> <p>20 procedures where I cut the mesh, individually, for the</p> <p>21 procedure that -- or the defect that I'm repairing.</p> <p>22 Q. What kind of synthetic mesh do you use today,</p> <p>23 for your augmented repairs?</p> <p>24 A. Most of it is polypropylene.</p>	<p>1 Q. Did you ever use Prolift+M, when it was</p> <p>2 available?</p> <p>3 A. I did not.</p> <p>4 Q. Was there a reason why you didn't use any of</p> <p>5 the meshes with an absorbable component?</p> <p>6 A. I was having great results with the mesh that</p> <p>7 I was using, and so I didn't see a need for it.</p> <p>8 Q. Were the meshes with an absorbable component</p> <p>9 available to you?</p> <p>10 A. They were.</p> <p>11 Q. All right. Let's go back to when you began.</p> <p>12 So, initially, these synthetic meshes weren't</p> <p>13 available, and then at some point in your career the</p> <p>14 synthetic meshes became available for prolapse repair;</p> <p>15 is that correct?</p> <p>16 A. That's fair.</p> <p>17 Q. Okay. And you went from using traditional</p> <p>18 obliterative SSC native augmented repairs, and then at</p> <p>19 some point Gynecare presented the Gynemesh PS; is that</p> <p>20 correct?</p> <p>21 A. That's correct.</p> <p>22 Q. Okay. Was that the first synthetic mesh that</p> <p>23 you used to treat prolapse?</p> <p>24 A. Yes, I think it was. Yeah.</p>
Page 7	Page 9
<p>1 Q. Okay. And who makes that?</p> <p>2 A. There are different companies. Gynecare --</p> <p>3 or Ethicon makes it. Coloplast has one. Bard has some.</p> <p>4 Boston Scientific has some.</p> <p>5 Q. Do you have a preference for any one of those</p> <p>6 polypropylene meshes as opposed to another?</p> <p>7 A. It depends on the type of procedure I'm doing</p> <p>8 and the defect that I'm repairing.</p> <p>9 Q. With respect to Gynecare synthetic meshes, in</p> <p>10 your practice today, do you have an understanding of</p> <p>11 what specific mesh it is you're using?</p> <p>12 A. It's Gynemesh.</p> <p>13 Q. Gynemesh PS?</p> <p>14 A. PS, yes. Sorry.</p> <p>15 Q. And that's Prolene Soft --</p> <p>16 A. Yes.</p> <p>17 Q. -- correct?</p> <p>18 A. Yes.</p> <p>19 Q. Have you had any experience using meshes with</p> <p>20 a partially absorbable component?</p> <p>21 A. I have not.</p> <p>22 Q. You've never used any Gynecare meshes, such</p> <p>23 as ULTRAPRO?</p> <p>24 A. I have not.</p>	<p>1 Q. And that was a similar situation, where you</p> <p>2 would take a mesh and cut it yourself for the procedure</p> <p>3 that you were performing; is that correct?</p> <p>4 A. That's correct.</p> <p>5 Q. Okay. When you would cut a Gynecare Gynemesh</p> <p>6 PS mesh for your specific procedure, would you agree</p> <p>7 that the total amount of mesh you were using was less</p> <p>8 than what would be used in a Prolift total repair?</p> <p>9 A. Not necessarily, because it would depend on</p> <p>10 the size of a prolapse. If you have a big prolapse or</p> <p>11 what we call a complete procidentia, where they have the</p> <p>12 entire vaginal vault everting out, that's going to</p> <p>13 require probably more mesh than a Prolift.</p> <p>14 Q. Okay. And with your typical repair, would it</p> <p>15 be less mesh, using the Gynemesh PS versus a Prolift</p> <p>16 total repair?</p> <p>17 A. It would depend on the anatomical</p> <p>18 abnormality.</p> <p>19 Q. So using the -- with that understanding,</p> <p>20 using the Prolift, were there some situations where you</p> <p>21 didn't have enough mesh to accommodate the defect?</p> <p>22 A. There were times, yes, that was the case.</p> <p>23 Q. And that's because every patient is</p> <p>24 different?</p>

3 (Pages 6 to 9)

Michael Karram, M.D.

Page 10	Page 12
<p>1 A. And the larger the prolapse, the more surface</p> <p>2 area you have to cover.</p> <p>3 Q. Okay. So you started using synthetic meshes</p> <p>4 that were made by Gynecare, which was the Gynemesh PS;</p> <p>5 and then, after that, did you subsequently transition</p> <p>6 into another mesh product?</p> <p>7 A. I've used other mesh products, but mostly</p> <p>8 kits.</p> <p>9 Q. Okay.</p> <p>10 A. Okay?</p> <p>11 Q. And what was the first kit you used?</p> <p>12 A. Prolift.</p> <p>13 Q. Prolift. And when did that become available,</p> <p>14 if you remember?</p> <p>15 A. I think it was around 2006 or 2007.</p> <p>16 Q. Okay. And did you use any mesh kits made by</p> <p>17 other companies?</p> <p>18 A. Prior to Prolift?</p> <p>19 Q. Or -- yes, prior to Prolift.</p> <p>20 A. No.</p> <p>21 Q. After Prolift became available, did you use</p> <p>22 any other mesh kits made by other companies?</p> <p>23 A. Yes.</p> <p>24 Q. Okay. And what kits did you use?</p>	<p>1 be?</p> <p>2 A. It's a little lighter weight.</p> <p>3 Q. And it has a different weave?</p> <p>4 A. Weave.</p> <p>5 Q. Do you find that --</p> <p>6 MR. WALKER: I'm sorry to interrupt. But</p> <p>7 just so the record's clear, can the doctor specify</p> <p>8 which is the lighter weight?</p> <p>9 MR. BENTLEY: Oh, sure.</p> <p>10 BY MR. BENTLEY:</p> <p>11 Q. Do you have an understanding of the</p> <p>12 differences between the Gynecare Gynemesh PS, and the</p> <p>13 Gynecare Prolene that's used in the TVT family of</p> <p>14 products, Doctor?</p> <p>15 A. Yes, I do.</p> <p>16 Q. And what is that?</p> <p>17 A. The TVT product is a little heavier weight</p> <p>18 mesh.</p> <p>19 Q. Okay. And the Prolene mesh that's used in</p> <p>20 the TVT products has been around for a longer time than</p> <p>21 the Gynecare Gynemesh PS; correct?</p> <p>22 A. That's correct.</p> <p>23 Q. Okay. So once you started using the Gynecare</p> <p>24 Prolift kit, then you subsequently also used the kits</p>
Page 11	Page 13
<p>1 A. I've used Apogee and Perigee.</p> <p>2 Q. Okay. And who makes those?</p> <p>3 A. That was American Medical Systems.</p> <p>4 And I've used anterior or posterior Elevate,</p> <p>5 which is also American Medical Systems.</p> <p>6 Q. And do you have an understanding of whether</p> <p>7 that mesh construction, in the AMS products, is</p> <p>8 different than the Gynecare mesh?</p> <p>9 A. My understanding was, they were all about the</p> <p>10 same.</p> <p>11 Q. Do you have an understanding of whether or</p> <p>12 not they have a proprietary weaving process?</p> <p>13 A. They may. They may. I think they may have,</p> <p>14 with the Elevate. I know, with the Monarc, they do,</p> <p>15 because they have the suture that goes through the mesh.</p> <p>16 But I think, if you're talking about just</p> <p>17 mesh, they were both polypropylene macroporous</p> <p>18 monofilament A mid I type mesh.</p> <p>19 Q. Okay. Do you have an understanding of the</p> <p>20 fact that the Gynecare Prolene mesh, using the TVT</p> <p>21 family of products, is different from the Gynecare</p> <p>22 Prolene Soft, using the Prolift?</p> <p>23 A. Yes.</p> <p>24 Q. And what do you understand that difference to</p>	<p>1 made by AMS; is that correct?</p> <p>2 A. That's correct.</p> <p>3 Q. Did you have a preference for either of</p> <p>4 those -- did you have a preference for either of the</p> <p>5 kits made by those two companies?</p> <p>6 A. No. Most of it was dependent on the</p> <p>7 abnormality that I was treating.</p> <p>8 Q. Okay. And could you explain to me in what</p> <p>9 situations you felt that the Prolift was advantageous as</p> <p>10 compared to the AMS product?</p> <p>11 A. The Prolift, because of its design, in a</p> <p>12 large prolapse --</p> <p>13 Q. Um-hmm.</p> <p>14 A. -- it would be probably my preferred product,</p> <p>15 because it gave you better apical support with the</p> <p>16 posterior Prolift. Whereas, with the Apogee and</p> <p>17 Perigee, the Apogee never went to the sacrospinous</p> <p>18 ligament, it went to the iliococcygeus muscle, which was</p> <p>19 not as strong, whereas Prolift went to the sacrospinous</p> <p>20 ligament.</p> <p>21 And so, in smaller anterior-only defects --</p> <p>22 sometimes it would depend -- but I might use an AMS</p> <p>23 product in those.</p> <p>24 Q. So is it fair to say that you didn't think</p>

4 (Pages 10 to 13)

Michael Karram, M.D.

Page 14	Page 16
<p>1 the Prolift was necessarily the best surgical product</p> <p>2 for every patient?</p> <p>3 A. I would agree with that statement, yes.</p> <p>4 Q. There are some situations where you thought</p> <p>5 it was more appropriate, maybe, to use another mesh kit</p> <p>6 to treat the prolapse; is that fair?</p> <p>7 A. Or more appropriate to even use a native</p> <p>8 tissue repair.</p> <p>9 Q. Thank you.</p> <p>10 So from the time when you began using the</p> <p>11 Prolift and then you began also using the AMS kits, did</p> <p>12 you begin using any other surgical kits made by</p> <p>13 manufacturers to treat prolapse?</p> <p>14 A. I never used the Boston Scientific and I</p> <p>15 never used the Bard. So Avaulta, no; and Pinnacle and</p> <p>16 Uphold, no. So I think that was all of them.</p> <p>17 Q. Okay. And did you --</p> <p>18 A. If you have another one, you can give me the</p> <p>19 name, and I'll tell you if I used it or not. But I</p> <p>20 don't know of any.</p> <p>21 Q. Okay. So then -- and then, today, as we</p> <p>22 previously discussed, the Prolift is no longer</p> <p>23 available; correct?</p> <p>24 A. Correct.</p>	<p>1 A. We read the IFUs. We read some company</p> <p>2 literature. But at the case, itself, no, no videos; it</p> <p>3 was all live.</p> <p>4 Q. So you watched a video prior to attending the</p> <p>5 live surgery --</p> <p>6 A. Um-hmm.</p> <p>7 Q. -- correct?</p> <p>8 A. Um-hmm.</p> <p>9 Q. And then did you attend the live surgery led</p> <p>10 by a preceptor?</p> <p>11 A. Yes.</p> <p>12 Q. Okay. And how many of those live surgeries</p> <p>13 did you attend?</p> <p>14 A. I think, that day, he did three.</p> <p>15 Q. Three. And then, after observing those three</p> <p>16 surgeries, you then began using the Prolift yourself?</p> <p>17 A. That's correct.</p> <p>18 Q. Okay. Did you attend any follow-up training,</p> <p>19 after that initial training on Prolift?</p> <p>20 A. For myself, personally? No. But I attended</p> <p>21 conferences and was a proctor in a lecture and other</p> <p>22 Ethicon courses, yes.</p> <p>23 Q. Okay. So you taught other Ethicon courses?</p> <p>24 A. That's correct.</p>
Page 15	Page 17
<p>1 Q. Okay. From the time when you began using the</p> <p>2 Prolift and sometimes the AMS products, did you continue</p> <p>3 using those surgical kits through the time when the</p> <p>4 Prolift was no longer available?</p> <p>5 A. Yes.</p> <p>6 Q. Okay. Did you receive any Prolift-specific</p> <p>7 training?</p> <p>8 A. I did.</p> <p>9 Q. Where was this training at?</p> <p>10 A. Reading, Pennsylvania.</p> <p>11 Q. And that was put on by Ethicon?</p> <p>12 A. It was put on by Ethicon. That's correct.</p> <p>13 Q. And do you recall how many days that training</p> <p>14 was?</p> <p>15 A. It was two days.</p> <p>16 Q. Two days. Two full days of training?</p> <p>17 A. One night and one full day of training.</p> <p>18 Q. Okay. And that would have involved a cadaver</p> <p>19 portion?</p> <p>20 A. Actually, no. It was on live patients.</p> <p>21 Q. Okay. Did you watch a video component in the</p> <p>22 training?</p> <p>23 A. Prior to that? We watched it prior.</p> <p>24 Q. Okay.</p>	<p>1 Q. Did you teach the Prolift procedure?</p> <p>2 A. Yes.</p> <p>3 Q. Approximately how many times did you teach</p> <p>4 the Prolift procedure?</p> <p>5 A. I would say we probably did -- I, myself, did</p> <p>6 probably 10 to 15.</p> <p>7 Q. And over how many years would you say that</p> <p>8 was?</p> <p>9 A. Probably about three or four.</p> <p>10 Q. Doctor, in your report, is it fair to say</p> <p>11 that your opinions are based on your training,</p> <p>12 experience, and review of the medical literature?</p> <p>13 A. Yes, and education.</p> <p>14 Q. And education?</p> <p>15 A. Yeah.</p> <p>16 Q. With the AMS Elevate product, did you feel</p> <p>17 there is any advantage to not having the external trocar</p> <p>18 passers?</p> <p>19 A. No.</p> <p>20 Q. Do you have an understanding of how many</p> <p>21 Prolift procedures you've performed?</p> <p>22 A. I don't know the exact number, but I would</p> <p>23 say it was probably in the neighborhood of two or three</p> <p>24 hundred.</p>

5 (Pages 14 to 17)

Michael Karram, M.D.

Page 18	Page 20
<p>1 Q. And do you have an understanding of how many</p> <p>2 prolapse procedures you performed with the AMS products?</p> <p>3 A. Probably maybe 50 to 75.</p> <p>4 Q. So is it fair to say that the total number of</p> <p>5 mesh kits you've used to treat prolapse is 250 to 375,</p> <p>6 if my math is correct?</p> <p>7 A. Something in that neighborhood.</p> <p>8 Q. Okay. And then, do you have an understanding</p> <p>9 of how many prolapse procedures you've done using</p> <p>10 synthetic mesh not sold in a kit?</p> <p>11 A. That would probably be going back early in my</p> <p>12 career. I'd say, probably in the neighborhood of,</p> <p>13 again, two or three hundred, maybe even more.</p> <p>14 Q. In your practice today, do you have an</p> <p>15 estimate of in what percentage of the surgeries you</p> <p>16 perform to treat prolapse you use a synthetic mesh</p> <p>17 implant?</p> <p>18 A. Today?</p> <p>19 Q. Yes.</p> <p>20 A. Less than five percent.</p> <p>21 Q. And do you have an estimate, today, as to how</p> <p>22 many surgeries you perform, on an annual basis, to treat</p> <p>23 women suffering from prolapse?</p> <p>24 A. Well, my practice is completely pelvic --</p>	<p>1 A. It's gotten more -- busier.</p> <p>2 Q. Okay. In your practice, do you treat</p> <p>3 patients suffering from complications related to</p> <p>4 mesh-based products?</p> <p>5 A. I do.</p> <p>6 Q. Do you treat patients suffering from</p> <p>7 complications after being implanted with the Prolift</p> <p>8 product?</p> <p>9 A. I do.</p> <p>10 Q. What percent of your practice would you</p> <p>11 estimate is related to treating mesh-based</p> <p>12 complications?</p> <p>13 A. Now, this does include slings; right? Yeah.</p> <p>14 MR. WALKER: I'm going to object to the form.</p> <p>15 A. Oh, okay. I would say, in the neighborhood</p> <p>16 of five to eight percent, maybe.</p> <p>17 Q. Okay. So, Doctor, is it fair to say that</p> <p>18 five to eight percent of your practice, you treat women</p> <p>19 suffering from mesh-based complications? Is that fair?</p> <p>20 MR. WALKER: Object to form.</p> <p>21 A. I think that's an estimate, yes.</p> <p>22 Q. Okay. Then, Doctor, do you have an</p> <p>23 understanding as to what percent of your practice is you</p> <p>24 treating women suffering from mesh-based complications</p>
Page 19	Page 21
<p>1 well, pelvic floor urogynecology. So if you're</p> <p>2 considering slings in that, too -- or, no, just --</p> <p>3 Q. Just prolapse.</p> <p>4 A. -- prolapse?</p> <p>5 I would say 80 percent of my practice would</p> <p>6 be -- 80 to 90 percent of my practice would be that.</p> <p>7 And I, you know -- I operate two days a week -- if you</p> <p>8 want to extrapolate this thing out -- usually do three</p> <p>9 or four procedures a week. So let's say four times four</p> <p>10 is sixteen, times twelve. What's that? Get your</p> <p>11 calculator. Whatever that is. And then you calculate.</p> <p>12 And that's a year? Do you want --</p> <p>13 Q. That's just prolapse surgeries?</p> <p>14 A. That's prolapse surgeries.</p> <p>15 Q. Okay. So less than 200 per year?</p> <p>16 A. I would say, if that calculates out.</p> <p>17 MR. WALKER: I got 182.</p> <p>18 THE WITNESS: Close enough. Yeah, there you</p> <p>19 go?</p> <p>20 A. (Continuing answer.) Less than 200, right.</p> <p>21 Between -- yeah.</p> <p>22 BY MR. BENTLEY:</p> <p>23 Q. And has that number stayed fairly consistent</p> <p>24 throughout your career or has it changed?</p>	<p>1 from a prolapse repair?</p> <p>2 MR. WALKER: Object to form.</p> <p>3 A. I would say it's probably less. In the</p> <p>4 neighborhood of maybe two to three percent or less --</p> <p>5 two percent, I would say. I would think it's more with</p> <p>6 slings.</p> <p>7 Q. Okay. And then, do you have an understanding</p> <p>8 of what percent of your practice you spend treating</p> <p>9 women who suffer from complications related to the</p> <p>10 Prolift procedure?</p> <p>11 MR. WALKER: Object to form.</p> <p>12 A. Right now, I can't really give you that</p> <p>13 amount, because the number is becoming less and less as</p> <p>14 it hasn't been being used, and we -- so I can't really</p> <p>15 give you an estimate.</p> <p>16 Q. Can you give me an estimate of how many cases</p> <p>17 you've treated where a woman suffered complications from</p> <p>18 a Prolift procedure?</p> <p>19 A. I'd say, probably in the neighborhood of 30</p> <p>20 or 40.</p> <p>21 MR. WALKER: I'm sorry, was that a number --</p> <p>22 a total number or a percentage?</p> <p>23 THE WITNESS: No, a total number that I've</p> <p>24 treated in my career.</p>

6 (Pages 18 to 21)

Michael Karram, M.D.

Page 22	Page 24
<p>1 MR. WALKER: Thank you. Sorry.</p> <p>2 BY MR. BENTLEY:</p> <p>3 Q. Are you referred women who have been</p> <p>4 implanted with the Prolift product by another doctor and</p> <p>5 they're referred to you to treat the complication?</p> <p>6 A. That's usually how it comes, yes.</p> <p>7 Q. And, likewise, you may have implanted a woman</p> <p>8 with a Prolift product, and she may seek a referral to</p> <p>9 another doctor to be treated for a complication; is that</p> <p>10 fair?</p> <p>11 A. That's fair.</p> <p>12 Q. And you might not necessarily know that she</p> <p>13 went and saw another doctor for a complication; is that</p> <p>14 fair?</p> <p>15 A. That's true.</p> <p>16 Q. Okay. Doctor, have you ever reported an</p> <p>17 adverse event to the FDA, when you've treated a woman</p> <p>18 that suffered from a complication from the Prolift</p> <p>19 device?</p> <p>20 MR. WALKER: Object to form.</p> <p>21 A. I have not personally reported anything to</p> <p>22 the FDA or the MAUDE database, no.</p> <p>23 Q. And would that include your office; your</p> <p>24 office, on your behalf, hasn't reported to the FDA MAUDE</p>	<p>1 BY MR. BENTLEY:</p> <p>2 Q. Right.</p> <p>3 A. So if you're asking if a patient came in to</p> <p>4 me, what would my -- what would I be the most happy with</p> <p>5 taking care of? An obliterative procedure, because it</p> <p>6 takes care of the problem and it's an hour procedure and</p> <p>7 everybody's happy.</p> <p>8 Q. Okay. That's fair.</p> <p>9 A. But it depends on the situation.</p> <p>10 Q. Okay.</p> <p>11 A. Every clinical situation, usually, is very</p> <p>12 unique to the individual and her anatomy, and it depends</p> <p>13 on what her complaints are.</p> <p>14 Q. Right.</p> <p>15 A. And then you tailor the treatment based on</p> <p>16 that.</p> <p>17 Q. It's fair to say, the obliterative procedure</p> <p>18 is probably not the most common procedure to treat</p> <p>19 prolapse?</p> <p>20 A. It's not, but you sure wish it was. But</p> <p>21 you're right. No, it's usually an elderly lady who's</p> <p>22 not sexually active and it's more of a sanitary issue</p> <p>23 than anything else.</p> <p>24 Q. When the Prolift kits were available, do you</p>
Page 23	Page 25
<p>1 database?</p> <p>2 A. Not directly, no.</p> <p>3 Q. And that's not just limited to Prolift. In</p> <p>4 your practice you've never reported to MAUDE?</p> <p>5 A. Correct.</p> <p>6 Q. Is there any reason why you haven't reported</p> <p>7 any adverse events to the MAUDE database?</p> <p>8 A. Because most of the adverse events that I've</p> <p>9 managed have been known complications and known risks of</p> <p>10 the surgery. So I didn't think it was related to the</p> <p>11 device, itself.</p> <p>12 Q. It's your understanding that the MAUDE</p> <p>13 database only tracks adverse events that are related to</p> <p>14 the device specifically?</p> <p>15 MR. WALKER: Object to form.</p> <p>16 A. I think, yeah. That's what I thought.</p> <p>17 Q. Today, do you have a preference for any of</p> <p>18 the surgical treatments for prolapse?</p> <p>19 MR. WALKER: Object to form.</p> <p>20 Are you asking about anterior, posterior, or</p> <p>21 just more generally?</p> <p>22 MR. BENTLEY: General.</p> <p>23 A. I mean, there is no one procedure that's</p> <p>24 going to treat all.</p>	<p>1 have an understanding of what percentage of your</p> <p>2 surgeries to treat prolapse you used Prolift for?</p> <p>3 A. When I started using Prolift and first -- in</p> <p>4 the first few years, I was using it probably about 20 to</p> <p>5 30 percent of the time, maybe more.</p> <p>6 Q. Okay.</p> <p>7 A. But it's hard to estimate.</p> <p>8 Q. And then, with the remainder percentage, how</p> <p>9 could you estimate what other procedures you were using?</p> <p>10 Some of that -- some of those other surgeries would</p> <p>11 entail the AMS product; right?</p> <p>12 A. Or they would entail a native tissue</p> <p>13 repair --</p> <p>14 Q. Okay.</p> <p>15 A. -- or a sacrocolpopexy --</p> <p>16 Q. Right.</p> <p>17 A. -- something like that.</p> <p>18 Q. And can you estimate for me what percentage</p> <p>19 of your other patients would be native tissue repair?</p> <p>20 A. I would say the majority of them were native</p> <p>21 tissue repair.</p> <p>22 Q. And is that still true today?</p> <p>23 A. Almost all of them are true, yes. Much</p> <p>24 higher today, now, because we don't have the kits.</p>

7 (Pages 22 to 25)

Michael Karram, M.D.

Page 26	Page 28
<p>1 Q. Do you have good results with native tissue</p> <p>2 repair?</p> <p>3 A. It depends on the procedure. It depends on</p> <p>4 the procedure and the anatomy that we're dealing with.</p> <p>5 Q. So is that a yes?</p> <p>6 A. Yes.</p> <p>7 Q. Do you have an understanding as to what</p> <p>8 percentage of your patients you treat with native tissue</p> <p>9 repair have to undergo a repeat operation because that</p> <p>10 initial procedure didn't work for the prolapse repair?</p> <p>11 A. I don't. I don't have a percentage, no.</p> <p>12 Q. How long would you typically follow up with a</p> <p>13 patient after you'd implanted a Prolift product?</p> <p>14 A. I would see them back at two weeks, four</p> <p>15 weeks, six weeks; and then I would see them back at six</p> <p>16 months and a year; and then, thereafter, if they were</p> <p>17 doing fine and not having any problems, I would see them</p> <p>18 back yearly.</p> <p>19 Q. Do you have an understanding as to whether</p> <p>20 Prolift complications can arise after the one year?</p> <p>21 A. I'm sure they can.</p> <p>22 Q. Did you experience that with any of your</p> <p>23 patients?</p> <p>24 A. There were a few, yes.</p>	<p>1 procedure?</p> <p>2 A. Well, if somebody came in and they were a</p> <p>3 recurrent prolapse, I would say, your native tissue</p> <p>4 repair that Dr. So-and-So did was not effective; you had</p> <p>5 a failure; and if we do another native tissue repair,</p> <p>6 the likelihood is you're going to have another failure;</p> <p>7 but we have a product available that's a mesh-based</p> <p>8 product, and I've had good results in my hands, and I</p> <p>9 think she'd be a great candidate for this. And then she</p> <p>10 would ask me questions, and we would discuss the issue</p> <p>11 and come up with a plan of action.</p> <p>12 Q. So you would inform the patient that the</p> <p>13 Prolift product could be favorable in a situation where</p> <p>14 a previous surgery may not have had a successful outcome</p> <p>15 to treat prolapse; is that fair?</p> <p>16 A. That would be one, yes.</p> <p>17 Q. So, Doctor, in your eyes, you viewed a</p> <p>18 favorable patient for the Prolift as a patient who is</p> <p>19 maybe high risk or had failed at a previous surgery; is</p> <p>20 that fair?</p> <p>21 A. That would be one, yes.</p> <p>22 Q. Were there any other benefits you would</p> <p>23 describe to a patient, when you're undergoing the</p> <p>24 informed-consent process discussing whether or not to</p>
Page 27	Page 29
<p>1 Q. Have you read any literature that evidences</p> <p>2 women suffering from complications well past one year</p> <p>3 from their Prolift procedure?</p> <p>4 MR. WALKER: Object to form.</p> <p>5 A. I have. And I have also seen patients like</p> <p>6 that from other physicians, yes.</p> <p>7 Q. When Prolift is available and you're talking</p> <p>8 to your patients about the risks and benefits, that</p> <p>9 would be a conversation between you and the patient to</p> <p>10 make a joint decision; is that fair?</p> <p>11 A. That's fair.</p> <p>12 Q. Okay. And you, as a doctor, would be</p> <p>13 educating the patient as to the risks and benefits of</p> <p>14 the product and the alternative procedures; is that</p> <p>15 correct?</p> <p>16 A. That's correct.</p> <p>17 Q. And you'd want to give the patient as much</p> <p>18 information as possible, so they can make an informed</p> <p>19 decision as to whether or not to undergo that procedure</p> <p>20 versus another procedure; is that fair?</p> <p>21 MR. WALKER: Object to form.</p> <p>22 A. That's correct.</p> <p>23 Q. Okay. And what would you tell the patient,</p> <p>24 specifically, were the benefits as to using the Prolift</p>	<p>1 undergo a Prolift procedure?</p> <p>2 A. The size of her prolapse. The larger the</p> <p>3 size and the more advanced the stage, the less likely</p> <p>4 she was going to get a really good repair with a native</p> <p>5 tissue repair.</p> <p>6 Q. Okay. When you were discussing whether or</p> <p>7 not to undergo a Prolift procedure with a patient in the</p> <p>8 informed consent, would you discuss some of the medical</p> <p>9 literature with your patients?</p> <p>10 A. I would give her my experience with it. And</p> <p>11 then, I wouldn't actually cite specific medical</p> <p>12 literature --</p> <p>13 Q. Okay.</p> <p>14 A. -- no.</p> <p>15 Q. Would you discuss the medical literature</p> <p>16 might show a range of success rates, for example?</p> <p>17 A. I would say yes. Yes.</p> <p>18 Q. Okay. So I'm guessing you never gave your</p> <p>19 patients medical literature to take home with them?</p> <p>20 A. I did not.</p> <p>21 Q. Is it fair to say that you've stayed abreast</p> <p>22 of the medical literature regarding Prolift, from when</p> <p>23 you began using the product?</p> <p>24 A. I've tried, yes.</p>

8 (Pages 26 to 29)

Michael Karram, M.D.

Page 30	Page 32
<p>1 Q. Would you agree that some doctors don't have</p> <p>2 time to review all the literature?</p> <p>3 MR. WALKER: Object to form.</p> <p>4 A. It's tough to keep up with all the</p> <p>5 literature, yes. That's correct.</p> <p>6 Q. And would you agree that some doctors likely</p> <p>7 aren't as knowledgeable about the Prolift literature as</p> <p>8 you might be, for example?</p> <p>9 MR. WALKER: Object to form.</p> <p>10 A. I'm sure there probably are people like that.</p> <p>11 Q. And even you were in a special place, because</p> <p>12 you were actually proctoring for the Prolift procedure</p> <p>13 for Ethicon; isn't that correct?</p> <p>14 MR. WALKER: Object to form.</p> <p>15 A. That's correct.</p> <p>16 Q. So you were probably well educated in the</p> <p>17 medical literature regarding the Prolift, as compared to</p> <p>18 some other doctors?</p> <p>19 MR. WALKER: Object to form.</p> <p>20 Q. Is that fair?</p> <p>21 A. I would hope so, yes.</p> <p>22 Q. In the informed-consent process with a</p> <p>23 patient, what risks would you discuss with your</p> <p>24 patients?</p>	<p>1 Q. I'm sorry. I didn't --</p> <p>2 A. All right. Specifically to the mesh would be</p> <p>3 urinary tract injury, bowel injury, erosions,</p> <p>4 extrusions, scarring, pelvic pain, dyspareunia, and the</p> <p>5 possible need for another procedure to correct one of</p> <p>6 those problems, if they did occur --</p> <p>7 Q. And some --</p> <p>8 A. -- that would be specific to the Prolift.</p> <p>9 Q. And sometimes there might actually be</p> <p>10 multiple procedures; is that fair?</p> <p>11 A. That's correct, yes.</p> <p>12 Q. Would you discuss the frequency of any of</p> <p>13 those risks, when you're performing the informed-consent</p> <p>14 process with the patient?</p> <p>15 A. I would.</p> <p>16 Q. And where would you draw that frequency</p> <p>17 information for those risks from?</p> <p>18 A. The medical literature available to us. And,</p> <p>19 from the time it was available to now, obviously there's</p> <p>20 more medical literature than there was before. So...</p> <p>21 Q. Would you discuss the severity of any of</p> <p>22 those complications with your patient, when doing the</p> <p>23 informed consent regarding a Prolift procedure?</p> <p>24 A. It's hard to quantify "severity." I think</p>
Page 31	Page 33
<p>1 A. I would tell them --</p> <p>2 MR. WALKER: And this is for Prolift; right?</p> <p>3 MR. BENTLEY: Yes.</p> <p>4 A. Yeah. I would tell them that anytime you</p> <p>5 have surgery, you have anesthetic risks, risks of</p> <p>6 infection, hemorrhage, urinary tract injury, bowel</p> <p>7 injury. Risks associated with synthetic mesh: Erosion,</p> <p>8 extrusion, dyspareunia, pelvic pain, the possible need</p> <p>9 for another procedure to correct these problems if they</p> <p>10 do occur.</p> <p>11 Q. And you mentioned risks associated with a</p> <p>12 mesh implant; is that fair?</p> <p>13 A. And I would also give them the same risks</p> <p>14 with a native tissue repair. The only difference is, no</p> <p>15 mesh.</p> <p>16 Q. That's fine. Now I want to talk about the</p> <p>17 mesh complications --</p> <p>18 A. Okay.</p> <p>19 Q. -- specifically.</p> <p>20 A. Okay.</p> <p>21 Q. What complications, related to the mesh</p> <p>22 implant specifically, would you discuss with your</p> <p>23 patients?</p> <p>24 A. I thought I just told you that.</p>	<p>1 any patient believes that when they have a complication,</p> <p>2 it's severe, regardless of how minimal or how maximum it</p> <p>3 is. So it's hard to quantify "severity."</p> <p>4 Q. But you understand, some women have suffered</p> <p>5 life-changing complications as a result of the Prolift</p> <p>6 procedure; is that fair?</p> <p>7 MR. WALKER: Object to form.</p> <p>8 A. I'd have to look at that case specifically.</p> <p>9 I'm sure there are women that have had problems with the</p> <p>10 procedure. But until I actually examined the -- you</p> <p>11 know, the procedure or the patient's medical records and</p> <p>12 saw exactly what happened and what took place, I can't</p> <p>13 really say that, you know, I know for a fact that there</p> <p>14 are people that have life-threatening complications</p> <p>15 related to the Prolift. I can't say that.</p> <p>16 Q. You haven't read medical literature</p> <p>17 discussing women that had serious complications after a</p> <p>18 Prolift procedure?</p> <p>19 A. I've read literature that have complications.</p> <p>20 And, like I said, everybody considers a complication</p> <p>21 serious. But I've also seen those patients, and we've</p> <p>22 managed those patients and they've done fine and they</p> <p>23 don't have any long-lasting, life-threatening -- or</p> <p>24 life-changing complications. They go about their</p>

9 (Pages 30 to 33)

Michael Karram, M.D.

Page 34	Page 36
<p>1 business and they live a normal life.</p> <p>2 Q. Just so I'm clear --</p> <p>3 A. Yes.</p> <p>4 Q. -- it's your opinion that some women might</p> <p>5 have a complication, but they don't have life-altering</p> <p>6 complications?</p> <p>7 MR. WALKER: Object to form.</p> <p>8 A. How do you define "life-altering"?</p> <p>9 Q. Doctor, are there attendant risks with any</p> <p>10 surgery?</p> <p>11 A. Absolutely.</p> <p>12 Q. And so, if you're subjecting a woman to</p> <p>13 multiple repeat surgeries to repair a complication</p> <p>14 related to Prolift, do you think that's important?</p> <p>15 A. I think that's important. That's correct.</p> <p>16 Q. Do you think she would consider that serious?</p> <p>17 A. She considers the first complication serious.</p> <p>18 MR. WALKER: Object to the form of the</p> <p>19 question.</p> <p>20 Q. And each time you're adding on another</p> <p>21 procedure, that increases the risks associated with it;</p> <p>22 isn't that fair?</p> <p>23 A. Not necessarily. It depends on the procedure</p> <p>24 you're doing and how good you perform the procedure.</p>	<p>1 discuss women who have had to undergo repeated multiple</p> <p>2 surgeries to treat complications related to Prolift,</p> <p>3 that you would prefer to use in this deposition, Doctor?</p> <p>4 MR. WALKER: Object to the form.</p> <p>5 A. I would just like to say they've had multiple</p> <p>6 procedures to deal with multiple complications.</p> <p>7 Q. Okay.</p> <p>8 A. Okay?</p> <p>9 Q. Doctor, we discussed some complications that</p> <p>10 you feel were unique to mesh. And I wanted to see,</p> <p>11 would you agree that contraction of mesh is a unique</p> <p>12 complication to mesh implants?</p> <p>13 MR. WALKER: Object to form.</p> <p>14 A. I don't agree that mesh contracts.</p> <p>15 Q. That wasn't exactly my question. It might be</p> <p>16 a bad question.</p> <p>17 But --</p> <p>18 A. Okay.</p> <p>19 Q. -- absent mesh implant, can you have</p> <p>20 contraction of mesh? Obviously not; right?</p> <p>21 MR. WALKER: Object to form.</p> <p>22 A. If you say mesh contracts when it goes in the</p> <p>23 bodies, and that's your opinion, and you don't put mesh</p> <p>24 in the body, yes, it won't contract.</p>
Page 35	Page 37
<p>1 Q. There's not increased risk with each</p> <p>2 subsequent pelvic surgery?</p> <p>3 A. Well, these aren't pelvic surgeries; they're</p> <p>4 vaginal surgeries.</p> <p>5 Q. It's in the pelvis; right?</p> <p>6 MR. WALKER: Object to the form.</p> <p>7 A. It's outside the pelvis. The pelvis is above</p> <p>8 the pelvic floor. This is below the pelvic floor.</p> <p>9 Q. So it's your opinion that additional</p> <p>10 surgeries carry no increased risk?</p> <p>11 A. No, I didn't say that. I think additional</p> <p>12 surgery -- every time you do a surgery, there is more</p> <p>13 risk. Yes, I agree with that.</p> <p>14 Q. And as you go along that stratosphere of</p> <p>15 increased surgeries, wouldn't you consider that a</p> <p>16 serious complication?</p> <p>17 A. I would consider it a serious complication,</p> <p>18 but it doesn't necessarily have to be life-altering. I</p> <p>19 think that the phrase, "life-altering," is kind of --</p> <p>20 Q. You just don't like the phrase,</p> <p>21 "life-altering"?</p> <p>22 MR. WALKER: Object to form.</p> <p>23 A. I don't think it's appropriate.</p> <p>24 Q. Okay. Is there a better medical term to</p>	<p>1 MR. BENTLEY: I want to strike that as</p> <p>2 nonresponsive.</p> <p>3 BY MR. BENTLEY:</p> <p>4 Q. And we'll look at some literature.</p> <p>5 So it's your opinion that mesh contraction</p> <p>6 doesn't exist?</p> <p>7 A. It's my opinion that the body incorporates in</p> <p>8 the mesh and the actual fibrosis of the incorporation</p> <p>9 causes contraction. But I don't --</p> <p>10 MR. BENTLEY: Appreciate that. I'm going to</p> <p>11 strike that as nonresponsive.</p> <p>12 And, with all due respect, Doctor, we have</p> <p>13 two hours. And I'm going to ask just if you can</p> <p>14 try to answer my question. I might have had a bad</p> <p>15 question. That's fair. If you'd like me to</p> <p>16 rephrase it, that's fine.</p> <p>17 THE WITNESS: Okay.</p> <p>18 BY MR. BENTLEY:</p> <p>19 Q. Is it your opinion that there's not mesh</p> <p>20 contraction related to Prolift implants?</p> <p>21 A. What's your definition of "mesh contraction"?</p> <p>22 Q. Is it your opinion that the medical</p> <p>23 literature does not refer to mesh contraction?</p> <p>24 A. The medical literature shows that there isn't</p>

10 (Pages 34 to 37)

Michael Karram, M.D.

Page 38	Page 40
<p>1 any mesh contraction.</p> <p>2 Q. And that's your opinion?</p> <p>3 A. That's in the medical literature.</p> <p>4 Q. Okay. Is it your opinion that mesh does not</p> <p>5 become bunched up once it's implanted?</p> <p>6 MR. WALKER: Object to form.</p> <p>7 A. That's correct.</p> <p>8 Q. And it's your opinion that the medical</p> <p>9 literature does not reference and evidence mesh becoming</p> <p>10 bunched up once it's implanted?</p> <p>11 A. Mesh can become bunched up, but it's at the</p> <p>12 time of implantation, not later on.</p> <p>13 Q. Is it your opinion that mesh retraction</p> <p>14 happens after implantation?</p> <p>15 A. What's your definition of "mesh retraction"?</p> <p>16 Q. Is it your opinion, Doctor, that the medical</p> <p>17 literature does not document mesh retraction related to</p> <p>18 Prolift implants?</p> <p>19 A. How are you defining "retraction"?</p> <p>20 Q. If you'd just please answer my question,</p> <p>21 Doctor.</p> <p>22 A. I don't have an answer to that, because I</p> <p>23 don't know what you mean by "retraction." Does it --</p> <p>24 Q. I'm not -- that's not my -- my turn, Doctor.</p>	<p>1 from bunched mesh?</p> <p>2 MR. WALKER: Object to form.</p> <p>3 A. Yes.</p> <p>4 Q. And what happens when the mesh becomes</p> <p>5 bunched, after a Prolift procedure?</p> <p>6 A. It rolls in on itself because it probably</p> <p>7 wasn't placed correctly.</p> <p>8 Q. Okay. And that can lead to pain?</p> <p>9 A. That can lead to pain, yes.</p> <p>10 Q. And that can lead to removal of the mesh?</p> <p>11 A. Yes.</p> <p>12 Q. Which can be an invasive procedure?</p> <p>13 A. Correct.</p> <p>14 Q. And lead to --</p> <p>15 A. And, well, sometimes.</p> <p>16 Q. Okay.</p> <p>17 A. And sometimes it can be noninvasive, if you</p> <p>18 consider using nonsurgical methods, which can help, or</p> <p>19 noninvasive medicine -- or techniques, where you use --</p> <p>20 remove it in the office.</p> <p>21 I don't know if you would consider that</p> <p>22 invasive. I don't.</p> <p>23 Q. All right. Sometimes bunched mesh can lead</p> <p>24 to multiple removal surgeries; isn't that true?</p>
Page 39	Page 41
<p>1 My question, specifically: In your opinion,</p> <p>2 does the medical literature reference mesh retraction</p> <p>3 related to Prolift implants?</p> <p>4 MR. WALKER: Object to form.</p> <p>5 Q. Yes or no?</p> <p>6 A. In vivo, in vitro, in dogs, in rats? What</p> <p>7 literature are you referring to?</p> <p>8 Q. That's fair.</p> <p>9 Doctor, does the medical literature studying</p> <p>10 women who have undergone Prolift implants in vivo --</p> <p>11 A. Um-hmm.</p> <p>12 Q. -- does it reference mesh retraction?</p> <p>13 A. I think there are articles that will</p> <p>14 reference that, yes.</p> <p>15 Q. But you disagree that that is an occurrence?</p> <p>16 A. I disagree.</p> <p>17 Q. Okay. Have you ever treated a woman who's</p> <p>18 suffered from mesh retraction?</p> <p>19 A. I can't answer that question.</p> <p>20 Q. Fine. Have you ever treated a woman who</p> <p>21 suffered mesh contraction?</p> <p>22 A. Again, I can't answer that question.</p> <p>23 MR. WALKER: Object to form.</p> <p>24 Q. Have you ever treated a woman who suffered</p>	<p>1 A. That's correct.</p> <p>2 Q. And sometimes, even after those multiple</p> <p>3 surgeries, a woman still suffers from pain; isn't that</p> <p>4 correct?</p> <p>5 A. There are some, yes.</p> <p>6 Q. Doctor, do you keep a case log of all the</p> <p>7 patients you've perform surgery on?</p> <p>8 A. In my entire career? No.</p> <p>9 Q. Doctor, do you have an understanding, today,</p> <p>10 as to why the Prolift is no longer available?</p> <p>11 A. It would just be some -- a hypothetical, my</p> <p>12 thought. I don't know. I don't know why, other than I</p> <p>13 think the companies didn't want to deal with the legal</p> <p>14 issues. I think. I don't know. That's just my</p> <p>15 opinion. I don't know.</p> <p>16 Q. And on your reliance list, there's a number</p> <p>17 of internal Ethicon documents, close to 500; right?</p> <p>18 A. Yes.</p> <p>19 Q. And in any of those documents, it didn't</p> <p>20 discuss why the Prolift is no longer available?</p> <p>21 A. None that I saw.</p> <p>22 Q. Did any of those documents discuss a 522</p> <p>23 order?</p> <p>24 A. I think so, yes.</p>

11 (Pages 38 to 41)

Michael Karram, M.D.

Page 42	Page 44
<p>1 Q. Okay. Do you have an understanding as to</p> <p>2 what a 522 order is?</p> <p>3 A. Yes.</p> <p>4 Q. Could you describe that, please?</p> <p>5 A. It's a more extensive trial to get a product</p> <p>6 approved by the FDA.</p> <p>7 Q. And you've previously testified you're not a</p> <p>8 regulatory expert; right?</p> <p>9 A. That is not -- that's correct, I'm not a</p> <p>10 regulatory expert.</p> <p>11 Q. And that's true today; right?</p> <p>12 A. That's true, today, absolutely.</p> <p>13 Q. Doctor, in reaching your opinions today, is</p> <p>14 the FDA's analysis of the studies regarding the safety</p> <p>15 and the efficacy of the Prolift device -- are those --</p> <p>16 is that analysis of those studies important to you?</p> <p>17 A. It is.</p> <p>18 Q. Do you think the FDA has scientists and</p> <p>19 epidemiologists that are highly qualified to look at</p> <p>20 that type of data?</p> <p>21 A. I'm sure they do.</p> <p>22 Q. And if the FDA reviewed the literature and</p> <p>23 came to a conclusion that the safety and effectiveness</p> <p>24 of Prolift had not been reached through that literature,</p>	<p>1 not important to my opinions.</p> <p>2 Q. I don't understand.</p> <p>3 It would be important to your opinions here</p> <p>4 or --</p> <p>5 A. But -- yeah. But it doesn't change my</p> <p>6 opinion of the procedure, the device, and the</p> <p>7 indications, and the use of it.</p> <p>8 Q. It might impact your opinions regarding the</p> <p>9 medical literature, but it wouldn't impact your opinions</p> <p>10 regarding your personal experience; is that fair?</p> <p>11 A. Yeah, that's fair.</p> <p>12 Q. Would you like to see that analysis, if it</p> <p>13 existed?</p> <p>14 A. An FDA analysis of Prolift?</p> <p>15 Q. I'm sorry. That was a bad question.</p> <p>16 A. Okay.</p> <p>17 Q. That's fair.</p> <p>18 If the FDA did undertake an analysis of the</p> <p>19 medical literature, regarding the safety and efficacy of</p> <p>20 Prolift, and concluded that it was insufficient, would</p> <p>21 you have liked to have seen that analysis --</p> <p>22 MR. WALKER: Object to form.</p> <p>23 Q. -- in preparing your report here?</p> <p>24 A. If that analysis existed, yes.</p>
Page 43	Page 45
<p>1 would that be important to you?</p> <p>2 MR. WALKER: Object to form.</p> <p>3 A. It would.</p> <p>4 Q. Would you agree that the FDA's viewpoints as</p> <p>5 to whether there's a need for more rigorous studies</p> <p>6 regarding the safety and efficacy of Prolift -- is that</p> <p>7 important?</p> <p>8 MR. WALKER: Object to the form.</p> <p>9 A. It is.</p> <p>10 Q. Did you take any of the FDA's analysis of the</p> <p>11 medical literature regarding Prolift into account, when</p> <p>12 you were forming your opinions here?</p> <p>13 A. I took the FDA notices into account, yes.</p> <p>14 Q. And you're talking about the public health</p> <p>15 notices?</p> <p>16 A. That's correct.</p> <p>17 Q. Okay. So if the FDA had requested Ethicon to</p> <p>18 perform additional, more rigorous studies regarding the</p> <p>19 Prolift procedure because the FDA concluded that the</p> <p>20 current literature was insufficient to establish the</p> <p>21 safety and efficacy, that would have been important to</p> <p>22 your opinions here?</p> <p>23 MR. WALKER: Object to form.</p> <p>24 A. I think that would be important. But it's</p>	<p>1 Q. Because it might inform your opinions</p> <p>2 regarding the medical literature here; right?</p> <p>3 MR. WALKER: Object to form.</p> <p>4 A. Possibly.</p> <p>5 Q. Okay. So, Doctor, is it your testimony,</p> <p>6 today, that you don't know whether or not the FDA did</p> <p>7 request Ethicon to perform additional studies on the</p> <p>8 Prolift procedure?</p> <p>9 A. I'm not -- yeah, you're right, I don't know</p> <p>10 that.</p> <p>11 Q. Okay. And you don't know if Ethicon chose to</p> <p>12 withdraw the Prolift from the market instead of doing</p> <p>13 those studies? You don't know that; right?</p> <p>14 A. I don't know that.</p> <p>15 MR. WALKER: Object to form.</p> <p>16 Q. If Ethicon did withdraw the Prolift instead</p> <p>17 of doing the 522 studies, would you like to know that?</p> <p>18 MR. WALKER: Object to form.</p> <p>19 A. It would be hard, unless you understood the</p> <p>20 context of what it was all about. I mean, you know, to</p> <p>21 do more studies is very expensive, and to get randomized</p> <p>22 control trials and to recruit patients. So it might not</p> <p>23 just be because they don't want to do it because they</p> <p>24 feel that the product isn't good; it might be that just</p>

12 (Pages 42 to 45)

Michael Karram, M.D.

Page 46	Page 48
<p>1 from a financial and economic standpoint, they can't do</p> <p>2 it. So...</p> <p>3 Q. But you don't know, because you haven't</p> <p>4 reviewed --</p> <p>5 A. I don't know.</p> <p>6 Q. -- those documents?</p> <p>7 A. Yeah, I don't know.</p> <p>8 Q. So would you have liked to be able to review</p> <p>9 those documents demonstrating the process and the</p> <p>10 discussions, to see the full context of why the Prolift</p> <p>11 was pulled from the market?</p> <p>12 MR. WALKER: Object to form.</p> <p>13 A. I don't think it really matters. I mean,</p> <p>14 they have to make a decision as a company. Other</p> <p>15 companies made a decision to move forward with their</p> <p>16 mesh products and to go ahead and do the randomized</p> <p>17 control trials. And companies are doing that.</p> <p>18 So, you know, to me, it's a company decision;</p> <p>19 it's not -- it really doesn't have any relevance or --</p> <p>20 on my decisions or my opinions.</p> <p>21 Q. Do you know if -- I probably know the answer.</p> <p>22 But do you know if Ethicon tried to convince</p> <p>23 the FDA to accept studies that already existed, rather</p> <p>24 than doing new studies, as requested by the FDA?</p>	<p>1 Q. Okay. And was it important for you to</p> <p>2 approach the issues in a fair and balanced way, to give</p> <p>3 a full picture of the important data?</p> <p>4 MR. WALKER: Object to form.</p> <p>5 A. I tried, yes.</p> <p>6 Q. Because that's important to you, as being an</p> <p>7 objective expert; right?</p> <p>8 A. That's correct.</p> <p>9 Q. And would you agree that it was your</p> <p>10 obligation to give both sides of the story, to the</p> <p>11 extent both sides of the story were presented in an</p> <p>12 article?</p> <p>13 MR. WALKER: Object to form.</p> <p>14 A. Correct.</p> <p>15 Q. You wouldn't want to cherry-pick only</p> <p>16 favorable evidence from an article or ignore data that's</p> <p>17 contrary to your opinion?</p> <p>18 A. No, definitely not.</p> <p>19 Q. Because that wouldn't be objective; right?</p> <p>20 A. Correct.</p> <p>21 Q. Doctor, in forming your opinions regarding</p> <p>22 the Prolift device, did you rely on TVT data to form any</p> <p>23 of your opinions regarding the safety and efficacy of</p> <p>24 Prolift?</p>
Page 47	Page 49
<p>1 MR. WALKER: Object to form.</p> <p>2 A. I don't know if that happened. But I know</p> <p>3 that's pretty standard in the industry. When the FDA</p> <p>4 asks for more information, then companies go back and</p> <p>5 say, well, we have more information, look at these</p> <p>6 studies, review this, and things like that. So -- but</p> <p>7 I'm not --</p> <p>8 Q. I'm sorry.</p> <p>9 A. Yeah, go ahead.</p> <p>10 Q. And you testified that other companies, in</p> <p>11 fact, did do more studies; isn't that fair?</p> <p>12 A. Well, actually, AMS started to, and then they</p> <p>13 pulled out.</p> <p>14 Q. Okay.</p> <p>15 A. So they do not have their 522 on Elevate</p> <p>16 anymore, it's gone; and they don't have their capture</p> <p>17 study, it's gone.</p> <p>18 Q. Doctor, you don't hold yourself out as an</p> <p>19 expert in epidemiology, do you?</p> <p>20 A. For sure not.</p> <p>21 Q. When you cited data in your report from the</p> <p>22 medical literature, was it important to you to approach</p> <p>23 the issues in an objective fashion?</p> <p>24 A. It was.</p>	<p>1 A. Only in the sense of cytotoxicity,</p> <p>2 carcinogenesis, and some of the other products that are</p> <p>3 mesh products that plaintiffs are saying cause problems.</p> <p>4 Q. So you're only relying upon TVT literature</p> <p>5 regarding cytotoxicity and carcinogenesis?</p> <p>6 A. I'll tell you -- no. I'll tell you exactly</p> <p>7 what I'm relying on.</p> <p>8 It would be degradation and particle loss.</p> <p>9 It would be pore size and weight; malignant potential of</p> <p>10 mesh; biocompatibility of mesh. And that's it.</p> <p>11 Q. Cytotoxicity, carcinogenesis, degradation,</p> <p>12 pore size and weight. And what was the last --</p> <p>13 A. Biocompatibility of mesh.</p> <p>14 Q. Okay. Doctor, you previously testified that</p> <p>15 the TVT Prolene mesh is a different weave as compared to</p> <p>16 the Gynecare Gynemesh PS; isn't that correct?</p> <p>17 A. It's a heavier mesh, yes.</p> <p>18 Q. Because it has a different weave; isn't that</p> <p>19 correct?</p> <p>20 A. Um-hmm.</p> <p>21 Q. Which, necessarily, involves a different</p> <p>22 amount of polypropylene filament that's woven together;</p> <p>23 right?</p> <p>24 A. I'm not an expert, but I think so, yes.</p>

13 (Pages 46 to 49)

Michael Karram, M.D.

Page 50	Page 52
<p>1 Q. Okay. And that means it's going to have a</p> <p>2 different pore construction or geometry; wouldn't you</p> <p>3 agree with that?</p> <p>4 A. It may change it, yes.</p> <p>5 Q. If it has a different weave, obviously it's</p> <p>6 going to be a different --</p> <p>7 A. Correct.</p> <p>8 Q. -- design; right?</p> <p>9 A. Correct.</p> <p>10 Q. And so it's going to -- as you said, it has a</p> <p>11 different weight; right?</p> <p>12 A. Yes.</p> <p>13 Q. Okay. So do you still think it's reliable to</p> <p>14 rely upon the TVT literature regarding pore size and</p> <p>15 weight, when you're looking at the safety and efficacy</p> <p>16 of the Prolift device?</p> <p>17 A. I think so.</p> <p>18 Q. Can you explain why you think a different</p> <p>19 mesh with a different weave is relevant to the Prolene</p> <p>20 mesh with a different weave, regarding pore size and</p> <p>21 weight?</p> <p>22 A. Well, because the pore size is macroporous</p> <p>23 and it's monofilament and it's a Type 1. And so, even</p> <p>24 though it's a little heavier, it reacts the same.</p>	<p>1 Q. Okay. Do you know whether Ethicon internally</p> <p>2 thought the TVT data and studies should not be</p> <p>3 considered, regarding Prolift?</p> <p>4 MR. WALKER: Object to form.</p> <p>5 A. I do not.</p> <p>6 Q. Would you defer to Ethicon's viewpoint,</p> <p>7 regarding the construction of the mesh and what evidence</p> <p>8 is relevant?</p> <p>9 MR. WALKER: Object to form.</p> <p>10 A. I would.</p> <p>11 Q. If there were some analysis or documents that</p> <p>12 existed discussing those very issues, would you have</p> <p>13 liked to have seen those?</p> <p>14 A. Yes.</p> <p>15 Q. Because that could impact your opinions in</p> <p>16 your report; isn't that fair?</p> <p>17 A. Possibly, yes.</p> <p>18 Q. Okay. Do you know whether the FDA thought</p> <p>19 that TVT data and studies should not be considered</p> <p>20 regarding the Prolift?</p> <p>21 MR. WALKER: Object to form.</p> <p>22 A. No, I don't.</p> <p>23 Q. Again, would you defer to the FDA's viewpoint</p> <p>24 on such matters?</p>
Page 51	Page 53
<p>1 Knitted mesh has a high porosity and -- just as I state</p> <p>2 here. So...</p> <p>3 Q. So, to you, any knitted mesh made of</p> <p>4 polypropylene --</p> <p>5 A. Not necessarily. In these two it does.</p> <p>6 Q. Okay. And what analysis did you undertake to</p> <p>7 come to that conclusion, that the TVT literature</p> <p>8 regarding pore size and weight is relevant to the</p> <p>9 Prolene mesh -- I'm sorry, to the Prolene Soft mesh used</p> <p>10 in the Prolift device?</p> <p>11 A. The Prolift studies that ratify the mesh</p> <p>12 properties.</p> <p>13 Q. Can you identify what Prolift studies</p> <p>14 indicate that the TVT literature is relevant for these</p> <p>15 biomechanical --</p> <p>16 A. Well, I don't think --</p> <p>17 Q. -- properties?</p> <p>18 A. -- it's the TVT literature. It's the mesh</p> <p>19 used in synthetic slings.</p> <p>20 Q. Okay. And can you identify any studies, as</p> <p>21 you sit here today, that indicate the biomechanical</p> <p>22 properties of the TVT mesh is related to the Prolene</p> <p>23 Soft mesh, regarding the safety and efficacy?</p> <p>24 A. I can't quote any now, no.</p>	<p>1 A. I would.</p> <p>2 Q. And we discussed that the Prolift is no</p> <p>3 longer available, but the TVT products are available on</p> <p>4 the market still; right?</p> <p>5 A. That's correct.</p> <p>6 Q. Okay. And the TVT products use a different</p> <p>7 weave, which is Prolene; correct?</p> <p>8 A. Correct.</p> <p>9 Q. Okay. Doctor, can you explain any of the</p> <p>10 biomechanical differences between the Prolene mesh used</p> <p>11 in the TVT and the Prolene Soft Gynemesh that's used in</p> <p>12 the Prolift?</p> <p>13 A. I really can't. I'm not a biomechanical --</p> <p>14 Q. You would defer --</p> <p>15 A. -- engineer.</p> <p>16 Q. -- to a biomechanical expert?</p> <p>17 A. Engineer, right.</p> <p>18 Q. And, likewise, you don't know the clinical</p> <p>19 impacts of those biomechanical differences, do you?</p> <p>20 A. Only in comparison to patients that I've</p> <p>21 treated with both of them.</p> <p>22 Q. Can you identify any evidence discussing or</p> <p>23 evaluating the clinical impacts of the biomechanical</p> <p>24 differences between the TVT products and the Prolift</p>

14 (Pages 50 to 53)

Michael Karram, M.D.

Page 54	Page 56
<p>1 Gynemesh Prolene Soft?</p> <p>2 A. I can't, no.</p> <p>3 Q. Would you agree that the TVT implant uses a</p> <p>4 much smaller piece of mesh, as compared to the Prolift</p> <p>5 mesh?</p> <p>6 A. Yes.</p> <p>7 Q. Doctor, did you review any of the clinical</p> <p>8 data regarding the Prolift product in those Ethicon</p> <p>9 internal documents that are on your reliance list?</p> <p>10 A. Any clinical data?</p> <p>11 Q. You have a number of articles listed in your</p> <p>12 literature section; correct?</p> <p>13 A. Right.</p> <p>14 Q. Okay.</p> <p>15 A. Right.</p> <p>16 Q. And then, aside from that data, is there --</p> <p>17 do you have any understanding that you reviewed any of</p> <p>18 the clinical data, aside from the publicly available</p> <p>19 stuff, that was provided to you from the internal</p> <p>20 Ethicon documents?</p> <p>21 A. No.</p> <p>22 Q. Would you have liked to review any of the</p> <p>23 internal French TVM data, in reaching your opinions</p> <p>24 here?</p>	<p>1 discussed in your report; right?</p> <p>2 A. Correct.</p> <p>3 Q. Okay. And I'm not sure that would be even</p> <p>4 feasible, honestly.</p> <p>5 But how did you decide which articles to</p> <p>6 discuss in your report?</p> <p>7 A. I guess I looked at the most scientific,</p> <p>8 which would be the meta-analyses, the randomized control</p> <p>9 trials, the trials that had large patient numbers, the</p> <p>10 trials that were maybe done at one center or where you</p> <p>11 could rely on the fact that the procedures are</p> <p>12 reproducible. But, yeah. But it is mainly the more</p> <p>13 scientific ones, the meta-analyses and the randomized</p> <p>14 control trials.</p> <p>15 Q. So you tried to focus your review on Level 1</p> <p>16 evidence, which is meta-analyses or systematic reviews?</p> <p>17 A. There you go.</p> <p>18 Q. Okay. And RTCs; is that fair?</p> <p>19 A. Correct.</p> <p>20 Q. Okay. And those are the studies you tried to</p> <p>21 discuss in your report, because you felt those were more</p> <p>22 informative on the issue as to the safety and efficacy</p> <p>23 of the Prolift device --</p> <p>24 A. I think they --</p>
Page 55	Page 57
<p>1 A. I've seen some of the TVM French material.</p> <p>2 So I've reviewed some of that.</p> <p>3 Q. In the internal Ethicon documents or in the</p> <p>4 published literature?</p> <p>5 A. In the published literature.</p> <p>6 Q. Would you have liked to have seen the</p> <p>7 internal documents Ethicon has regarding those studies?</p> <p>8 A. I think the published literature's in</p> <p>9 peer-reviewed journals, and it really doesn't matter.</p> <p>10 Q. But you don't know what's in those other</p> <p>11 documents, do you?</p> <p>12 A. I do not.</p> <p>13 Q. How did you decide which studies to cite in</p> <p>14 your report, Doctor?</p> <p>15 A. Oh, I tried to do a search of all the mesh</p> <p>16 products that were out there, and specifically in</p> <p>17 relationship to Prolift, and reviewed them all as best I</p> <p>18 could.</p> <p>19 Q. Let me make sure I understand.</p> <p>20 A. Yeah.</p> <p>21 Q. So you have a number of scientific articles</p> <p>22 listed on your reliance list?</p> <p>23 A. That's correct.</p> <p>24 Q. Okay. But not all those articles are</p>	<p>1 Q. -- is that fair?</p> <p>2 A. -- carry a higher weight, yes.</p> <p>3 Q. And you didn't deliberately decide not to</p> <p>4 cite studies in your report that were unfavorable to</p> <p>5 Prolift; right?</p> <p>6 A. No.</p> <p>7 MR. WALKER: We've been going almost an hour.</p> <p>8 Do you need a break?</p> <p>9 (Brief recess taken.)</p> <p>10 BY MR. BENTLEY:</p> <p>11 Q. Doctor, we're back from a short break. Are</p> <p>12 you ready to go?</p> <p>13 A. I am.</p> <p>14 Q. Okay. Doctor, if you could please turn your</p> <p>15 attention to your report, which I believe we marked as</p> <p>16 Exhibit 1.</p> <p>17 A. Um-hmm.</p> <p>18 Q. On page 21, you have a section that begins,</p> <p>19 "Adequacy of Company IFU and Patient Brochures."</p> <p>20 A. That's correct.</p> <p>21 Q. Do you see that?</p> <p>22 A. Yes.</p> <p>23 Q. Okay. And in this section, you discuss</p> <p>24 adequacy of the warnings; is that correct?</p>

15 (Pages 54 to 57)

Michael Karram, M.D.

Page 58	Page 60
<p>1 A. That's correct.</p> <p>2 Q. It's your opinion, that you intend to offer</p> <p>3 to the jury, that Ethicon adequately warned doctors</p> <p>4 regarding the complications of the Prolift device; is</p> <p>5 that correct?</p> <p>6 A. Yes.</p> <p>7 Q. Okay. And you explain, on page 22, that one</p> <p>8 of the bases for your opinions is that although you're</p> <p>9 not a regulatory expert, you've reviewed 21 CFR 801.</p> <p>10 Do you see that?</p> <p>11 A. Yes.</p> <p>12 Q. Okay. And how did you come to review 21 CFR</p> <p>13 801, Section 109?</p> <p>14 A. I was looking for a -- some kind of a</p> <p>15 document to support the fact that any pelvic floor</p> <p>16 surgeon that has experience in pelvic floor surgery,</p> <p>17 whether it's mesh or non-mesh, and he start -- he or she</p> <p>18 starts to use any kind of products, does the company</p> <p>19 have the responsibility to let them know of every</p> <p>20 possible complication, even if they don't know the</p> <p>21 complications exist or that these are well-known</p> <p>22 complications. And this is how I got to that document.</p> <p>23 Q. Okay. And your reliance list actually</p> <p>24 reflects that you looked at that subsection, 109; right?</p>	<p>1 And you begin, "There is no clinical</p> <p>2 significance to claims of alleged particle loss and mesh</p> <p>3 degradation over time."</p> <p>4 So my question is, is there no degradation,</p> <p>5 or there's no clinical significance to the degradation</p> <p>6 that occurs?</p> <p>7 A. It says there's no clinical significance.</p> <p>8 Q. Okay. So degradation does occur, but you</p> <p>9 believe there's no clinical significance to it?</p> <p>10 A. All the literature that I saw and I know --</p> <p>11 and AUGS and SUFU have looked at this, and they feel</p> <p>12 that there's no clinical significance. I don't know if</p> <p>13 there's any real degradation, but I do know there's no</p> <p>14 clinical significance -- or my opinion is, no clinical</p> <p>15 significance.</p> <p>16 (Exhibit 4 marked for identification.)</p> <p>17 BY MR. BENTLEY:</p> <p>18 Q. Okay. I'm going to hand you what's being</p> <p>19 marked as Exhibit 4. And this is an article from Arnaud</p> <p>20 Clavé, entitled "Polypropylene as a reinforcement in</p> <p>21 pelvic surgery is not inert: comparative analysis of 100</p> <p>22 explants."</p> <p>23 Do you see that?</p> <p>24 A. Yes.</p>
Page 59	Page 61
<p>1 A. Yes.</p> <p>2 (Exhibit 3 marked for identification.)</p> <p>3 BY MR. BENTLEY:</p> <p>4 Q. Okay. I've just handed you what's been</p> <p>5 marked as Exhibit 3. And this is actually the entire --</p> <p>6 A. Yes.</p> <p>7 Q. -- CFR of that section.</p> <p>8 A. Okay.</p> <p>9 Q. And so you're testifying, today, that you</p> <p>10 reviewed this entire CFR, not being a regulatory expert,</p> <p>11 and honed in on, this is the applicable regulatory</p> <p>12 requirement for labeling; is that --</p> <p>13 A. I did not read the whole thing.</p> <p>14 Q. Okay, thank you.</p> <p>15 MR. WALKER: Does that save you some time?</p> <p>16 Q. Doctor, you've testified that you do not</p> <p>17 believe that that polypropylene and Prolene Soft mesh</p> <p>18 degrades over time; is that correct?</p> <p>19 A. That's correct.</p> <p>20 Q. Okay. And if you could turn your attention</p> <p>21 to page 27 in your report --</p> <p>22 A. Right.</p> <p>23 Q. -- to the section called -- entitled</p> <p>24 "Degradation and Particle Loss."</p>	<p>1 Q. Okay. And are you familiar with this</p> <p>2 article?</p> <p>3 A. I think I've looked at it sometime in the</p> <p>4 past, yes.</p> <p>5 Q. Okay. I'll represent to you that it's, in</p> <p>6 fact, on your reliance list.</p> <p>7 A. Yes.</p> <p>8 Q. And, just briefly, if you'll turn your</p> <p>9 attention to page 265, in the top right.</p> <p>10 A. Okay.</p> <p>11 Q. You can see, there are pictures in two</p> <p>12 columns; and, on the left, it says "Intact," and on the</p> <p>13 right, it says "Degraded"?</p> <p>14 A. Okay.</p> <p>15 Q. Do you see that?</p> <p>16 A. I do.</p> <p>17 Q. Okay. And it appears those are zoomed-in</p> <p>18 photos, using scientific equipment to evaluate whether</p> <p>19 or not there's degradation, and they've listed those</p> <p>20 photos as "Degraded."</p> <p>21 Do you see that?</p> <p>22 A. I see that.</p> <p>23 Q. Okay. And if you'll turn back to the front</p> <p>24 page of this article. You'll see the second sentence --</p>

16 (Pages 58 to 61)

Michael Karram, M.D.

Page 62	Page 64
<p>1 or we'll read the conclusions.</p> <p>2 It says, "This is the first study to evaluate</p> <p>3 synthetic implants using a vaginal approach for pelvic</p> <p>4 floor reinforcement. This study provides evidence</p> <p>5 contrary to published literature characterizing</p> <p>6 polypropylene (PP) as inert in such applications."</p> <p>7 Did I read that correct?</p> <p>8 A. Yes.</p> <p>9 Q. Okay. So these authors in this article,</p> <p>10 Arnaud Clavé, that's on your reliance list, conclude</p> <p>11 that there's actually evidence of degradation; is that</p> <p>12 fair?</p> <p>13 MR. WALKER: Object to form.</p> <p>14 A. It says that they show, on these photos,</p> <p>15 degradation in patients who have had explanted</p> <p>16 polypropylene due to complications of the polypropylene,</p> <p>17 yes.</p> <p>18 Q. Okay. And Prolift is made from a Prolene</p> <p>19 mesh, right; it uses a polypropylene?</p> <p>20 A. Yes.</p> <p>21 Q. And so what they're discussing is directly on</p> <p>22 point to the question here of whether or not degradation</p> <p>23 exists regarding polypropylene implants; is that</p> <p>24 correct?</p>	<p>1 today?</p> <p>2 A. No, other than understand that it's from</p> <p>3 explanted complicated patients, yes -- no.</p> <p>4 Q. And, in your report, you don't provide any</p> <p>5 reason or description of why you discounted this</p> <p>6 evidence; is that correct?</p> <p>7 A. Because it was explanted complicated</p> <p>8 patients. That's why.</p> <p>9 MR. BENTLEY: I'm going to move to strike as</p> <p>10 nonresponsive.</p> <p>11 BY MR. BENTLEY:</p> <p>12 Q. Doctor, in your report, do you provide any</p> <p>13 analysis or criticism of this article?</p> <p>14 A. Yes.</p> <p>15 Q. In your report, what page do you cite --</p> <p>16 A. Oh. I don't -- no, I don't. In my opinion,</p> <p>17 I do.</p> <p>18 Q. Okay. So let me just --</p> <p>19 A. Okay.</p> <p>20 Q. -- rephrase it.</p> <p>21 A. Okay.</p> <p>22 Q. In your report, you don't disclose any</p> <p>23 critique or analysis of why this article --</p> <p>24 A. No.</p>
Page 63	Page 65
<p>1 MR. WALKER: Object to form.</p> <p>2 A. Not necessarily, because they didn't explant</p> <p>3 anybody who was not having a complication.</p> <p>4 Q. Okay. So is it your opinion that</p> <p>5 complications are more likely to have degradation?</p> <p>6 A. Possibly. But, again, I'm not a</p> <p>7 biomechanical whatever.</p> <p>8 Q. Okay.</p> <p>9 A. But --</p> <p>10 Q. And if, in fact, the complications were tied</p> <p>11 to degradation, then there would be clinical</p> <p>12 significance; is that true?</p> <p>13 A. Or, vice versa, the complication caused the</p> <p>14 degradation.</p> <p>15 Q. Okay. So does this article impact your</p> <p>16 opinion that there's no clinical significance of</p> <p>17 degradation?</p> <p>18 A. No.</p> <p>19 Q. Based on the evidence in this article, would</p> <p>20 you agree that there is evidence of degradation in</p> <p>21 polypropylene implants?</p> <p>22 A. This article suggests that, yes.</p> <p>23 Q. Okay. And you don't have any reason to</p> <p>24 discount or critique this article, as you sit here</p>	<p>1 Q. -- demonstrating degradation --</p> <p>2 A. Sorry.</p> <p>3 Q. -- is not accurate?</p> <p>4 A. No, I don't.</p> <p>5 (Exhibit 5 marked for identification.)</p> <p>6 BY MR. BENTLEY:</p> <p>7 Q. Doctor, I'm going to hand you what's being</p> <p>8 marked as Exhibit 5. This is an article by Vladimir</p> <p>9 Iakovlev, entitled "Degradation of polypropylene in</p> <p>10 vivo: A microscopic analysis of meshes explanted from</p> <p>11 patients."</p> <p>12 Do you see that?</p> <p>13 A. I do.</p> <p>14 Q. Are you familiar with this article?</p> <p>15 A. Again, I think I've seen this. And it's</p> <p>16 probably on my reliance list, yes.</p> <p>17 Q. And I'll represent to you that there's a</p> <p>18 number of articles on your reliance list from Iakovlev.</p> <p>19 A. Yes.</p> <p>20 Q. Okay. And, just briefly, if I could turn</p> <p>21 your attention to page 10.</p> <p>22 A. Okay.</p> <p>23 Q. There's a section entitled "Clinical</p> <p>24 significance of polypropylene degradation."</p>

17 (Pages 62 to 65)

Michael Karram, M.D.

Page 66	Page 68
<p>1 Do you see that?</p> <p>2 A. I do.</p> <p>3 Q. Okay. And the authors in this article</p> <p>4 discuss a number of clinically significant events, such</p> <p>5 as, this second full paragraph, they start, "The</p> <p>6 clinical descriptions provided with the specimens</p> <p>7 indicated that in many cases mesh-related complications</p> <p>8 developed several years after mesh implantation."</p> <p>9 Did I read that correct?</p> <p>10 A. You did.</p> <p>11 Q. And that's similar to what we've discussed</p> <p>12 earlier, that these complications can, in fact, occur</p> <p>13 many years after the implant; is that correct?</p> <p>14 A. That's correct.</p> <p>15 Q. Okay. Further down, they state, "As we</p> <p>16 showed, the degraded layer becomes thicker over time</p> <p>17 while its cracking indicated brittleness and loss of</p> <p>18 flexibility."</p> <p>19 Did I read that correct?</p> <p>20 A. Yes.</p> <p>21 Q. Okay. In the last sentence in that</p> <p>22 paragraph, the authors state, "Degradation-related</p> <p>23 stiffening of the mesh is expected to increase over</p> <p>24 time."</p>	<p>1 that caused the complication, for the mesh to degrade.</p> <p>2 Q. Could you give me examples, so I understand,</p> <p>3 of what complication it -- would happen to cause</p> <p>4 degradation?</p> <p>5 A. If you have an exposed mesh and you get a</p> <p>6 severe infection and the infection is of a certain</p> <p>7 bacterial type, it could cause a problem with the mesh.</p> <p>8 Q. Gotcha. And then, lastly, the next</p> <p>9 paragraph, second sentence, "The debris from prosthetic</p> <p>10 joints is well-known to cause tissue necrosis,</p> <p>11 inflammation and fibrosis around the joints. For</p> <p>12 polypropylene meshes, we observed occasional particles</p> <p>13 of degraded polypropylene in the surrounding tissue and</p> <p>14 macrophages."</p> <p>15 A. Where are you again? I'm sorry.</p> <p>16 Q. We're on the same page, on 10.</p> <p>17 A. On 10. Same page. Right. Okay.</p> <p>18 Q. We're looking at the --</p> <p>19 A. 9, 10. Okay, got it --</p> <p>20 Q. -- one, two, three -- fourth --</p> <p>21 A. Yep.</p> <p>22 Q. -- full paragraph --</p> <p>23 A. Yeah.</p> <p>24 Q. -- discussing the third clinical impact --</p>
Page 67	Page 69
<p>1 Did I read that correctly?</p> <p>2 A. You did.</p> <p>3 Q. And if the mesh became stiffer over time,</p> <p>4 that could have a clinical impact for the patient; isn't</p> <p>5 that correct?</p> <p>6 MR. WALKER: Object to form.</p> <p>7 A. Possibly, yes.</p> <p>8 Q. Okay. And the next paragraph begins,</p> <p>9 "Another clinically important aspect of degradation is</p> <p>10 the potential for bacterial colonization of the fissures</p> <p>11 within the degraded material."</p> <p>12 Did I read that correctly?</p> <p>13 A. Yes.</p> <p>14 Q. And, of course, that's another clinically --</p> <p>15 a potential clinical impact from the degradation; is</p> <p>16 that correct?</p> <p>17 A. Or from the reason the complication occurred,</p> <p>18 yes.</p> <p>19 Q. Right. Which would be a clinically</p> <p>20 significant result; right?</p> <p>21 A. Again, you're saying that the degradation</p> <p>22 occurred, caused the complication. And I'm saying,</p> <p>23 since this was a mesh that was explanted from somebody</p> <p>24 who had a complication, there might have been something</p>	<p>1 A. Yes.</p> <p>2 Q. -- potential impact of degradation --</p> <p>3 A. I got it, um-hmm.</p> <p>4 Q. -- second sentence. They're discussing the</p> <p>5 debris from the prosthetic joints is well known to cause</p> <p>6 tissue necrosis, inflammation and fibrosis around the</p> <p>7 joints.</p> <p>8 That's talking about hip implants, I think.</p> <p>9 Is that fair?</p> <p>10 A. I think, yes.</p> <p>11 Q. Okay. But the next sentence, they state,</p> <p>12 "For polypropylene meshes, we observed occasional</p> <p>13 particles of degraded polypropylene in surrounding</p> <p>14 tissue and macrophages."</p> <p>15 Did I read that correctly?</p> <p>16 A. You did.</p> <p>17 Q. Okay. So if the mesh is degrading and</p> <p>18 floating around, that -- these authors say that could be</p> <p>19 a clinical impact; is that correct?</p> <p>20 MR. WALKER: Object to form.</p> <p>21 A. They're not saying that. They're saying it</p> <p>22 was a clinical impact in joints. They observed</p> <p>23 occasional particles, but they don't really say there's</p> <p>24 a clinical impact.</p>

18 (Pages 66 to 69)

Michael Karram, M.D.

Page 70	Page 72
<p>1 Q. Right. But it's under their section entitled</p> <p>2 "Clinical significance of polypropylene degradation" --</p> <p>3 A. I don't think you can assume that.</p> <p>4 Q. I'm sorry. What's the section header title</p> <p>5 for that section --</p> <p>6 A. "Clinical significance of polypropylene</p> <p>7 degradation." But they're talking about joints.</p> <p>8 MR. BENTLEY: Move to strike from what</p> <p>9 they're talking about.</p> <p>10 BY MR. BENTLEY:</p> <p>11 Q. Doctor, if you could please turn to page 5 of</p> <p>12 your report, which is marked as Exhibit 1.</p> <p>13 A. Okay.</p> <p>14 Q. You're discussing your opinions and the bases</p> <p>15 for your opinions. And you say that one of the bases is</p> <p>16 from meetings and literature put out by AUGS and ACOG;</p> <p>17 is that correct?</p> <p>18 A. That's correct.</p> <p>19 Q. Okay. And I think, in your last deposition</p> <p>20 regarding the TVT-O, you actually, in fact, discuss one</p> <p>21 of those position statements from these organizations;</p> <p>22 isn't that correct?</p> <p>23 A. That's correct.</p> <p>24 Q. Okay. And you're familiar with the ACOG and</p>	<p>1 ACOG and AUGS, are talking about life-altering sequelae;</p> <p>2 isn't that correct?</p> <p>3 A. That's correct.</p> <p>4 Q. Okay. So the evidence does reflect there are</p> <p>5 life-altering complications from these devices; correct?</p> <p>6 MR. WALKER: Object to form.</p> <p>7 A. In their opinion, if they -- whatever they</p> <p>8 define as life-altering. But, yes, that is correct.</p> <p>9 Q. Okay. And is one of your opinions for why</p> <p>10 you believe that Ethicon adequately warned of the</p> <p>11 complications associated with Prolift, because you feel</p> <p>12 that doctors already know all these complications?</p> <p>13 MR. WALKER: Object to form.</p> <p>14 A. I feel that surgeons that are performing</p> <p>15 pelvic organ prolapse surgery are aware of all these</p> <p>16 complications, yes.</p> <p>17 Q. You would hope that they are; isn't that</p> <p>18 correct?</p> <p>19 A. No, I would think they would be.</p> <p>20 Q. Okay. If you could look at the first</p> <p>21 paragraph --</p> <p>22 A. Um-hmm.</p> <p>23 Q. -- third sentence, the ACOG and AUGS note</p> <p>24 that "Surgeons who perform those procedures may have</p>
Page 71	Page 73
<p>1 AUGS Position Statement No. 513, published in December</p> <p>2 of 2011, aren't you?</p> <p>3 A. If you can show it to me and let me read it.</p> <p>4 Q. I'll represent to you that this is on your</p> <p>5 reliance list.</p> <p>6 A. I'm sure it is.</p> <p>7 (Exhibit 6 marked for identification.)</p> <p>8 BY MR. BENTLEY:</p> <p>9 Q. We're marking this as Exhibit 6.</p> <p>10 A. Yes.</p> <p>11 Q. Okay. And you're familiar with this article;</p> <p>12 isn't that correct?</p> <p>13 A. I am.</p> <p>14 Q. In the abstract, ACOG and AUGS state, in</p> <p>15 their second sentence, "Based on the currently available</p> <p>16 limited data, although many patients undergoing mesh</p> <p>17 augmented vaginal repairs heal well without problems,</p> <p>18 there seems to be a small but significant group of</p> <p>19 patients who experience permanent and life-altering</p> <p>20 sequelae, including pain and dyspareunia, from the use</p> <p>21 of vaginal mesh."</p> <p>22 Did I read that correctly?</p> <p>23 A. You did.</p> <p>24 Q. Okay. So it seems like these organizations,</p>	<p>1 questions related to the FDA's notification."</p> <p>2 Isn't that correct?</p> <p>3 A. Correct.</p> <p>4 Q. And that notification was in response to the</p> <p>5 complications of these devices; isn't that correct?</p> <p>6 A. It was.</p> <p>7 Q. And these organizations that you rely upon</p> <p>8 are stating that maybe doctors might need some more</p> <p>9 information; is that fair?</p> <p>10 A. Yes.</p> <p>11 Q. Okay. And this is like we discussed. You're</p> <p>12 well-positioned to be well-versed in the literature;</p> <p>13 right?</p> <p>14 A. Um-hmm.</p> <p>15 Q. And some doctors might --</p> <p>16 A. I hope.</p> <p>17 Q. -- might not be as well-versed in the</p> <p>18 literature; right?</p> <p>19 MR. WALKER: Object to form.</p> <p>20 A. Possibly, yes.</p> <p>21 Q. And that's what these organizations right</p> <p>22 here are noting, is that some doctors would like some</p> <p>23 more information; right?</p> <p>24 MR. WALKER: Object to form.</p>

19 (Pages 70 to 73)

Michael Karram, M.D.

Page 74	Page 76
<p>1 A. Right.</p> <p>2 Q. If you could turn to page 2. You can see,</p> <p>3 under the section titled "What outcome data exists for</p> <p>4 vaginal placement of synthetic mesh for pelvic organ</p> <p>5 prolapse," the second paragraph, the last sentence, they</p> <p>6 say, "Although the risk of mesh erosion varied, it was a</p> <p>7 risk that did not exist for native tissue repairs."</p> <p>8 You would agree with that; right?</p> <p>9 A. No, I would not --</p> <p>10 Q. You think --</p> <p>11 A. -- agree with that.</p> <p>12 Q. -- the risk of mesh erosion existed for</p> <p>13 native tissue repair?</p> <p>14 A. I would say, risk of synthetic material</p> <p>15 during native tissue repair can occur.</p> <p>16 Q. Just to be clear, you're saying that the risk</p> <p>17 of mesh erosion exists with native tissue repair?</p> <p>18 A. In some native tissue repairs, yes.</p> <p>19 Q. So you dis --</p> <p>20 A. Not mesh, but synthetic material.</p> <p>21 Q. I don't understand. I'm sorry.</p> <p>22 A. Okay.</p> <p>23 Q. Let me rephrase.</p> <p>24 A. Okay.</p>	<p>1 Q. Well, the quantity is, the rate of total</p> <p>2 reoperation rate, they're saying, is higher for</p> <p>3 mesh-based repairs --</p> <p>4 A. How do you quantify "reoperation," though?</p> <p>5 That's the question. If somebody has a small piece of</p> <p>6 mesh removed from her vagina in the office, is that a</p> <p>7 reoperation? Right?</p> <p>8 Q. Right. If they're doing --</p> <p>9 A. Or does she go to the OR?</p> <p>10 Q. I'm sorry. So are you disagreeing or</p> <p>11 agreeing with ACOG and AUGS' statement, as presented to</p> <p>12 you?</p> <p>13 A. I know the study they're quoting. It's the</p> <p>14 Diwadkar study. And, yes, if you look at all the</p> <p>15 reasons why the mesh was removed, then, yes, there were</p> <p>16 more reoperations, if you consider an office procedure a</p> <p>17 reoperation. Yes.</p> <p>18 Q. So you agree with this statement --</p> <p>19 A. Yes.</p> <p>20 Q. -- here? Okay. Thank you.</p> <p>21 A. Yes.</p> <p>22 Q. Doctor, if you could turn your attention to</p> <p>23 page 3.</p> <p>24 A. Okay.</p>
Page 75	Page 77
<p>1 Q. So the last sentence of this section states,</p> <p>2 "Although the risk of mesh erosion varied, it was a risk</p> <p>3 that did not exist for native tissue repairs."</p> <p>4 My question for you, Doctor: Do you agree</p> <p>5 with AUGS' and ACOG's statement right there?</p> <p>6 A. Well, if you don't use mesh, then there's no</p> <p>7 risk for mesh -- whatever you're talking about -- for</p> <p>8 mesh erosion.</p> <p>9 Q. So you agree with their statement?</p> <p>10 A. Yes.</p> <p>11 Q. Okay.</p> <p>12 A. Yes.</p> <p>13 Q. Thank you.</p> <p>14 And in the next paragraph, the last sentence,</p> <p>15 they state, "In this review, the rate of reoperation to</p> <p>16 correct complications, as well as the total reoperation</p> <p>17 rate, was highest for vaginal mesh kits compared with</p> <p>18 vaginal native tissue and abdominal repairs, despite</p> <p>19 shorter overall follow-up."</p> <p>20 Did I read that correctly?</p> <p>21 A. Yes.</p> <p>22 Q. Okay. And you would agree with that,</p> <p>23 wouldn't you?</p> <p>24 A. You'd have to quantify that.</p>	<p>1 Q. On the left column, at the bottom of the</p> <p>2 page, these committees are discussing that "Pelvic pain,</p> <p>3 groin pain, and dyspareunia can occur with pelvic</p> <p>4 reconstructive surgery regardless of the use or nonuse</p> <p>5 of mesh."</p> <p>6 And that's your position; right?</p> <p>7 A. That's correct.</p> <p>8 Q. Okay. And they continue, though, "However, a</p> <p>9 complication unique to mesh is erosion (also described</p> <p>10 as exposure extrusion), which seems to be the most</p> <p>11 common complication, and may sometimes present several</p> <p>12 years after the index procedure."</p> <p>13 You would agree with that; right?</p> <p>14 A. I do.</p> <p>15 Q. Okay. And they continue there, "Increasing</p> <p>16 reports of vaginal pain associated with changes that can</p> <p>17 occur with mesh (contraction, retraction or shrinkage)</p> <p>18 that result in taut sections of mesh."</p> <p>19 Did I read that correctly?</p> <p>20 A. You did.</p> <p>21 Q. And that's what we were previously</p> <p>22 discussing, that, in fact, mesh can contract; isn't that</p> <p>23 correct?</p> <p>24 A. That's what they say, yes.</p>

20 (Pages 74 to 77)

Michael Karram, M.D.

Page 78	Page 80
<p>1 Q. And do you disagree with that?</p> <p>2 A. I do.</p> <p>3 Q. Okay. And anywhere in your report, do you</p> <p>4 discuss your disagreement with this position statement?</p> <p>5 A. With this position statement, itself?</p> <p>6 Q. Yes.</p> <p>7 A. No. I just --</p> <p>8 Q. Anywhere in your report, do you discuss why</p> <p>9 you think that the medical literature evidencing mesh</p> <p>10 contraction, as referenced in ACOG and AUGS' statement</p> <p>11 right here -- do you discuss, anywhere in your report,</p> <p>12 that mesh contraction doesn't exist?</p> <p>13 A. Well, let's see.</p> <p>14 MR. WALKER: If I could point the doctor in</p> <p>15 the right direction?</p> <p>16 MR. BENTLEY: Sure.</p> <p>17 MR. WALKER: Page 27.</p> <p>18 THE WITNESS: Okay. Um-hmm.</p> <p>19 MR. WALKER: I think, in that first full</p> <p>20 paragraph, Doctor.</p> <p>21 BY MR. BENTLEY:</p> <p>22 Q. Doctor, counsel has directed your attention</p> <p>23 to page --</p> <p>24 A. Yes.</p>	<p>1 3 centimeters. And it doesn't, it stays the same --</p> <p>2 Q. Okay. If you can --</p> <p>3 A. -- by contracture --</p> <p>4 Q. -- draw your attention down to the next</p> <p>5 paragraph.</p> <p>6 A. Okay.</p> <p>7 Q. You'll see, at the end of that paragraph,</p> <p>8 "One ultrasound study evaluating women at three months</p> <p>9 after anterior vaginal mesh placement" --</p> <p>10 A. Um-hmm.</p> <p>11 Q. -- "found severe contraction or shrinkage</p> <p>12 defined as a decrease of more than 50 percent of the</p> <p>13 size of the mesh in 9.3 percent of patients."</p> <p>14 Would that count as shrinkage to you, a</p> <p>15 reduction of 50 percent of the mesh?</p> <p>16 A. At three months, it would count as shrinkage.</p> <p>17 But there are other studies that have followed them out</p> <p>18 later, that did not show shrinkage. And I would assume</p> <p>19 this shrinkage was due to implantation technique.</p> <p>20 MR. BENTLEY: Move to strike after the</p> <p>21 nonresponsive answer.</p> <p>22 BY MR. BENTLEY:</p> <p>23 Q. In the next paragraph, they continue, "Based</p> <p>24 on the currently available limited data, although many</p>
Page 79	Page 81
<p>1 Q. -- 27, the first --</p> <p>2 A. Right.</p> <p>3 Q. -- full paragraph.</p> <p>4 A. Right.</p> <p>5 Q. And my question was: Anywhere in your</p> <p>6 report, do you discuss your disagreement with the</p> <p>7 existence of mesh contraction, as evidenced in this</p> <p>8 position statement by AUGS and ACOG?</p> <p>9 A. This paragraph addresses that. But I don't</p> <p>10 specifically address this para -- this AUGS statement --</p> <p>11 Q. Can you please --</p> <p>12 A. -- this --</p> <p>13 Q. -- direct your attention to where you discuss</p> <p>14 that mesh contraction doesn't exist?</p> <p>15 A. Okay.</p> <p>16 Q. Well, counsel can probably revisit that on</p> <p>17 redirect.</p> <p>18 As you sit here today, can you explain to me</p> <p>19 why you disagree with ACOG's --</p> <p>20 A. Because I don't think the mesh contracts. I</p> <p>21 think the tissue around the mesh contracts.</p> <p>22 Q. Resulting in shrinkage?</p> <p>23 A. No. Shrinkage would mean that the mesh</p> <p>24 actually changes, goes from 6 centimeters to</p>	<p>1 patients who undergo mesh augmented vaginal repairs heal</p> <p>2 well without problems, there seems to be a small but</p> <p>3 significant group of patients who experience permanent</p> <p>4 and life-altering sequelae, including pain and</p> <p>5 dyspareunia, from the use of vaginal mesh."</p> <p>6 Did I read that correctly?</p> <p>7 A. You did.</p> <p>8 Q. And again, this is another piece of medical</p> <p>9 literature that you relied upon; correct?</p> <p>10 A. That's correct.</p> <p>11 Q. That's evidencing life-altering problems with</p> <p>12 these products; isn't that correct?</p> <p>13 MR. WALKER: Object to form.</p> <p>14 A. That's correct.</p> <p>15 Q. Okay. You simply disagree with their</p> <p>16 statement?</p> <p>17 A. I disagree.</p> <p>18 Q. Okay. And in your report, you don't discuss</p> <p>19 your disagreement with that statement from ACOG and</p> <p>20 AUGS; correct?</p> <p>21 A. No.</p> <p>22 Q. Okay. As you sit here today, can you explain</p> <p>23 why you don't believe that there's life-altering</p> <p>24 problems with these complications --</p>

21 (Pages 78 to 81)

Michael Karram, M.D.

Page 82	Page 84
<p>1 A. Because I --</p> <p>2 Q. -- as evidenced by this position statement?</p> <p>3 A. Because I've seen these patients and I've</p> <p>4 seen them over and over and over again; and you can --</p> <p>5 they can get treated; and there are many patients that</p> <p>6 don't have life-altering. So it depends on how you</p> <p>7 define "life-altering."</p> <p>8 Q. Okay. So just based on your personal</p> <p>9 experience treating women, you haven't seen it, so</p> <p>10 that's why you disagree with the medical literature?</p> <p>11 A. No. Based on my education, training, and</p> <p>12 experience, yes.</p> <p>13 Q. But the rest of your opinions in your report</p> <p>14 are based upon the medical literature; correct?</p> <p>15 A. And my education, experience, and training.</p> <p>16 Q. Right. But you can't, as you sit here today,</p> <p>17 provide any reason as to why you disagree with medical</p> <p>18 literature that you rely upon, other than your personal</p> <p>19 experience, including your training and experience and</p> <p>20 education?</p> <p>21 A. This isn't medical literature. This is a</p> <p>22 committee opinion. It's not medical literature.</p> <p>23 Medical literature is a meta-analysis, randomized</p> <p>24 control trial, prospective cohort, retrospective cohort.</p>	<p>1 Doctor, as you sit here today, can you please</p> <p>2 explain why you're discounting the conclusions of ACOG</p> <p>3 and AUGS, regarding the existence of evidence</p> <p>4 demonstrating life-altering complications associated</p> <p>5 with these products?</p> <p>6 A. Because, in looking at their references that</p> <p>7 they looked at, there are many other references that</p> <p>8 contradict what they're saying.</p> <p>9 Q. What references are you referring to that</p> <p>10 state there's no existence of life-altering</p> <p>11 complications related to these products?</p> <p>12 A. I don't know if there's a definition of</p> <p>13 "life-altering." So we can go back to that, but...</p> <p>14 Q. But this statement uses that terminology;</p> <p>15 correct?</p> <p>16 A. This statement uses that terminology --</p> <p>17 Q. And you indicate --</p> <p>18 A. -- in their --</p> <p>19 Q. -- in your report that these statements and</p> <p>20 these organizations are important to your opinions;</p> <p>21 correct?</p> <p>22 A. They are.</p> <p>23 Q. Okay. Doctor, is one of the reasons that you</p> <p>24 feel that the risk-benefit profile for Prolift is</p>
Page 83	Page 85
<p>1 The list goes on. This is a committee opinion.</p> <p>2 Q. And in your last deposition, you actually</p> <p>3 relied upon a committee opinion from these very</p> <p>4 organizations; isn't that correct?</p> <p>5 A. I relied on a statement -- position</p> <p>6 statement. That's different than a committee opinion.</p> <p>7 Q. And this committee opinion's actually a</p> <p>8 review of the medical literature; isn't that correct?</p> <p>9 A. In 2004.</p> <p>10 Q. Do you want to read the front page to correct</p> <p>11 your date?</p> <p>12 A. It says since 2004. Oh, I'm sorry, 2011.</p> <p>13 Okay. My --</p> <p>14 Q. Right. And this is a review --</p> <p>15 A. My mistake.</p> <p>16 Q. -- of the medical literature --</p> <p>17 A. Correct.</p> <p>18 Q. -- about up to the point when Prolift was</p> <p>19 withdrawn; isn't that correct?</p> <p>20 A. Well, let's see.</p> <p>21 (Off-the-record comments between Mr. Bentley</p> <p>22 and the court reporter.)</p> <p>23 BY MR. BENTLEY:</p> <p>24 Q. Withdraw.</p>	<p>1 beneficial is because you feel that native tissue</p> <p>2 repairs weren't as efficacious as the Prolift?</p> <p>3 A. In some people's hands, yes.</p> <p>4 Q. And is that based upon some earlier evidence,</p> <p>5 that native tissue repair wasn't as efficacious --</p> <p>6 A. Yes.</p> <p>7 Q. -- as hopeful?</p> <p>8 And, in fact, you discuss that information in</p> <p>9 your report; isn't that correct?</p> <p>10 A. I do.</p> <p>11 Q. Okay. And are you aware that some scientists</p> <p>12 went back and reevaluated that data and, in fact, found</p> <p>13 native tissue repair was more efficacious than</p> <p>14 previously thought?</p> <p>15 MR. WALKER: Object to form.</p> <p>16 A. That's not necessarily correct. But, yes --</p> <p>17 Q. Are you aware that --</p> <p>18 A. -- they did -- I am aware that they went back</p> <p>19 and looked at objective data and subjective data --</p> <p>20 Q. And they found that native --</p> <p>21 A. -- and they quantified it. It doesn't</p> <p>22 necessarily mean that it's any better. It just means</p> <p>23 that if the patient had a native tissue repair and she</p> <p>24 had a recurrence of her prolapse, but it didn't bother</p>

22 (Pages 82 to 85)

Michael Karram, M.D.

Page 86	Page 88
<p>1 her, then they considered that a positive result and</p> <p>2 that she didn't need a reoperation. That's what that</p> <p>3 study was about.</p> <p>4 Q. If you could please turn your attention to</p> <p>5 page 4 of this committee opinion reviewing the medical</p> <p>6 literature regarding --</p> <p>7 A. Okay.</p> <p>8 Q. -- this product. You can see, on the top</p> <p>9 left, it states, "A 2001 randomized trial of three</p> <p>10 methods of anterior wall repair, including native</p> <p>11 tissue, ultralateral anterior colporrhaphy, and</p> <p>12 absorbable vaginal mesh, reported success rates (based</p> <p>13 on anatomic success definitions) of only 30 to</p> <p>14 46 percent"?</p> <p>15 A. Correct.</p> <p>16 Q. And they have a citation that says "Study</p> <p>17 No. 22," which is the Weber --</p> <p>18 A. The Weber study.</p> <p>19 Q. -- study, 2001.</p> <p>20 A. That's correct.</p> <p>21 Q. And you actually cite to the Weber study in</p> <p>22 your report --</p> <p>23 A. I do.</p> <p>24 Q. -- on page 10?</p>	<p>1 the Cleveland Clinic, I think. But --</p> <p>2 Q. Right. Not just one surgeon; right?</p> <p>3 A. Well, but you can't -- you can't extrapolate</p> <p>4 that to the general population. Native tissue repairs</p> <p>5 are all done differently. If I do a native tissue</p> <p>6 repair and you do a native tissue repair, if you're a</p> <p>7 pelvic floor surgeon, we're going to do it differently.</p> <p>8 Q. Okay.</p> <p>9 A. Okay? So there's no standardization of</p> <p>10 native tissue repairs.</p> <p>11 Q. If you can draw your attention to the next</p> <p>12 section, Doctor --</p> <p>13 A. Um-hmm.</p> <p>14 Q. -- entitled "Who are the best patients for</p> <p>15 transvaginally placed mesh?" Second sentence, "Pelvic</p> <p>16 organ prolapse vaginal mesh repair should be reserved</p> <p>17 for high-risk individuals in whom the benefit of mesh</p> <p>18 placement may justify the risk, such as individuals with</p> <p>19 recurrent prolapse (particularly of the anterior</p> <p>20 compartment)" -- which we discussed; correct?</p> <p>21 A. Correct.</p> <p>22 Q. "...or with medical comorbidities that</p> <p>23 preclude more invasive and lengthier open and endoscopic</p> <p>24 procedures."</p>
Page 87	Page 89
<p>1 A. I do.</p> <p>2 Q. And then the authors of ACOG and AUGS go on</p> <p>3 to continue that "These low success rates were</p> <p>4 frequently cited as a reason why innovations such as</p> <p>5 vaginal mesh were needed to decrease failure rates."</p> <p>6 And we just discussed that; correct?</p> <p>7 A. Correct.</p> <p>8 Q. Okay. And they continue, "The original data</p> <p>9 from this study were recently reanalyzed using modern</p> <p>10 outcome measures (a composite of anatomic outcomes and</p> <p>11 subjective success), and the revised success rates for</p> <p>12 the three arms of this RCT" -- randomized control trial</p> <p>13 -- "were comparable, with 89 percent of women having no</p> <p>14 objective prolapse beyond the hymen."</p> <p>15 Did I read that correctly?</p> <p>16 A. You did.</p> <p>17 Q. And would you agree then an 89 percent</p> <p>18 success rate is pretty good?</p> <p>19 MR. WALKER: Object to form.</p> <p>20 A. In the hands of one surgeon, yes.</p> <p>21 Q. Okay. But the Weber study was using a</p> <p>22 database that wasn't just one surgeon; isn't that</p> <p>23 correct?</p> <p>24 A. It was -- no, it was a group of surgeons at</p>	<p>1 Would you agree with that, also?</p> <p>2 A. I would agree with that.</p> <p>3 Q. Okay. So you would agree with the author's</p> <p>4 statement here, that mesh kits such as Prolift should be</p> <p>5 reserved for high-risk patients?</p> <p>6 A. I do.</p> <p>7 Q. Okay. Doctor, are you aware that Anne Weber,</p> <p>8 the author of these original native tissue repair</p> <p>9 studies, has actually written reports in this very</p> <p>10 litigation?</p> <p>11 MR. WALKER: Object to form.</p> <p>12 A. For the plaintiff?</p> <p>13 Q. Yes.</p> <p>14 A. Yes.</p> <p>15 Q. Have you read her reports?</p> <p>16 A. I skimmed it.</p> <p>17 Q. Are you aware that her reports discussing</p> <p>18 this very issue are contrary to your opinions, using her</p> <p>19 very data?</p> <p>20 A. Yes.</p> <p>21 Q. That doesn't impact your opinion?</p> <p>22 A. Yes.</p> <p>23 Q. It does impact your opinions?</p> <p>24 A. Oh, no. No, I'm sorry, it doesn't. But I'm</p>

23 (Pages 86 to 89)

Michael Karram, M.D.

Page 90	Page 92
<p>1 aware that it's different than hers --</p> <p>2 Q. Okay.</p> <p>3 A. -- yes.</p> <p>4 Q. If you could turn to the page in your report</p> <p>5 -- to page 11 of Exhibit 1.</p> <p>6 A. Oh.</p> <p>7 Q. You had previously stated that you don't</p> <p>8 believe that the ACOG AUGS position statement is helpful</p> <p>9 evidence or reliable evidence; is that correct?</p> <p>10 MR. WALKER: Object to form.</p> <p>11 MR. BENTLEY: Strike that.</p> <p>12 BY MR. BENTLEY:</p> <p>13 Q. Doctor --</p> <p>14 A. Are you talk --</p> <p>15 Q. -- how would you characterize the AUGS</p> <p>16 position statement -- or the AUGS position statement, in</p> <p>17 the levels of evidence?</p> <p>18 Was it important enough to include in your</p> <p>19 report?</p> <p>20 A. Yes.</p> <p>21 Q. Okay. But they had some conclusions that</p> <p>22 were contrary to your opinions here; isn't that correct?</p> <p>23 A. Are you talking about the AUGS position --</p> <p>24 Q. Yes.</p>	<p>1 conclusions to your opinions here; correct?</p> <p>2 A. That's correct.</p> <p>3 Q. Okay. Doctor, on your report, on page 11,</p> <p>4 you begin discussing the evidence regarding Gynemesh PS,</p> <p>5 starting in 2002. Do you see that?</p> <p>6 A. On page 11 of my report?</p> <p>7 Q. Yes.</p> <p>8 A. Yes.</p> <p>9 Q. Okay.</p> <p>10 A. Okay.</p> <p>11 Q. And then on the next page, you cite to a</p> <p>12 number of studies, including the Nilsson 2013 study.</p> <p>13 Do you see that?</p> <p>14 A. Yes, I do.</p> <p>15 Q. Okay. And that's a study regarding the TVT</p> <p>16 mesh; right?</p> <p>17 A. That's correct.</p> <p>18 Q. Okay. And then you cite to the Ford Cochrane</p> <p>19 Review, also --</p> <p>20 A. Um-hmm.</p> <p>21 Q. -- 2015?</p> <p>22 And that's also another --</p> <p>23 A. Right.</p> <p>24 Q. -- study regarding the TVTs; right?</p>
Page 91	Page 93
<p>1 A. -- or are you talking about the ACOG</p> <p>2 committee report? You said the AUGS position. I'm a --</p> <p>3 Q. Well, it's AUGS --</p> <p>4 A. -- little confused.</p> <p>5 Q. -- it's -- let me re-ask.</p> <p>6 A. But that's an ACOG committee bulletin. So</p> <p>7 it's from ACOG. AUGS might have had some, you know,</p> <p>8 effect in drafting it --</p> <p>9 Q. Right.</p> <p>10 A. -- but it's an ACOG, it's not an AUGS --</p> <p>11 Q. That's fair.</p> <p>12 A. -- position statement.</p> <p>13 Q. I appreciate that.</p> <p>14 A. That's fine. So you're referring to this</p> <p>15 one?</p> <p>16 Q. Yes, sir.</p> <p>17 A. Okay.</p> <p>18 Q. So let me rephrase that. I'm sorry.</p> <p>19 A. Okay.</p> <p>20 Q. Was the ACOG 2011 committee opinion that we</p> <p>21 just reviewed, dated December 2011, important enough for</p> <p>22 you to include in your report?</p> <p>23 A. It was.</p> <p>24 Q. Okay. But the authors had some contrary</p>	<p>1 A. Yes.</p> <p>2 Q. Okay. Or midurethral slings; right?</p> <p>3 A. Midurethral, right.</p> <p>4 Q. And then, in the next paragraph, you cite to</p> <p>5 a number of studies, all published before the Prolift</p> <p>6 was available; isn't that correct?</p> <p>7 A. That's correct.</p> <p>8 Q. Okay. And then turning the page, turning to</p> <p>9 page 14, you begin discussing some of the Prolift data;</p> <p>10 is that correct?</p> <p>11 A. That's correct.</p> <p>12 Q. And then, on page 15, your first full</p> <p>13 paragraph states, "According to the latest Cochrane</p> <p>14 Review," and you cite Maher 2013.</p> <p>15 Do you see that?</p> <p>16 A. Yes.</p> <p>17 Q. And that's not a correct statement; isn't</p> <p>18 that correct? That was a horrible question.</p> <p>19 Now, on page 15, you start out, "According to</p> <p>20 the latest Cochrane Review Maher 2013..."</p> <p>21 A. Right.</p> <p>22 Q. That's not correct. There's a more recent</p> <p>23 Cochrane Review regarding mesh kits to treat prolapse;</p> <p>24 isn't that correct?</p>

24 (Pages 90 to 93)

Michael Karram, M.D.

Page 94	Page 96
<p>1 A. I'm not aware of it, if it is. If I cited</p> <p>2 it...</p> <p>3 Q. If you could turn your attention to page 18.</p> <p>4 A. Right.</p> <p>5 Q. On the bottom of the page, you discuss, "In</p> <p>6 the most recent Cochrane Review Maher 2016."</p> <p>7 Do you see that?</p> <p>8 A. Ah, okay.</p> <p>9 Q. So --</p> <p>10 A. Yes.</p> <p>11 Q. -- your discussion on page 15 is not actually</p> <p>12 of the latest Cochrane Review --</p> <p>13 A. That's correct.</p> <p>14 Q. -- isn't that correct?</p> <p>15 A. That's correct. And it might be a type</p> <p>16 error, I think. A typing error. It should be --</p> <p>17 Q. But if --</p> <p>18 A. But if it -- yeah.</p> <p>19 Q. If the data on page 15 is, in fact, from the</p> <p>20 Maher 2013 Cochrane Review, that's actually outdated,</p> <p>21 now, by the new 2016 Maher; isn't that correct?</p> <p>22 A. That's correct.</p> <p>23 Q. Okay. And so you would like to update that,</p> <p>24 maybe, to include the actual updated, most recent</p>	<p>1 Q. -- the most recent --</p> <p>2 A. You said on page 16. I'm sorry.</p> <p>3 MR. WALKER: 18.</p> <p>4 A. 18? Okay.</p> <p>5 Q. Page 18 --</p> <p>6 A. Gotcha.</p> <p>7 Q. -- you discussed --</p> <p>8 A. Gotcha.</p> <p>9 Q. The --</p> <p>10 A. Yes.</p> <p>11 Q. And you provide a couple of --</p> <p>12 A. Right.</p> <p>13 Q. -- findings from --</p> <p>14 A. No, no, I thought we were on page 16. I --</p> <p>15 Q. Okay. And --</p> <p>16 A. -- wasn't looking. Okay.</p> <p>17 Q. -- the findings you discuss in your report --</p> <p>18 A. Um-hmm, yes.</p> <p>19 Q. Well, let's look at the review.</p> <p>20 So, on Exhibit 7, page 2 --</p> <p>21 A. Okay.</p> <p>22 Q. -- under "Authors' Conclusions" --</p> <p>23 A. Yes.</p> <p>24 Q. -- they begin, "While transvaginal permanent</p>
Page 95	Page 97
<p>1 Cochrane Review that includes all of the current</p> <p>2 evidence; isn't that correct?</p> <p>3 A. That's correct.</p> <p>4 (Exhibit 7 marked for identification.)</p> <p>5 BY MR. BENTLEY:</p> <p>6 Q. Okay. And I'm going to hand you what's being</p> <p>7 marked as Exhibit 7, which is the 2016 Maher Cochrane</p> <p>8 Review.</p> <p>9 A. Okay.</p> <p>10 Q. Now, on page 18 of your report, you discuss a</p> <p>11 number of findings from the 2016 Maher Review; isn't</p> <p>12 that correct?</p> <p>13 A. Yes.</p> <p>14 Q. Okay. And let's look at Exhibit 7, that we</p> <p>15 just marked, which is the Maher Cochrane Review.</p> <p>16 If you could turn to page 2.</p> <p>17 A. Now, wait a minute. Can you go back? What</p> <p>18 did you say on the last one?</p> <p>19 Q. I was referencing --</p> <p>20 A. The Maher -- on page 16.</p> <p>21 Q. On page 8 -- well --</p> <p>22 A. Oh.</p> <p>23 Q. -- we agreed that page 15 is not --</p> <p>24 A. Yes, yes.</p>	<p>1 mesh is associated with lower rates of awareness of</p> <p>2 prolapse, reoperation for prolapse, and prolapse on</p> <p>3 examination than native tissue repair, it is also</p> <p>4 associated with higher rates of reoperation for prolapse</p> <p>5 or stress urinary incontinence or mesh exposure and</p> <p>6 higher rates of bladder injury at surgery and de novo</p> <p>7 stress urinary incontinence."</p> <p>8 Did I read that correctly?</p> <p>9 A. You did.</p> <p>10 Q. Okay. And we've discussed some studies that</p> <p>11 found that similar finding, that there's a higher</p> <p>12 reoperation rate if you include all of these different</p> <p>13 surgical procedures that might happen after a Prolift</p> <p>14 implant; isn't that correct?</p> <p>15 A. Correct.</p> <p>16 Q. Okay. And they continue, "The risk-benefit</p> <p>17 profile means that transvaginal mesh has limited utility</p> <p>18 in primary surgery."</p> <p>19 Did I read that correctly?</p> <p>20 A. You did.</p> <p>21 Q. And, Doctor, you would agree with that,</p> <p>22 because you've previously testified that you think</p> <p>23 Prolift is appropriate for some patients, but not</p> <p>24 necessarily for all patients; isn't that correct?</p>

25 (Pages 94 to 97)

Michael Karram, M.D.

Page 98	Page 100
<p>1 MR. WALKER: Object to form.</p> <p>2 A. That's correct.</p> <p>3 Q. And they continue, "While it is possible that</p> <p>4 in women with higher risk of recurrence the benefits may</p> <p>5 outweigh the risks, there is currently no evidence to</p> <p>6 support this position."</p> <p>7 Did I read that correctly?</p> <p>8 A. Yes.</p> <p>9 Q. Now, you disagree with that sentence from</p> <p>10 these authors; correct?</p> <p>11 A. Correct.</p> <p>12 Q. And nowhere in your report do you provide an</p> <p>13 analysis or criticism of why you disagree with this</p> <p>14 conclusion; isn't that correct?</p> <p>15 A. No. But I think I support -- show other data</p> <p>16 that contradicts that.</p> <p>17 Q. Okay.</p> <p>18 A. Okay?</p> <p>19 Q. If you could please turn your attention to</p> <p>20 the next page. Under the section "Key Results" --</p> <p>21 A. Yes.</p> <p>22 Q. -- the first paragraph, the second-to-last</p> <p>23 sentence, they state, "If the reoperation rate for</p> <p>24 prolapse urinary incontinence or mesh exposure after</p>	<p>1 correctly, and this is what the data shows; is that</p> <p>2 fair?</p> <p>3 A. Correct.</p> <p>4 MR. WALKER: Object to form.</p> <p>5 Q. And then they continue, "Eight percent of</p> <p>6 women in the mesh groups required repeat surgery for</p> <p>7 mesh exposure."</p> <p>8 Is that correct?</p> <p>9 A. Where is that?</p> <p>10 Q. Very last sentence. I'm sorry. They</p> <p>11 conclude that paragraph, "Eight percent" --</p> <p>12 A. Oh, yeah, it's written out. I'm looking for</p> <p>13 an "8." Okay, I gotcha.</p> <p>14 Q. Did I read that correctly?</p> <p>15 A. Yes, you did.</p> <p>16 Q. Okay. And again, you don't have any</p> <p>17 criticisms of them reaching that finding based off the</p> <p>18 data they looked at; right?</p> <p>19 A. No.</p> <p>20 Q. And this is, as we discussed, one of the</p> <p>21 Level 1 evidence, a systematic review; correct?</p> <p>22 A. Correct.</p> <p>23 Q. This is the highest evidence you can get;</p> <p>24 correct?</p>
Page 99	Page 101
<p>1 native tissue repair is assumed to be 5 percent, the</p> <p>2 risk would be between 7 percent and 8 [sic] percent</p> <p>3 after permanent mesh repair."</p> <p>4 Did I read that correct?</p> <p>5 A. 7 and 18 percent.</p> <p>6 Q. Right. So they're saying that mesh kits,</p> <p>7 like Prolift, have a higher reoperation rate --</p> <p>8 A. After permanent mesh repair.</p> <p>9 MR. WALKER: Object to form.</p> <p>10 Q. Is that correct?</p> <p>11 A. That's correct. That's what it says.</p> <p>12 Q. Do you agree with that finding?</p> <p>13 A. Well, I don't agree with the fact that you</p> <p>14 can assume reoperation rate with the native tissue</p> <p>15 repair is 5 percent.</p> <p>16 Q. I appreciate that. But my question is: Do</p> <p>17 you have any criticism or critique of their analysis, in</p> <p>18 reviewing all of this medical literature that reach this</p> <p>19 conclusion that --</p> <p>20 A. No.</p> <p>21 Q. -- we just read?</p> <p>22 A. No.</p> <p>23 Q. So you feel okay, assuming that they did</p> <p>24 their calculations right, they looked at the evidence</p>	<p>1 The Cochrane Review group's very reputable;</p> <p>2 correct?</p> <p>3 A. Yes.</p> <p>4 Q. And, in fact, you rely upon this group;</p> <p>5 correct?</p> <p>6 A. Right.</p> <p>7 Q. And they looked at all the data and came to</p> <p>8 these conclusions based off that data; isn't that</p> <p>9 correct?</p> <p>10 A. That's correct.</p> <p>11 Q. And they have findings. And you agree with</p> <p>12 their findings, you just disagree with their</p> <p>13 conclusions; correct?</p> <p>14 A. Correct.</p> <p>15 Q. Okay. And nowhere in your report do you</p> <p>16 provide an analysis of why you disagree with their</p> <p>17 conclusions, other than you cite to some other evidence?</p> <p>18 A. Correct.</p> <p>19 Q. And, lastly, if you could turn your attention</p> <p>20 to page 16, please.</p> <p>21 A. Of my report or --</p> <p>22 Q. I'm sorry, of the Cochrane --</p> <p>23 A. Cochrane?</p> <p>24 Q. Sorry.</p>

26 (Pages 98 to 101)

Michael Karram, M.D.

Page 102	Page 104
<p>1 A. Okay.</p> <p>2 Q. On 16, under Section 1.4.2...</p> <p>3 A. Got it.</p> <p>4 Q. On page 16, the authors of the Cochrane</p> <p>5 Review have a section entitled "1.4.2 mesh Exposure."</p> <p>6 A. Okay.</p> <p>7 Q. And, here, they're looking at 19 RCTs, one to</p> <p>8 three-year review. Do you see that?</p> <p>9 A. Yes.</p> <p>10 Q. And we discussed, the RCTs are also in the</p> <p>11 highest level of evidence; correct?</p> <p>12 A. They are.</p> <p>13 Q. And they looked at 19 of them. And they</p> <p>14 state, "While a woman undergoing a native tissue repair</p> <p>15 has no risk of mesh exposure, overall, 134 out of 1,097,</p> <p>16 or 12 percent, women in the transvaginal permanent mesh</p> <p>17 groups had mesh exposure."</p> <p>18 Did I read that correctly?</p> <p>19 A. Yes, you did.</p> <p>20 Q. Okay. And they're just stating that after</p> <p>21 they looked at 19 RTCs, they found that 12 percent of</p> <p>22 the women had exposure; correct?</p> <p>23 A. Correct.</p> <p>24 Q. Okay. And then, as we were discussing</p>	<p>1 A. I do not.</p> <p>2 Q. Okay. Doctor, if you could turn back to</p> <p>3 Exhibit 1, your report. On page 19 --</p> <p>4 A. Okay.</p> <p>5 Q. -- you have a section entitled "Mesh</p> <p>6 Exposure." Do you see that?</p> <p>7 A. Yes.</p> <p>8 Q. Okay. And you start, "An overall mesh</p> <p>9 explosive rate of 3 to 8 percent is an acceptable rate</p> <p>10 by today's standards."</p> <p>11 Did I read that correctly?</p> <p>12 A. Yes, you did.</p> <p>13 Q. And we just looked at the Cochrane Review</p> <p>14 that found at least a 50 percent higher exposure rate;</p> <p>15 correct?</p> <p>16 A. Correct.</p> <p>17 Q. What is your standard for determining what's</p> <p>18 an acceptable rate of erosion?</p> <p>19 A. Just the medical literature and my experience</p> <p>20 and education.</p> <p>21 Q. Okay. And the Cochrane Review from 2016,</p> <p>22 from this year, actually found at least a 50 percent</p> <p>23 higher rate; isn't that correct?</p> <p>24 A. That's correct.</p>
Page 103	Page 105
<p>1 earlier, down in Section 1.4.4 on that same page, they</p> <p>2 state that "Surgery for mesh exposure was required in</p> <p>3 8 percent of women, 100 out of 1227."</p> <p>4 Did I read that correctly?</p> <p>5 A. Yes.</p> <p>6 Q. Okay. And so of the, you know, 12 percent of</p> <p>7 women that had erosion, 8 percent of all of the women,</p> <p>8 overall, had to have surgery for that erosion; correct?</p> <p>9 A. Correct.</p> <p>10 MR. WALKER: I'm sorry, counselor, where was</p> <p>11 the 8 percent?</p> <p>12 MR. BENTLEY: At the bottom of the page on</p> <p>13 16, under 1.4.4.</p> <p>14 MR. WALKER: Got it. Thanks.</p> <p>15 BY MR. BENTLEY:</p> <p>16 Q. So, well over half of the women that had the</p> <p>17 erosion had to have some sort of surgical revision</p> <p>18 procedure to treat their --</p> <p>19 A. Correct.</p> <p>20 Q. And that's consistent with your review of the</p> <p>21 medical literature; correct?</p> <p>22 A. Correct.</p> <p>23 Q. And you don't have any reason to doubt the</p> <p>24 findings of the Cochrane Review, do you?</p>	<p>1 Q. Okay. So would you like to update your</p> <p>2 report, where you said that 3 to 8 percent is</p> <p>3 acceptable?</p> <p>4 A. No, I don't go -- I'm not just looking at the</p> <p>5 Cochrane; I'm looking at everything. And most of the</p> <p>6 randomized trials and most of the experts in the field</p> <p>7 think that a 3 to 8 percent is acceptable in today's</p> <p>8 standards.</p> <p>9 Q. So, if it was well above that, would it be</p> <p>10 unacceptable?</p> <p>11 A. It would be above the standard.</p> <p>12 Q. Okay. So if, in fact, the exposure rate was</p> <p>13 12 percent, that would be above the standard by today's</p> <p>14 standards?</p> <p>15 A. I would think so, yes.</p> <p>16 Q. Okay. And the Cochrane Review actually</p> <p>17 looked at 19 RCTs; correct?</p> <p>18 A. Correct.</p> <p>19 Q. Okay. Doctor, if you could turn to page 21</p> <p>20 in your report. We briefly looked at this earlier, but</p> <p>21 I forgot to ask.</p> <p>22 A. Okay.</p> <p>23 Q. Your section's entitled "Adequacy of company</p> <p>24 IFU in patient brochures."</p>

27 (Pages 102 to 105)

Michael Karram, M.D.

Page 106	Page 108
<p>1 Do you see that?</p> <p>2 A. Yes, I do.</p> <p>3 Q. Did you look at any patient brochures?</p> <p>4 A. I've seen them, yes.</p> <p>5 Q. Okay. But in your report, do you discuss any</p> <p>6 of their brochures or why you feel they're adequate?</p> <p>7 A. Patient brochures?</p> <p>8 Q. Yes.</p> <p>9 A. I didn't discuss them, no. But I've used</p> <p>10 them with patients.</p> <p>11 Q. Okay.</p> <p>12 A. And so I know of them and I've seen them.</p> <p>13 And we used to use them in the courses.</p> <p>14 Q. Okay. But you don't present or disclose any</p> <p>15 opinions regarding the patient brochures in your report;</p> <p>16 correct?</p> <p>17 A. Other than my experience with them has been</p> <p>18 they're adequate.</p> <p>19 Q. Sure. But in your report, you don't have a</p> <p>20 single sentence discussing patient brochures, correct,</p> <p>21 other than that section header?</p> <p>22 A. No. No. No. Correct.</p> <p>23 Q. And like the legal regulatory requirements</p> <p>24 for the IFUs, you haven't reviewed those same</p>	<p>1 Q. And what study is that?</p> <p>2 A. It's a study that -- I think it was quoted</p> <p>3 with -- what's his name -- I can't remember. I do have</p> <p>4 a study. I don't know which one it is, but I do have a</p> <p>5 study that gives you the reaction to mesh from</p> <p>6 implantation to six to eight weeks, and at that point it</p> <p>7 shows no foreign-body reaction.</p> <p>8 Q. So you haven't reviewed any documents from</p> <p>9 Ethicon scientists discussing the existence of a chronic</p> <p>10 and ongoing foreign-body reaction related --</p> <p>11 A. No.</p> <p>12 Q. -- to polypropylene implants?</p> <p>13 A. No.</p> <p>14 MR. WALKER: Object to form.</p> <p>15 Q. Would you have liked to have seen those</p> <p>16 documents, if they exist?</p> <p>17 A. In the context of whatever they were</p> <p>18 discussing.</p> <p>19 Q. Right.</p> <p>20 A. Yeah.</p> <p>21 Q. And would you agree that the foreign-body</p> <p>22 reaction and the inflammatory processes that occurred --</p> <p>23 those can lead to scarring and scar plating?</p> <p>24 MR. WALKER: Object to form.</p>
Page 107	Page 109
<p>1 requirements for patient labeling; correct?</p> <p>2 MR. WALKER: Object to form.</p> <p>3 A. No. I didn't even know there was regulation</p> <p>4 for patient labeling.</p> <p>5 Q. And have you reviewed the Ethicon internal</p> <p>6 standards for patient labeling?</p> <p>7 A. I have not.</p> <p>8 Q. Okay. And have you reviewed Ethicon's</p> <p>9 internal standards for what needs to go into an IFU?</p> <p>10 A. No.</p> <p>11 Q. Okay. Doctor, do you have an understanding</p> <p>12 of whether or not the mesh in the Prolift elicits a</p> <p>13 foreign-body reaction in the body?</p> <p>14 A. It does.</p> <p>15 Q. Okay. And does that continue for as long as</p> <p>16 the implant is inside the woman's body?</p> <p>17 A. I don't think so, no.</p> <p>18 Q. You think the foreign-body reaction, at some</p> <p>19 point, stops?</p> <p>20 A. It ends at about six to eight weeks.</p> <p>21 Q. Okay. And what evidence are you relying upon</p> <p>22 for that opinion?</p> <p>23 A. Some explanted evidence that was done in</p> <p>24 rats, I think.</p>	<p>1 A. That can, yes.</p> <p>2 Q. Do you have an understanding that the</p> <p>3 foreign-body reaction, leading into the scar plating,</p> <p>4 can lead to pain for a woman?</p> <p>5 MR. WALKER: Object to form.</p> <p>6 A. I don't think the scar plating is the cause</p> <p>7 of pain, no.</p> <p>8 Q. Okay. Do you know whether the amount of mesh</p> <p>9 implanted impacts the intensity of the foreign-body</p> <p>10 reaction?</p> <p>11 A. Well, the more mesh, the more foreign-body</p> <p>12 reaction, yes.</p> <p>13 Q. So you would agree that with a bigger piece</p> <p>14 of mesh, there's more foreign body reaction?</p> <p>15 A. Yes.</p> <p>16 Q. Which could potentially lead to more scar</p> <p>17 plating; correct?</p> <p>18 MR. WALKER: Object to form.</p> <p>19 A. Yes.</p> <p>20 Q. Doctor, are you familiar with bridging</p> <p>21 fibrosis?</p> <p>22 A. I am not.</p> <p>23 Q. You haven't reviewed any of the medical</p> <p>24 literature regarding bridging fibrosis in mesh implants?</p>

28 (Pages 106 to 109)

Michael Karram, M.D.

Page 110	Page 112
<p>1 A. I haven't seen anything specific to bridging</p> <p>2 fibrosis.</p> <p>3 Q. And you haven't reviewed any of Ethicon's</p> <p>4 internal documents discussing bridging fibrosis and the</p> <p>5 Prolift implant?</p> <p>6 A. No.</p> <p>7 Q. Doctor, if you could please turn to page 18</p> <p>8 of your report.</p> <p>9 A. Do you mind if I stand while I talk to you?</p> <p>10 Q. Sure.</p> <p>11 A. Are you sure?</p> <p>12 Q. No video.</p> <p>13 A. What's that?</p> <p>14 Q. If you turn to 18 --</p> <p>15 A. I got it, yeah.</p> <p>16 Q. -- in your report.</p> <p>17 A. Okay.</p> <p>18 Q. Your first full paragraph, you state,</p> <p>19 "Medical societies (ACOG, AUGS, SUFU, AUA, SGS) have all</p> <p>20 put four favorable position statements in regards to</p> <p>21 mesh used in pelvic organ prolapse." Is that correct?</p> <p>22 A. Correct.</p> <p>23 Q. Okay. And we just looked at a committee</p> <p>24 opinion by ACOG. Do you remember that?</p>	<p>1 MR. WALKER: Object to form.</p> <p>2 A. Because pelvic floor surgeons learn from</p> <p>3 training, from working with other pelvic floor surgeons,</p> <p>4 from their experience, the medical literature, and their</p> <p>5 experience with their patients. And these are all</p> <p>6 complications that can occur with any type of pelvic</p> <p>7 organ prolapse.</p> <p>8 Q. Okay. So you're not citing to any specific</p> <p>9 study reviewing the general knowledge of surgeons; is</p> <p>10 that fair?</p> <p>11 A. No.</p> <p>12 Q. Okay. And you haven't --</p> <p>13 A. That's correct.</p> <p>14 Q. And you haven't undertaken any type of effort</p> <p>15 to poll or take a survey of the other doctors; correct?</p> <p>16 A. No.</p> <p>17 Q. And we discussed that some surgeons have less</p> <p>18 access to medical literature than you do; correct?</p> <p>19 MR. WALKER: Object to form.</p> <p>20 A. Maybe not less access, but knowledge of</p> <p>21 medical literature.</p> <p>22 Q. Okay.</p> <p>23 A. Okay?</p> <p>24 Q. And so it would be fair to say that maybe</p>
Page 111	Page 113
<p>1 A. Yes.</p> <p>2 Q. Okay. And it was critical of using these</p> <p>3 mesh-based kits such as Prolift; correct?</p> <p>4 A. Correct.</p> <p>5 Q. Okay. So that opinion in your report isn't</p> <p>6 entirely accurate; isn't that correct?</p> <p>7 A. That's correct.</p> <p>8 Q. Doctor, if you could please turn your</p> <p>9 attention to page 20 in your report.</p> <p>10 A. Okay.</p> <p>11 Q. In that first paragraph, halfway through, you</p> <p>12 state, "It's common knowledge for pelvic floor surgeons</p> <p>13 that any surgery for stress urinary incontinence or</p> <p>14 pelvic organ prolapse, with or without the use of mesh,</p> <p>15 can potentially cause complications that can be</p> <p>16 temporary or permanent, including, but not limited to,</p> <p>17 pelvic pain, dyspareunia, or pain with sexual</p> <p>18 intercourse, scarring, vaginal narrowing, leg/groin</p> <p>19 pain, urinary retention, and other voiding problems."</p> <p>20 Did I read that correctly?</p> <p>21 A. You did.</p> <p>22 Q. Okay. And what's your basis for opining as</p> <p>23 to what the common knowledge is of all pelvic floor</p> <p>24 surgeons?</p>	<p>1 some doctors don't have the same level of knowledge as</p> <p>2 you might; isn't that fair?</p> <p>3 MR. WALKER: Object to form.</p> <p>4 A. That's correct.</p> <p>5 Q. Would you agree that Ethicon has access to</p> <p>6 the best information regarding the frequency and</p> <p>7 severity of complications related to its devices?</p> <p>8 MR. WALKER: Object to form.</p> <p>9 A. Not necessarily.</p> <p>10 Q. Would you agree that Ethicon has access to</p> <p>11 all the medical literature that you might have access</p> <p>12 to?</p> <p>13 A. Yes.</p> <p>14 Q. And Ethicon also has access to internal data;</p> <p>15 is that correct?</p> <p>16 A. That's correct.</p> <p>17 Q. And Ethicon has access to adverse events that</p> <p>18 are reported to its company from doctors like you;</p> <p>19 correct?</p> <p>20 A. Correct.</p> <p>21 Q. Okay. So Ethicon has access to a wealth of</p> <p>22 information regarding the complications of its devices;</p> <p>23 correct?</p> <p>24 MR. WALKER: Object to form.</p>

29 (Pages 110 to 113)

Michael Karram, M.D.

Page 114	Page 116
<p>1 A. Correct.</p> <p>2 Q. Would you agree that it would be reasonable</p> <p>3 for a company like Ethicon to share that information</p> <p>4 with doctors, in case they don't have your level of</p> <p>5 knowledge regarding the complications of these devices?</p> <p>6 MR. WALKER: Object to form.</p> <p>7 A. They did. I think they did.</p> <p>8 MR. BENTLEY: I'm sorry, I'm going to move to</p> <p>9 strike.</p> <p>10 THE WITNESS: Okay.</p> <p>11 BY MR. BENTLEY:</p> <p>12 Q. That wasn't exactly my question, though.</p> <p>13 A. Oh.</p> <p>14 Q. Doctor, would you agree that it would be</p> <p>15 reasonable for a company like Ethicon to share that</p> <p>16 information with doctors, in case those doctors don't</p> <p>17 have your level of knowledge regarding the complications</p> <p>18 of devices like Prolift?</p> <p>19 Would you agree that that would be</p> <p>20 reasonable, for Ethicon to share that information?</p> <p>21 MR. WALKER: Object to form.</p> <p>22 A. Yes.</p> <p>23 Q. Would you agree that it would be reasonable</p> <p>24 for Ethicon to share that information with doctors via</p>	<p>1 choose to undergo a procedure to have one of these</p> <p>2 devices permanently implanted; isn't that correct?</p> <p>3 MR. WALKER: Object to form.</p> <p>4 A. Correct.</p> <p>5 Q. And if patients don't have that information,</p> <p>6 they can't make an informed consent; isn't that correct?</p> <p>7 MR. WALKER: Object to form.</p> <p>8 A. That's correct.</p> <p>9 Q. Doctor, you offer opinions as to the adequacy</p> <p>10 of the warnings provided by Ethicon; isn't that correct?</p> <p>11 A. That's correct.</p> <p>12 Q. And you've reviewed the IFUs; isn't that</p> <p>13 correct?</p> <p>14 A. That's correct.</p> <p>15 Q. Do you understand that there's been multiple</p> <p>16 drafts of IFUs for the Prolift devices?</p> <p>17 A. I do.</p> <p>18 Q. Do you know what --</p> <p>19 MR. WALKER: Object to form.</p> <p>20 I'm sorry. Drafts, are you referring to</p> <p>21 actual IFUs or drafts of --</p> <p>22 MR. BENTLEY: I'll clear that.</p> <p>23 BY MR. BENTLEY:</p> <p>24 Q. Doctor, do you understand that there's been</p>
Page 115	Page 117
<p>1 the IFU or via a dear-healthcare-provider letter?</p> <p>2 MR. WALKER: Object to form.</p> <p>3 Q. Would that be reasonable?</p> <p>4 A. I don't think they need to put it in the IFU.</p> <p>5 MR. BENTLEY: Sorry, I move to strike as</p> <p>6 nonresponsive. Let me re-ask the question.</p> <p>7 BY MR. BENTLEY:</p> <p>8 Q. Would you agree that it would be reasonable</p> <p>9 for a company like Ethicon to share that information via</p> <p>10 the IFU or a dear-healthcare-provider, or some other way</p> <p>11 to get the information out to doctors, in case not all</p> <p>12 doctors had access to the information such as you?</p> <p>13 MR. WALKER: Object to form.</p> <p>14 Q. Would that be reasonable?</p> <p>15 A. Yes.</p> <p>16 Q. Okay. And, ultimately, that information</p> <p>17 regarding the complications, that's important to</p> <p>18 patients because that involves safety; isn't that</p> <p>19 correct?</p> <p>20 A. That's correct.</p> <p>21 Q. And that's important for the informed consent</p> <p>22 for the patient to make an informed decision, so they</p> <p>23 know what the risks are and what the true risks or</p> <p>24 complications regarding the device is, before they</p>	<p>1 multiple versions or iterations of final Prolift IFUs</p> <p>2 that Ethicon's released? Do you understand that there's</p> <p>3 been multiple versions of it?</p> <p>4 A. Yes.</p> <p>5 Q. And do you know which versions of the IFU</p> <p>6 you've reviewed to reach your --</p> <p>7 A. At one time or another --</p> <p>8 Q. -- opinions in this case?</p> <p>9 A. -- I've reviewed all of them.</p> <p>10 Q. Okay. And so is your opinion that all of the</p> <p>11 IFUs adequately warn doctors?</p> <p>12 A. I think the earlier IFUs had less warnings</p> <p>13 than the later IFUs.</p> <p>14 Q. And, ultimately, Ethicon decided to add more</p> <p>15 warning information; is that correct?</p> <p>16 A. That's correct.</p> <p>17 Q. And you would agree, that was reasonable?</p> <p>18 A. I would agree that was reasonable, yes.</p> <p>19 Q. And that could be helpful for patient safety;</p> <p>20 correct?</p> <p>21 MR. WALKER: Object to form.</p> <p>22 A. Yes.</p> <p>23 Q. Okay. And if Ethicon actually had the</p> <p>24 information available when it first put out the Prolift</p>

30 (Pages 114 to 117)

Michael Karram, M.D.

Page 118	Page 120
<p>1 IFU, regarding those complications and safety</p> <p>2 information -- if Ethicon had that information from the</p> <p>3 very beginning, should Ethicon have put that information</p> <p>4 in the IFU from the very beginning?</p> <p>5 MR. WALKER: Object to form.</p> <p>6 A. Any information that they had that was</p> <p>7 scientific, yes.</p> <p>8 Q. Okay. So let me clean that up.</p> <p>9 A. Okay.</p> <p>10 Q. Through time, Ethicon released a number of</p> <p>11 updated Prolift IFUs; correct?</p> <p>12 A. That's correct.</p> <p>13 Q. And we've discussed that, ultimately, Ethicon</p> <p>14 added more information regarding those warnings into the</p> <p>15 IFU; correct?</p> <p>16 A. That's correct.</p> <p>17 Q. And if Ethicon had had the information</p> <p>18 regarding those complications and that safety data from</p> <p>19 the very beginning, would you agree that Ethicon should</p> <p>20 have put that information in the very first IFU?</p> <p>21 MR. WALKER: Object to form.</p> <p>22 A. If they had the information, yes.</p> <p>23 Q. Doctor, do you think it's helpful for doctors</p> <p>24 if information regarding the appropriate patient for the</p>	<p>1 A. Patients who were high risk, for patients who</p> <p>2 are high risk for failure or recurrences, or advanced</p> <p>3 prolapse patients or patients who were, from a physical</p> <p>4 standpoint, a native tissue repair, and a large open</p> <p>5 repair would be detrimental to their health. Just</p> <p>6 clinical aspects like that. Yes.</p> <p>7 Q. It's your testimony that that was Ethicon's</p> <p>8 understanding of who the appropriate patient was for</p> <p>9 Prolift; is that correct?</p> <p>10 A. That --</p> <p>11 MR. WALKER: Object to form.</p> <p>12 A. Yes, that's my understanding.</p> <p>13 Q. And you agree that that information should</p> <p>14 have been put out there by Ethicon; correct?</p> <p>15 MR. WALKER: Object to form.</p> <p>16 A. It was.</p> <p>17 Q. I'm sorry. I'm just striking out.</p> <p>18 A. Well, you asked me.</p> <p>19 Q. Sorry.</p> <p>20 A. Because I was the one that put it out. When</p> <p>21 I give these courses, that's what I told the doctors.</p> <p>22 So it was out there.</p> <p>23 Q. Appreciate that.</p> <p>24 A. I appreciate that.</p>
Page 119	Page 121
<p>1 Prolift procedure had been conveyed to them from</p> <p>2 Ethicon?</p> <p>3 MR. WALKER: Object to form.</p> <p>4 A. Patient selection? No.</p> <p>5 Q. Bad question.</p> <p>6 We discussed, today, that you don't believe</p> <p>7 that the Prolift device is the appropriate device for</p> <p>8 every patient for a primary surgery; correct?</p> <p>9 MR. WALKER: Object to form.</p> <p>10 A. That's correct.</p> <p>11 Q. If Ethicon also had that same belief, that</p> <p>12 the Prolift was not appropriate for every patient</p> <p>13 suffering from prolapse, do you think it would have been</p> <p>14 helpful for Ethicon to get that information out to</p> <p>15 doctors?</p> <p>16 MR. WALKER: Object to form.</p> <p>17 A. Yes.</p> <p>18 Q. Do you know, as you sit here today, whether</p> <p>19 or not Ethicon internally believed that Prolift was not</p> <p>20 appropriate for all patients?</p> <p>21 A. Yes.</p> <p>22 Q. What's your understanding as to Ethicon's</p> <p>23 position on the appropriateness of the Prolift device</p> <p>24 for patients?</p>	<p>1 Q. I'm going to re-ask.</p> <p>2 A. Okay.</p> <p>3 Q. Can you agree that it would have been</p> <p>4 reasonable for Ethicon to put that information out there</p> <p>5 to doctors, regarding which patients the Prolift was</p> <p>6 appropriate for?</p> <p>7 A. Yes.</p> <p>8 Q. Yes. Okay.</p> <p>9 A. Okay.</p> <p>10 MR. BENTLEY: Doctor, thank you. That's all</p> <p>11 the questions I have.</p> <p>12 EXAMINATION</p> <p>13 BY MR. WALKER:</p> <p>14 Q. Doctor, let's begin --</p> <p>15 A. Let's do it.</p> <p>16 Q. -- where we ended.</p> <p>17 A. Yes, redirect.</p> <p>18 Q. All right.</p> <p>19 A. Famous words.</p> <p>20 Q. Doctor, I direct your attention to page 21 of</p> <p>21 your report.</p> <p>22 THE WITNESS: Do they get -- do you get to</p> <p>23 keep my articles that I brought?</p> <p>24 THE REPORTER: I do. I will give you the</p>

31 (Pages 118 to 121)

Michael Karram, M.D.

Page 122	Page 124
<p>1 originals back when I finalize --</p> <p>2 THE WITNESS: Oh, okay.</p> <p>3 BY MR. WALKER:</p> <p>4 Q. I direct your attention to page 21 --</p> <p>5 A. Okay.</p> <p>6 Q. -- of your report.</p> <p>7 A. Got it.</p> <p>8 Q. Specifically, the last paragraph.</p> <p>9 A. Um-hmm.</p> <p>10 Q. Doctor, you opine, in your report, that the</p> <p>11 Prolift IFU, in addition to other materials, adequately</p> <p>12 describes the risks that are specifically unique to</p> <p>13 Prolift; is that correct?</p> <p>14 MR. BENTLEY: Objection.</p> <p>15 A. That's correct.</p> <p>16 Q. And, Doctor, what is the basis for your</p> <p>17 opinion that the Prolift IFU adequately describes the</p> <p>18 risks that are specific or unique to Prolift?</p> <p>19 MR. BENTLEY: Objection.</p> <p>20 A. Based on the possible risks associated with</p> <p>21 Prolift, itself, I think they elicit them correctly.</p> <p>22 And based on the fact that any other pelvic organ</p> <p>23 prolapse can have other risks, and they don't have to</p> <p>24 list those if -- it should be common knowledge with</p>	<p>1 A. I am.</p> <p>2 Q. And how are you familiar with it?</p> <p>3 A. This was used for some of the teaching</p> <p>4 programs that we had with cadaver labs.</p> <p>5 Q. And was this a document that Ethicon provided</p> <p>6 to doctors not employed by the company?</p> <p>7 A. Yes.</p> <p>8 MR. BENTLEY: Objection, leading, scope.</p> <p>9 Q. And how do you know that?</p> <p>10 A. Because I saw them hand it out.</p> <p>11 Q. And does this document contain information</p> <p>12 about appropriate patient selection for a Prolift</p> <p>13 procedure?</p> <p>14 MR. BENTLEY: Objection.</p> <p>15 A. It does.</p> <p>16 Q. And does this document contain information</p> <p>17 about the risks or complications that are -- that can be</p> <p>18 associated with the Prolift device?</p> <p>19 MR. BENTLEY: Objection, leading.</p> <p>20 A. Yes.</p> <p>21 Q. And is this a document that you reviewed and</p> <p>22 relied upon in forming your opinions about the adequacy</p> <p>23 of the information Ethicon provided to the medical</p> <p>24 community?</p>
Page 123	Page 125
<p>1 pelvic floor surgeons, which I think it is.</p> <p>2 Q. And are your reasons for thinking that</p> <p>3 fleshed out on page 22 of your report?</p> <p>4 A. It is.</p> <p>5 MR. BENTLEY: Objection.</p> <p>6 Q. One of the documents that you mention on</p> <p>7 page 21 is the Surgeon's Resource Monograph for Prolift;</p> <p>8 correct?</p> <p>9 A. That's correct.</p> <p>10 MR. WALKER: I'd like to mark that. I'm</p> <p>11 going to mark this as Exhibit 8. And I only have</p> <p>12 one copy. I'm going to look on with you.</p> <p>13 THE WITNESS: All right.</p> <p>14 MR. WALKER: I've only got one copy.</p> <p>15 (Exhibit 8 marked for identification.)</p> <p>16 BY MR. WALKER:</p> <p>17 Q. If you'll turn the page. And then, on the</p> <p>18 third page, I think, essentially -- do you see that</p> <p>19 third page?</p> <p>20 A. Yes.</p> <p>21 Q. First of all, are you familiar with the</p> <p>22 Surgeon's Monograph that you're holding?</p> <p>23 A. I am.</p> <p>24 MR. BENTLEY: Objection, beyond the scope.</p>	<p>1 MR. BENTLEY: Objection.</p> <p>2 A. Yes.</p> <p>3 Q. That's all for that document --</p> <p>4 A. Okay.</p> <p>5 Q. -- Doctor.</p> <p>6 I direct your attention to page 14 of your</p> <p>7 report.</p> <p>8 A. Okay.</p> <p>9 Q. Do you remember being asked questions about</p> <p>10 the success rates --</p> <p>11 A. Yes.</p> <p>12 Q. -- of Prolift?</p> <p>13 A. I'm sorry. Yes.</p> <p>14 Q. And, Doctor, you have a chart on page 14 of</p> <p>15 your report; is that correct?</p> <p>16 A. That's correct.</p> <p>17 Q. What information does this chart contain?</p> <p>18 A. This chart contains information from some</p> <p>19 randomized control trials that show the number of</p> <p>20 patients and the compartments that were treated with the</p> <p>21 Prolift procedure, mesh anatomical cure, native</p> <p>22 anatomical cure, and the clinical significance.</p> <p>23 Q. And how many different studies are reflected</p> <p>24 in this chart?</p>

32 (Pages 122 to 125)

Michael Karram, M.D.

Page 126	Page 128
<p>1 A. Nine.</p> <p>2 Q. And are these all studies that you have</p> <p>3 reviewed and --</p> <p>4 A. They are.</p> <p>5 Q. -- relied upon?</p> <p>6 A. They are.</p> <p>7 Q. And what are the findings of these studies,</p> <p>8 in terms of the anatomic curative mesh versus native</p> <p>9 tissue repair?</p> <p>10 A. They all were higher in the mesh repair</p> <p>11 versus the native tissue repair.</p> <p>12 Q. I'm going to turn your attention to page 16</p> <p>13 of your report, Doctor.</p> <p>14 A. Um-hmm.</p> <p>15 Q. Strike that. Let's go to page 15.</p> <p>16 A. Okay.</p> <p>17 Q. There was testimony about the two different</p> <p>18 Cochrane Reviews.</p> <p>19 A. Right.</p> <p>20 Q. Do you remember that?</p> <p>21 A. Yes.</p> <p>22 Q. And you're citing, here, from a Cochrane</p> <p>23 Review in 2013; is that correct?</p> <p>24 A. That's correct.</p>	<p>1 BY MR. WALKER:</p> <p>2 Q. You're correct.</p> <p>3 A. The Altman study. Okay. The Altman study</p> <p>4 has a randomized control trial with Prolift and native</p> <p>5 tissue. The failure rate with Prolift was 39 percent</p> <p>6 and the failure, with traditional, 65 percent. And that</p> <p>7 reached statistical significance.</p> <p>8 Q. And you were initially asked some questions,</p> <p>9 I believe, regarding, you know, when you would want to</p> <p>10 use a Prolift to treat a patient prolapse.</p> <p>11 Do you remember those types of questions?</p> <p>12 A. I do.</p> <p>13 Q. Why would a doctor like yourself choose to</p> <p>14 use a synthetic mesh product like Prolift instead of</p> <p>15 just relying on native tissue repair?</p> <p>16 MR. BENTLEY: Objection.</p> <p>17 A. Under certain circumstances, a synthetic mesh</p> <p>18 repair would probably be safer for a patient.</p> <p>19 Q. And, Doctor --</p> <p>20 A. And if we feel that there is a higher risk</p> <p>21 for a recurrence or a failure, then this would help.</p> <p>22 Q. And how does Prolift help mitigate against</p> <p>23 the risk of a higher likelihood of recurrence?</p> <p>24 MR. BENTLEY: Objection.</p>
Page 127	Page 129
<p>1 Q. And that's after Prolift was</p> <p>2 decommercialized; correct?</p> <p>3 MR. BENTLEY: Objection.</p> <p>4 A. Correct.</p> <p>5 Q. And, Doctor, based on this meta-analysis,</p> <p>6 what was the failure rate of Prolift compared to native</p> <p>7 tissue or traditional repair?</p> <p>8 A. I'm not seeing that on this.</p> <p>9 Q. Oh, I'm sorry. I'm looking --</p> <p>10 A. It just has cure rate and then mesh exposure</p> <p>11 rate.</p> <p>12 Q. I'm sorry. I looking -- I'm not referring</p> <p>13 you to the chart.</p> <p>14 A. Oh, I'm sorry.</p> <p>15 Q. I'm sorry. Looking --</p> <p>16 A. Okay.</p> <p>17 Q. Looking --</p> <p>18 A. Okay. Okay.</p> <p>19 MR. WALKER: Can you repeat the question?</p> <p>20 THE REPORTER: (Q) And, Doctor, based on this</p> <p>21 meta-analysis, what was the failure rate of</p> <p>22 Prolift compared to native tissue or traditional</p> <p>23 repair?</p> <p>24 A. I think that's from the Altman.</p>	<p>1 A. With native tissue repair, you're using</p> <p>2 tissue that could already be damaged from previous</p> <p>3 whatever -- whatever issues that the patient had that</p> <p>4 caused her to develop the prolapse, whether it was</p> <p>5 childbirth or other surgeries, or anything like that.</p> <p>6 So by adding a synthetic reinforcement, you are now</p> <p>7 recreating a new support structure.</p> <p>8 Q. And, Doctor, do you remember being asked</p> <p>9 questions about the ideal rate of erosion?</p> <p>10 A. I do.</p> <p>11 Q. And I believe the reference was made in your</p> <p>12 report to 8 percent being the ceiling, in terms of the</p> <p>13 ideal rate of erosion. Do you recall that?</p> <p>14 A. 3 to 8 percent, yes.</p> <p>15 Q. If you'll turn to page 16 of your report,</p> <p>16 Doctor.</p> <p>17 A. Okay.</p> <p>18 Q. Does your report cite any medical literature</p> <p>19 that documents an erosion rate in Prolift below</p> <p>20 8 percent?</p> <p>21 MR. BENTLEY: Objection.</p> <p>22 A. Yes.</p> <p>23 Q. And what are those pieces of medical</p> <p>24 literature?</p>

33 (Pages 126 to 129)

Michael Karram, M.D.

Page 130	Page 132
<p>1 A. The Altman study had a 3.2 percent, 2 De Landsheere study had a 2.5 percent, and the 3 Benbouzoid had a 5.3 percent. 4 Q. And then, Doctor, have there been any 5 long-term studies that have looked at Prolift? 6 A. There have been. 7 Q. Did you review and rely upon any of those, in 8 formulating your opinions and drafting your report? 9 A. I did. 10 Q. Specifically, which ones? 11 A. There's a seven-year follow-up and -- the 12 Maher follow-up. 13 Q. What was the conclusion of the Maher 14 follow-up of seven years? 15 A. Their conclusions were, "Women undergoing 16 transvaginal mesh prolapse surgery using synthetic graft 17 continue to have positive objective and subjective 18 outcomes leading to significantly improved quality of 19 life at five-year follow-up." 20 MR. BENTLEY: What exhibit was that from? 21 MR. WALKER: It was just from his report, 22 page 17. Bottom of 16 and page 17. 23 BY MR. WALKER: 24 Q. Doctor, do you remember being asked questions</p>	<p>1 MR. BENTLEY: Objection, vague. 2 Q. Doctor, do you remember being shown the Clavé 3 study, regarding degradation of polypropylene? 4 A. Yes. 5 Q. And, Doctor, is the Clavé article a 6 meta-analysis? 7 A. No. 8 Q. Is it a randomized control trial? 9 A. No. 10 MR. BENTLEY: Leading. 11 Q. And do you remember being shown, Doctor, the 12 article on degradation of polypropylene in vivo by 13 Vladimir Iakovlev and Scott Guelcher? 14 A. Yes. 15 Q. Doctor, are you familiar with either of these 16 two authors? 17 A. Personally, no. 18 Q. And in terms of your consultation in these 19 cases, are you familiar -- 20 A. Yes. 21 Q. -- with these individuals? 22 A. Yes. 23 Q. How so? 24 A. I have read their articles or reviewed some</p>
Page 131	Page 133
<p>1 about the relevance of TVT, TVT-O, and TVT literature, 2 in formulating your opinions about the biocompatibility 3 of mesh? 4 A. Yes. 5 Q. Doctor, would you agree that TVT and TVT-O 6 are made of Prolene? 7 A. Yes. 8 Q. And would you also agree that Prolift is also 9 made of Prolene, just in a different construction? 10 MR. BENTLEY: Objection. 11 A. Yes. 12 Q. So why, then, do you believe that the TVT 13 literature is relevant, in terms of whether or not the 14 Prolift mesh is suitable in terms of its 15 biocompatibility? 16 MR. BENTLEY: Objection. 17 A. Because it's made from the same material. 18 Q. From your review of the medical literature, 19 what opinions have you formed regarding the 20 biocompatibility of the mesh in Prolift? 21 A. I think it's biocompatible. 22 Q. And upon what do you base that opinion? 23 A. On the medical literature and studies that 24 I've cited here.</p>	<p>1 of their publications. 2 Q. And do you recall either reviewing or seeing 3 any expert reports from Dr. Iakovlev? 4 MR. BENTLEY: Leading. 5 A. No. 6 Q. Are you aware that Dr. Iakovlev and 7 Dr. Guelcher are designated experts for the plaintiffs 8 in the mesh litigation? 9 MR. BENTLEY: Leading. 10 A. Actually, I am now aware Iakovlev is, I 11 think. I knew that one. 12 Q. And, Doctor, if you could -- do you have that 13 exhibit in front of you? 14 A. No. I can get it. What exhibit is it? 15 Q. I frankly don't remember. 16 A. Okay. Iakovlev. Got it. 17 Q. Doctor, if you'll turn to page 11. 18 A. Um-hmm. 19 Q. Do you see the section titled 20 "Acknowledgments"? 21 A. Yes. 22 Q. Doctor, do either of these two doctors 23 disclose, in this article, that they are paid experts 24 for the plaintiffs --</p>

34 (Pages 130 to 133)

Michael Karram, M.D.

Page 134	Page 136
<p>1 MR. BENTLEY: Objection.</p> <p>2 Q. -- in the mesh litigation?</p> <p>3 A. No.</p> <p>4 Q. And the date of this article is rather</p> <p>5 recent, correct, Doctor?</p> <p>6 MR. BENTLEY: Objection.</p> <p>7 A. July 2015, yes.</p> <p>8 Q. In your review of the medical literature, are</p> <p>9 you aware of any meta-analysis looking at Prolene mesh</p> <p>10 products that has concluded that Prolene degrades in any</p> <p>11 kind of clinically meaningful way?</p> <p>12 MR. BENTLEY: Objection.</p> <p>13 A. No.</p> <p>14 Q. Are you aware of any randomized control trial</p> <p>15 that has concluded that Prolene mesh degrades in any</p> <p>16 kind of clinically meaningful way?</p> <p>17 MR. BENTLEY: Objection.</p> <p>18 A. No.</p> <p>19 Q. In your practice, have you seen degradation</p> <p>20 of Prolene cause any clinically significant outcomes in</p> <p>21 your patients?</p> <p>22 MR. BENTLEY: Objection.</p> <p>23 A. No.</p> <p>24 Q. Have you reviewed or seen any medical</p>	<p>1 A. Polypropylene -- they have added oxidizing</p> <p>2 agents to the polypropylene.</p> <p>3 Q. It's late. I think you got that --</p> <p>4 A. Oh.</p> <p>5 Q. -- convoluted.</p> <p>6 A. Maybe the other way. Yeah, you're right.</p> <p>7 Q. Let's try that again.</p> <p>8 What is the difference between polypropylene</p> <p>9 and Prolene?</p> <p>10 MR. BENTLEY: Objection.</p> <p>11 A. Polypropylene has the oxidate -- the</p> <p>12 oxidizing agents added to it.</p> <p>13 Q. Doctor, do you remember reviewing any</p> <p>14 internal company documents that reflected the</p> <p>15 ingredients of Prolene?</p> <p>16 A. Yes.</p> <p>17 Q. And do you recall how anti-oxidizing</p> <p>18 ingredients were added to Prolene?</p> <p>19 A. Prolene, to get polypropylene.</p> <p>20 MR. BENTLEY: Objection.</p> <p>21 A. Right. Isn't that what I said?</p> <p>22 MR. BENTLEY: Objection.</p> <p>23 THE WITNESS: Objection. Can I breathe, or</p> <p>24 you are you going to object to that, too?</p>
Page 135	Page 137
<p>1 literature that comes to the conclusion that degradation</p> <p>2 of Prolene actually causes any kind of clinical harm in</p> <p>3 any circumstance?</p> <p>4 MR. BENTLEY: Objection.</p> <p>5 A. No.</p> <p>6 Q. And that's, Doctor, after reviewing a</p> <p>7 multitude of meta-analysis and randomized control trials</p> <p>8 relating to both TVT and Prolift?</p> <p>9 MR. BENTLEY: Objection.</p> <p>10 A. Correct.</p> <p>11 Q. And, Doctor, you've seen, in the Clavé study</p> <p>12 and the article by Iakovlev, the word "polypropylene"</p> <p>13 used --</p> <p>14 A. Yes.</p> <p>15 Q. -- throughout; is that correct?</p> <p>16 A. Yes.</p> <p>17 Q. And we've also talked about how the mesh</p> <p>18 products by Ethicon are made of Prolene; correct?</p> <p>19 MR. BENTLEY: Objection.</p> <p>20 A. That's correct.</p> <p>21 Q. Do you know what the difference is between</p> <p>22 polypropylene and Prolene?</p> <p>23 A. Yes.</p> <p>24 Q. And what is that difference?</p>	<p>1 MR. WALKER: It's late. It's late. We're</p> <p>2 almost there.</p> <p>3 THE WITNESS: Okay.</p> <p>4 BY MR. WALKER:</p> <p>5 Q. You were asked a number of questions about</p> <p>6 Ethicon's decision to decommercialize Prolift. Do you</p> <p>7 recall that?</p> <p>8 A. I do.</p> <p>9 Q. And I believe you testified that their</p> <p>10 decision to decommercialize Prolift doesn't impact any</p> <p>11 of your opinions regarding the safety and efficacy of</p> <p>12 Prolift. Is that correct?</p> <p>13 MR. BENTLEY: Objection.</p> <p>14 A. That's correct.</p> <p>15 Q. Why is that?</p> <p>16 A. Because all my patients that I have implanted</p> <p>17 with Prolift or have seen with Prolift have done very,</p> <p>18 very well. So I have a positive result with it.</p> <p>19 Q. Does Ethicon's decision, in 2012, to</p> <p>20 decommercialize Prolift, have any bearing on the</p> <p>21 integrity of the data that's reflected in the medical</p> <p>22 literature that you've reviewed?</p> <p>23 MR. BENTLEY: Objection.</p> <p>24 A. No.</p>

35 (Pages 134 to 137)

Michael Karram, M.D.

<p style="text-align: right;">Page 138</p> <p>1 Q. Doctor, you were asked a number of questions</p> <p>2 about life-altering complications. Do you remember</p> <p>3 that?</p> <p>4 A. Very vividly.</p> <p>5 Q. Doctor, is it fair to say that complications</p> <p>6 can be either short-term or long-term?</p> <p>7 A. Yes.</p> <p>8 MR. BENTLEY: Objection.</p> <p>9 Q. And are potential lifelong complications</p> <p>10 something that's unique to Prolift surgery?</p> <p>11 MR. BENTLEY: Objection.</p> <p>12 A. No.</p> <p>13 Q. And how do you know that?</p> <p>14 A. I know that because I've seen lifelong</p> <p>15 complications from traditional repairs and other repairs</p> <p>16 that we do that are not mesh.</p> <p>17 Q. Doctor, you were asked questions about the</p> <p>18 frequency of complications.</p> <p>19 A. Yes.</p> <p>20 Q. Do you remember that?</p> <p>21 A. Yes.</p> <p>22 Q. Is there more data in the medical literature</p> <p>23 regarding the frequency of complications for native</p> <p>24 tissue repair or for the Prolift procedure?</p>	<p style="text-align: right;">Page 140</p> <p>1 A. Yes.</p> <p>2 Q. And you testified, I believe, that you are</p> <p>3 not of the opinion that the mesh, itself, shrinks; is</p> <p>4 that correct?</p> <p>5 MR. BENTLEY: Objection.</p> <p>6 A. Yes.</p> <p>7 Q. And what is the basis for that opinion?</p> <p>8 A. Studies that have looked at ultrasounds after</p> <p>9 mesh implantation over a long period of time and showed</p> <p>10 no change in the size of the mesh.</p> <p>11 Q. Doctor, I believe you said that if there is</p> <p>12 anything happening in terms of shrinkage or contraction,</p> <p>13 it's a function of tissue and not of the mesh; is that</p> <p>14 accurate?</p> <p>15 MR. BENTLEY: Objection.</p> <p>16 A. That's accurate.</p> <p>17 Q. And what is your basis for saying that tissue</p> <p>18 contraction, as opposed to mesh contraction, is taking</p> <p>19 place?</p> <p>20 MR. BENTLEY: Objection.</p> <p>21 A. Because studies have showed that the mesh</p> <p>22 does not change in shape or size, but the tissue, when</p> <p>23 it incorporates into the mesh, will cause some scarring</p> <p>24 and some contraction. The tissue.</p>
<p style="text-align: right;">Page 139</p> <p>1 MR. BENTLEY: Objection.</p> <p>2 A. Is there more -- repeat the question again.</p> <p>3 Q. Do you know if -- I'll slightly rephrase it.</p> <p>4 A. Okay.</p> <p>5 Q. Do you know if there's more data in the</p> <p>6 medical literature, regarding the frequency of</p> <p>7 complications of native tissue repair or Prolift</p> <p>8 surgery?</p> <p>9 MR. BENTLEY: Objection.</p> <p>10 A. I do not.</p> <p>11 Q. Okay. You talked earlier about</p> <p>12 standardization that came with mesh kits like Prolift.</p> <p>13 Do you remember that?</p> <p>14 A. Yes.</p> <p>15 Q. And what is the relationship between the</p> <p>16 standardization of mesh kits and surgery to the quality</p> <p>17 of the data that you can gather from those procedures?</p> <p>18 A. It's much more accurate and scientific,</p> <p>19 because now you're comparing two exactly same procedures</p> <p>20 versus theoretically comparing the same procedures.</p> <p>21 Q. Do you remember, Doctor, being asked</p> <p>22 questions about mesh shrinkage --</p> <p>23 A. Yes.</p> <p>24 Q. -- or contraction?</p>	<p style="text-align: right;">Page 141</p> <p>1 Q. I want to go back to the topic of</p> <p>2 complications that are unique to mesh.</p> <p>3 Is pelvic pain, in your opinion, Doctor, a</p> <p>4 complication that is unique to Prolift?</p> <p>5 MR. BENTLEY: Objection.</p> <p>6 A. No.</p> <p>7 Q. Is dyspareunia a complication that is unique</p> <p>8 to Prolift?</p> <p>9 A. No.</p> <p>10 Q. Is scarring a complication that is unique to</p> <p>11 Prolift?</p> <p>12 MR. BENTLEY: Objection.</p> <p>13 A. No.</p> <p>14 Q. Is infection a complication that is unique to</p> <p>15 Prolift?</p> <p>16 MR. BENTLEY: Same objection.</p> <p>17 A. No.</p> <p>18 Q. And, Doctor, with what types of pelvic floor</p> <p>19 surgeries can those complications I just asked you about</p> <p>20 occur?</p> <p>21 A. Any pelvic floor surgery.</p> <p>22 Q. So when we're talking about complications</p> <p>23 that are unique to mesh, what are you referring to?</p> <p>24 A. Erosions and extrusions.</p>

36 (Pages 138 to 141)

Michael Karram, M.D.

Page 142	Page 144
<p>1 Q. And in terms of erosions and extrusions, can</p> <p>2 you have those complications in a native tissue repair</p> <p>3 utilizing sutures?</p> <p>4 A. That's correct.</p> <p>5 MR. BENTLEY: Objection.</p> <p>6 A. Yes.</p> <p>7 MR. WALKER: Were almost done. I'm making</p> <p>8 sure I got everything.</p> <p>9 That's all I have. Thank you.</p> <p>10 FURTHER EXAMINATION</p> <p>11 BY MR. BENTLEY:</p> <p>12 Q. Doctor, you discussed the Altman study. Do</p> <p>13 you remember that?</p> <p>14 A. Yes.</p> <p>15 Q. Do you know that the Altman study was</p> <p>16 included in the 2016 Cochrane Review?</p> <p>17 A. Yes.</p> <p>18 Q. And the Altman study is a lower level of</p> <p>19 evidence, as compared to systematic reviews like the</p> <p>20 2016 Cochrane Review; correct?</p> <p>21 A. Yes.</p> <p>22 Q. And, in fact, the 2016 Cochrane Review is a</p> <p>23 higher level of evidence than the De Landsheere study</p> <p>24 and the Benbouzoid study; correct?</p>	<p>1 yes.</p> <p>2 MR. BENTLEY: Thank you, Doctor. I have no</p> <p>3 further questions.</p> <p>4 MR. WALKER: Okay. We're done.</p> <p>5 THE REPORTER: Signature, Doctor?</p> <p>6 THE WITNESS: Yes, ma'am.</p> <p>7</p> <p>8</p> <p>9</p> <p>10</p> <p>11 ---</p> <p>12 DEPOSITION CONCLUDED AT 9:30 P.M.</p> <p>13 ---</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>
Page 143	Page 145
<p>1 A. Correct.</p> <p>2 Q. Doctor, you were asked some questions about</p> <p>3 the Iakovlev study. Do you remember that?</p> <p>4 A. Yes.</p> <p>5 Q. And if you'd just look at the second-to-last</p> <p>6 page. You were asked whether there were some</p> <p>7 disclosures by the authors.</p> <p>8 Under "Acknowledgments," do you see that the</p> <p>9 authors, in fact, disclosed that they're working as</p> <p>10 consultants in this litigation?</p> <p>11 A. "Others provided expert opinions for</p> <p>12 medicolegal cases in matters related to polypropylene</p> <p>13 mesh."</p> <p>14 Q. You'd agree, they made an accurate and honest</p> <p>15 disclosure; correct?</p> <p>16 A. That's what it says here, yeah.</p> <p>17 Q. So other than that, do you have any other</p> <p>18 reason to discount their findings in this peer-reviewed</p> <p>19 published article?</p> <p>20 A. Other than what we talked about earlier.</p> <p>21 Q. As you sit here today, can you tell the jury</p> <p>22 any reason why you discount the findings in this</p> <p>23 article -- specifically in this article?</p> <p>24 A. That it's not a randomized control trial,</p>	<p>1 C E R T I F I C A T E</p> <p>2 State of Ohio : : SS</p> <p>3 State at Large :</p> <p>4 I, Teresa A. Moore, RPR, CRR, the undersigned,</p> <p>5 a duly commissioned notary public within and for the</p> <p>6 State of Ohio, do hereby certify that before the giving</p> <p>7 of his aforesaid deposition, MICHAEL KARRAM, M.D. was by</p> <p>8 me first duly sworn to depose the truth, the whole truth</p> <p>9 and nothing but the truth; that the foregoing is the</p> <p>10 deposition given at said time and place by MICHAEL</p> <p>11 KARRAM, M.D.; that said deposition was taken in all</p> <p>12 respects pursuant to stipulations of counsel; that I am</p> <p>13 neither a relative of nor employee of any of their</p> <p>14 parties or their counsel, and have no interest whatever</p> <p>15 in the result of the action.</p> <p>16 IN WITNESS WHEREOF, I have hereunto set my</p> <p>17 hand and official seal of office on this 5th day of</p> <p>18 July, 2016.</p> <p>19</p> <p>20</p> <p>21</p> <p>22 TERESA A. MOORE Notary Public - State of Ohio My Commission expires: 06/17/21</p> <p>23</p> <p>24</p>

37 (Pages 142 to 145)

Michael Karram, M.D.

<p>1 INSTRUCTIONS TO WITNESS</p> <p>2</p> <p>3 Please read your deposition</p> <p>4 over carefully and make any necessary</p> <p>5 corrections. You should state the reason</p> <p>6 in the appropriate space on the errata</p> <p>7 sheet for any corrections that are made.</p> <p>8 After doing so, please sign</p> <p>9 the errata sheet and date it.</p> <p>10 You are signing same subject</p> <p>11 to the changes you have noted on the</p> <p>12 errata sheet, which will be attached to</p> <p>13 your deposition.</p> <p>14 It is imperative that you</p> <p>15 return the original errata sheet to the</p> <p>16 deposing attorney within thirty (30) days</p> <p>17 of receipt of the deposition transcript</p> <p>18 by you. If you fail to do so, the</p> <p>19 deposition transcript may be deemed to be</p> <p>20 accurate and may be used in court.</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>	<p>1</p> <p>2 ACKNOWLEDGMENT OF DEPONENT</p> <p>3</p> <p>4 I, _____, do</p> <p>5 hereby certify that I have read the</p> <p>6 foregoing pages, and that the same is</p> <p>7 a correct transcription of the answers</p> <p>8 given by me to the questions therein</p> <p>9 propounded, except for the corrections or</p> <p>10 changes in form or substance, if any,</p> <p>11 noted in the attached Errata Sheet.</p> <p>12</p> <p>13</p> <p>14 _____</p> <p>15 MICHAEL KARRAM, M.D. DATE</p> <p>16</p> <p>17</p> <p>18 Subscribed and sworn</p> <p>19 to before me this</p> <p>20 _____ day of _____, 20 ____.</p> <p>21 My commission expires: _____</p> <p>22 _____</p> <p>23 Notary Public</p> <p>24</p>
<p>1 - - - - -</p> <p>2 E R R A T A</p> <p>3 - - - - -</p> <p>4 PAGE LINE CHANGE</p> <p>5</p> <p>6 REASON: _____</p> <p>7</p> <p>8 REASON: _____</p> <p>9</p> <p>10 REASON: _____</p> <p>11</p> <p>12 REASON: _____</p> <p>13</p> <p>14 REASON: _____</p> <p>15</p> <p>16 REASON: _____</p> <p>17</p> <p>18 REASON: _____</p> <p>19</p> <p>20 REASON: _____</p> <p>21</p> <p>22 REASON: _____</p> <p>23</p> <p>24 REASON: _____</p>	<p></p>

Michael Karram, M.D.

Page 150

A				
abdominal 75:18	addition 122:11	amount 9:7 21:13	120:23,24	assumed 99:1
able 46:8	additional 35:9,11	49:22 109:8	approach 47:22	assuming 99:23
abnormality 9:18	43:18 45:7	AMS 11:7 13:1,10	48:2 62:3	attached 146:12
13:7	address 79:10	13:22 14:11 15:2	appropriate 14:5,7	148:11
abreast 29:21	addresses 79:9	17:16 18:2 25:11	35:23 97:23	attend 16:9,13,18
absent 36:19	adequacy 57:19,24	47:12	118:24 119:7,12	attendant 34:9
absolutely 34:11	105:23 116:9	analysis 3:14,17	119:20 120:8	attended 16:20
42:12	124:22	42:14,16 43:10	121:6 124:12	attending 16:4
absorbable 7:20	adequate 106:6,18	44:12,14,18,21,24	146:6	attention 57:15
8:5,8 86:12	adequately 58:3	51:6 52:11 60:21	appropriateness	59:20 61:9 65:21
abstract 71:14	72:10 117:11	64:13,23 65:10	119:23	76:22 78:22 79:13
accept 46:23	122:11,17	98:13 99:17	approved 42:6	80:4 86:4 88:11
acceptable 104:9	advanced 29:3	101:16	Approximately	94:3 98:19 101:19
104:18 105:3,7	120:2	anatomic 86:13	17:3	111:9 121:20
access 112:18,20	advantage 17:17	87:10 126:8	area 10:2	122:4 125:6
113:5,10,11,14,17	advantageous 13:9	anatomical 9:17	arms 87:12	126:12
113:21 115:12	adverse 22:17 23:7	125:21,22	Arnaud 3:12 60:19	attorney 4:7
accommodate 9:21	23:8,13 113:17	anatomy 24:12	62:10	146:16
account 43:11,13	aforsaid 145:7	26:4	article 48:12,16	AUA 110:19
accurate 65:3	age 4:2	anesthetic 31:5	60:19 61:2,24	augment 6:8
111:6 139:18	agents 136:2,12	Angela 1:9	62:9 63:15,19,22	augmented 6:5,19
140:14,16 143:14	agree 9:6 14:3 30:1	Anne 89:7	63:24 64:13,23	6:23 8:18 71:17
146:20	30:6 35:13 36:11	annual 18:22	65:8,14 66:3	81:1
ACKNOWLED...	36:14 43:4 48:9	answer 19:20 37:14	71:11 132:5,12	AUGS 3:18 60:11
148:2	50:3 54:3 63:20	38:20,22 39:19,22	133:23 134:4	70:16 71:1,14
Acknowledgments	74:8,11 75:4,9,22	46:21 80:21	135:12 143:19,23	72:1,23 79:8,10
133:20 143:8	76:18 77:13 87:17	answers 148:7	143:23	81:20 84:3 87:2
ACOG 3:18 70:16	89:1,2,3 97:21	anterior 11:4 23:20	articles 39:13	90:8,15,16,23
70:24 71:14 72:1	99:12,13 101:11	80:9 86:10,11	54:11 55:21,24	91:2,3,7,10
72:23 76:11 78:10	108:21 109:13	88:19	56:5 65:18 121:23	110:19
79:8 81:19 84:2	113:5,10 114:2,14	anterior-only	132:24	AUGS' 75:5 76:11
87:2 90:8 91:1,6,7	114:19,23 115:8	13:21	aside 54:16,18	78:10
91:10,20 110:19	117:17,18 118:19	anti-oxidizing	asked 120:18 125:9	author 89:8
110:24	120:13 121:3	136:17	128:8 129:8	author's 89:3
ACOG's 75:5	131:5,8 143:14	anybody 63:3	130:24 137:5	authors 62:9 66:3
79:19	agreed 95:23	anymore 47:16	138:1,17 139:21	66:22 69:18 87:2
action 28:11	agreeing 76:11	anytime 31:4	141:19 143:2,6	91:24 98:10 102:4
145:15	Ah 94:8	apical 13:15	asking 23:20 24:3	132:16 143:7,9
active 24:22	ahead 46:16 47:9	Apogee 11:1 13:16	asks 47:4	Authors' 96:22
actual 37:8 94:24	al 1:10	13:17	aspect 67:9	available 5:10,24
116:21	alleged 60:2	APPEARANCES	aspects 120:6	6:10 8:2,9,13,14
add 117:14	alternative 27:14	2:1	associated 31:7,11	10:13,21 14:23
added 118:14	Altman 127:24	appears 61:17	34:21 72:11 77:16	15:4 24:24 27:7
136:1,12,18	128:3,3 130:1	applicable 59:11	84:4 97:1,4	28:7 32:18,19
adding 34:20 129:6	142:12,15,18	applications 62:6	122:20 124:18	41:10,20 53:3,3
	American 1:17	appreciate 37:10	assume 70:3 80:18	54:18 71:15 80:24
	11:3,5	91:13 99:16	99:14	93:6 117:24

Avaulta 14:15	believes 33:1	131:21	carcinogenesis	128:13
aware 72:15 85:11	Benbouzoid 130:3	biologic 6:7	49:2,5,11	chose 45:11
85:17,18 89:7,17	142:24	biomechanical	care 24:5,6	chronic 108:9
90:1 94:1 133:6	beneficial 85:1	51:15,21 53:10,13	career 5:24 8:13	Cincinnati 1:18
133:10 134:9,14	benefit 88:17	53:16,19,23 63:7	18:12 19:24 21:24	circumstance
awareness 97:1	benefits 27:8,13,24	bladder 97:6	41:8	135:3
<hr/>	28:22 98:4	bodies 36:23	carefully 146:4	circumstances
B	Bentley 2:3 3:5 4:5	body 36:24 37:7	carry 35:10 57:2	128:17
back 6:6 8:11 18:11	4:6,12,19 12:9,10	107:13,16 109:14	case 1:11 9:22 16:2	citation 86:16
26:14,15,18 47:4	19:22 22:2 23:22	Boston 7:4 14:14	33:8 41:6 114:4	cite 29:11 55:13
57:11 61:23 84:13	24:1 31:3 37:1,3	bother 85:24	114:16 115:11	57:4 64:15 86:21
85:12,18 95:17	37:10,18 57:10	bottom 77:1 94:5	117:8	92:11,18 93:4,14
104:2 122:1 141:1	59:3 60:17 64:9	103:12 130:22	cases 21:16 66:7	101:17 129:18
bacterial 67:10	64:11 65:6 70:8	bovine 6:7	132:19 143:12	cited 47:21 87:4
68:7	70:10 71:8 78:16	bowel 31:6 32:3	causation 3:8 4:15	94:1 131:24
bad 36:16 37:14	78:21 80:20,22	break 57:8,11	cause 49:3 68:3,7	citing 112:8 126:22
44:15 119:5	83:21,23 90:11,12	breathe 136:23	68:10 69:5 109:6	claims 60:2
balanced 48:2	95:5 103:12,15	bridging 109:20,24	111:15 134:20	Clavé 3:12 60:20
Bard 7:3 14:15	114:8,11 115:5,7	110:1,4	140:23	62:10 132:2,5
base 131:22	116:22,23 121:10	Brief 57:9	caused 63:13 67:22	135:11
based 17:11 24:15	122:14,19 123:5	briefly 61:8 65:20	68:1 129:4	clean 4:14,21 118:8
63:19 71:15 80:23	123:24 124:8,14	105:20	causes 37:9 135:2	clear 12:7 34:2
82:8,11,14 85:4	124:19 125:1	brittleness 66:17	ceiling 129:12	74:16 116:22
86:12 100:17	127:3 128:16,24	brochures 57:19	center 56:10	Cleveland 88:1
101:8 122:20,22	129:21 130:20	105:24 106:3,6,7	centimeters 79:24	Clinic 88:1
127:5,20	131:10,16 132:1	106:15,20	80:1	clinical 24:11 53:18
bases 58:8 70:14,15	132:10 133:4,9	brought 121:23	certain 68:6 128:17	53:23 54:7,10,18
basis 18:22 111:22	134:1,6,12,17,22	Brown 1:17	Certified 1:16	60:1,5,7,9,12,14
122:16 140:7,17	135:4,9,19 136:10	bulletin 91:6	certify 145:6 148:5	60:14 63:11,16
bearing 137:20	136:20,22 137:13	bunched 38:5,10	CFR 3:11 58:9,12	65:23 66:6 67:4
becoming 21:13	137:23 138:8,11	38:11 40:1,5,23	59:7,10	67:15 68:24 69:19
38:9	139:1,9 140:5,15	busier 20:1	change 44:5 50:4	69:22,24 70:2,6
began 5:2,11,24	140:20 141:5,12	business 34:1	140:10,22 147:4	120:6 125:22
8:11 14:10,11	141:16 142:5,11	BUTLER 2:10	changed 19:24	135:2
15:1 16:16 29:23	144:2	<hr/>	changes 77:16	clinically 66:4 67:9
beginning 118:3,4	best 14:1 55:17	C 145:1,1	79:24 146:11	67:14,19 134:11
118:19	88:14 113:6	cadaver 15:18	148:10	134:16,20
begins 57:18 67:8	better 13:15 35:24	124:4	characterize 90:15	close 19:18 41:17
behalf 2:2,8 22:24	85:22	calculate 19:11	characterizing	Cochrane 3:19
belief 119:11	beyond 87:14	calculates 19:16	62:5	92:18 93:13,20,23
believe 4:14 57:15	123:24	calculations 99:24	CHARLESTON	94:6,12,20 95:1,7
59:17 60:9 72:10	big 9:10	calculator 19:11	1:3	95:15 101:1,22,23
81:23 90:8 119:6	bigger 109:13	call 9:11	chart 125:14,17,18	102:4 103:24
128:9 129:11	biocompatibility	called 59:23	125:24 127:13	104:13,21 105:5
131:12 137:9	49:10,13 131:2,15	candidate 28:9	cherry-pick 48:15	105:16 126:18,22
140:2,11	131:20	capture 47:16	childbirth 129:5	142:16,20,22
believed 119:19	biocompatible		choose 116:1	cohort 82:24,24

Michael Karram, M.D.

Page 152

colonization 67:10	88:20	96:22 101:8,13,17	62:5 89:18 90:22	97:15,24 98:2,10
Colony 2:10	compartments	130:15	91:24	98:11,14 99:4,10
Coloplast 7:3	125:20	conferences 16:21	control 45:22 46:17	99:11 100:3,8,21
Colorado 2:5	complaints 24:13	confused 91:4	56:8,14 82:24	100:22,24 101:2,5
colporrhaphy	complete 9:11	consent 29:8 32:23	87:12 125:19	101:9,10,13,14,18
86:11	completely 18:24	115:21 116:6	128:4 132:8	102:11,22,23
column 77:1	complicated 64:3,7	consider 34:16	134:14 135:7	103:8,9,19,21,22
columns 61:12	complication 22:5	35:15,17 40:18,21	143:24	104:15,16,23,24
come 28:11 51:7	22:9,13,18 33:1	76:16	conversation 27:9	105:17,18 106:16
58:12	33:20 34:5,13,17	considered 52:3,19	conveyed 119:1	106:20,22 107:1
comes 22:6 135:1	35:16,17 36:12	86:1	convince 46:22	109:17 110:21,22
comments 83:21	58:20 63:3,13	considering 19:2	convoluted 136:5	111:3,4,6,7
commission 145:22	67:17,22,24 68:1	considers 33:20	copy 4:14,21	112:13,15,18
148:20	68:3 77:9,11	34:17	123:12,14	113:4,15,16,19,20
commissioned	141:4,7,10,14	consistent 19:23	correct 4:16 5:17	113:23 114:1
145:5	complications 20:3	103:20	5:21 6:10,11 7:17	115:19,20 116:2,4
committee 82:22	20:7,12,19,24	construction 11:7	8:15,20,21 9:3,4	116:6,8,10,11,13
83:1,3,6,7 86:5	21:9,17 23:9	50:2 52:7 131:9	12:21,22 13:1,2	116:14 117:15,16
91:2,6,20 110:23	26:20 27:2 31:17	consultants 143:10	14:23,24 15:12	117:20 118:11,12
committees 77:2	31:21 32:22 33:5	consultation	16:7,17,24 18:6	118:15,16 119:8
common 24:18	33:14,17,19,24	132:18	23:5 27:15,16,22	119:10 120:9,14
77:11 111:12,23	34:6 36:2,6,9 58:4	contain 124:11,16	30:5,13,15 31:9	122:13,15 123:8,9
122:24	58:21,22 62:16	125:17	32:5,11 34:15	125:15,16 126:23
community 124:24	63:5,10 66:7,12	contains 125:18	38:7 40:13 41:1,4	126:24 127:2,4
comorbidities	72:5,11,12,16	context 45:20	42:9 43:16 48:8	128:2 134:5
88:22	73:5 75:16 81:24	46:10 108:17	48:14,20 49:16,19	135:10,15,18,20
companies 7:2	84:4,11 111:15	continue 15:2 77:8	50:7,9 53:5,7,8	137:12,14 140:4
10:17,22 13:5	112:6 113:7,22	77:15 80:23 87:3	54:12 55:23 56:2	142:4,20,24 143:1
41:13 46:15,17	114:5,17 115:17	87:8 97:16 98:3	56:19 57:20,24	143:15 148:7
47:4,10	115:24 118:1,18	100:5 107:15	58:1,5 59:18,19	corrections 146:5,7
company 16:1	124:17 138:2,5,9	130:17	62:7,24 64:6 66:9	148:9
46:14,18 57:19	138:15,18,23	Continuing 19:20	66:13,14,19 67:5	correctly 40:7 67:1
58:18 105:23	139:7 141:2,19,22	contract 36:24	67:16 69:19 70:17	67:12 69:15 71:22
113:18 114:3,15	142:2	77:22	70:18,22,23 71:12	75:20 77:19 81:6
115:9 124:6	component 7:20	contraction 36:11	72:2,3,5,8,18 73:2	87:15 97:8,19
136:14	8:5,8 15:21	36:20 37:5,9,20	73:3,5 75:16 77:7	98:7 100:1,14
comparable 87:13	composite 87:10	37:21,23 38:1	77:23 81:9,10,12	102:18 103:4
comparative 3:14	conclude 62:10	39:21 77:17 78:10	81:14,20 82:14	104:11 111:20
60:21	100:11	78:12 79:7,14	83:4,8,10,17,19	122:21
compared 13:10	concluded 43:19	80:11 139:24	84:15,21 85:9,16	counsel 78:22
30:17 49:15 54:4	44:20 134:10,15	140:12,18,18,24	86:15,20 87:6,7	79:16 145:12,14
75:17 127:6,22	144:12	contracts 36:14,22	87:23 88:20,21	counselor 103:10
142:19	conclusion 42:23	79:20,21	90:9,22 92:1,2,17	count 80:14,16
comparing 139:19	51:7 98:14 99:19	contracture 80:3	93:6,7,10,11,17	couple 96:11
139:20	130:13 135:1	contradict 84:8	93:18,22,24 94:13	course 67:14
comparison 53:20	conclusions 62:1	contradicts 98:16	94:14,15,21,22	courses 16:22,23
compartment	84:2 90:21 92:1	contrary 48:17	95:2,3,12 97:14	106:13 120:21

court 1:1 83:22 146:20 cover 10:2 cracking 66:17 critical 111:2 criticism 64:13 98:13 99:17 criticisms 100:17 critique 63:24 64:23 99:17 CRR 145:4 curative 126:8 cure 125:21,22 127:10 current 43:20 95:1 currently 71:15 80:24 98:5 cut 6:20 9:2,5 cytotoxicity 49:1,5 49:11	deal 36:6 41:13 dealing 26:4 dear-healthcare... 115:1,10 debris 68:9 69:5 December 71:1 91:21 decide 55:13 56:5 57:3 decided 117:14 decision 27:10,19 46:14,15,18 115:22 137:6,10 137:19 decisions 46:20 decommercialize 137:6,10,20 decommercialized 127:2 decrease 80:12 87:5 deemed 146:19 defect 6:21 7:8 9:21 defects 13:21 Defendants 2:8 defer 52:6,23 53:14 define 34:8 72:8 82:7 defined 80:12 defining 38:19 definitely 48:18 definition 37:21 38:15 84:12 definitions 86:13 degradation 3:15 49:8,11 59:24 60:3,4,5,8,13 61:19 62:11,15,22 63:5,11,14,17,20 65:1,9,24 67:9,15 67:21 68:4 69:2 70:2,7 132:3,12 134:19 135:1 Degradation-rela... 66:22 degrade 68:1 degraded 61:13,20	66:16 67:11 68:13 69:13 degrades 59:18 134:10,15 degrading 69:17 deliberately 57:3 demonstrating 46:9 65:1 84:4 Denver 2:5 depend 5:8 9:9,17 13:22 dependent 13:6 depends 7:7 24:9 24:12 26:3,3 34:23 82:6 DEPONENT 148:2 depose 145:8 deposed 4:3 deposing 146:16 deposition 1:13 4:8 4:22,23 36:3 70:19 83:2 144:12 145:7,10,11 146:3 146:13,17,19 deps@golkow.com 1:24 describe 28:23 42:4 described 6:15 77:9 describes 122:12 122:17 description 64:5 descriptions 66:6 design 13:11 50:8 designated 133:7 despite 75:18 determining 104:17 detrimental 120:5 develop 129:4 developed 66:8 device 22:19 23:11 23:14 42:15 44:6 48:22 50:16 51:10 56:23 58:4 115:24 119:7,7,23 124:18 devices 5:16,17	72:5 73:5 113:7 113:22 114:5,18 116:2,16 difference 11:24 31:14 135:21,24 136:8 differences 12:12 53:10,19,24 different 7:2 9:24 11:8,21 12:3 49:15,18,21 50:2 50:5,6,11,18,19 50:20 53:6 83:6 90:1 97:12 125:23 126:17 131:9 differently 88:5,7 direct 79:13 121:20 122:4 125:6 directed 78:22 direction 78:15 directly 23:2 62:21 dis 74:19 disagree 39:15,16 78:1 79:19 81:15 81:17 82:10,17 98:9,13 101:12,16 disagreeing 76:10 disagreement 78:4 79:6 81:19 disclose 64:22 106:14 133:23 disclosed 143:9 disclosure 143:15 disclosures 143:7 discount 63:24 143:18,22 discounted 64:5 discounting 84:2 discuss 28:10 29:8 29:15 30:23 31:22 32:12,21 36:1 41:20,22 56:6,21 57:23 66:4 70:20 78:4,8,11 79:6,13 81:18 85:8 94:5 95:10 96:17 106:5 106:9	discussed 4:22 14:22 36:9 53:2 56:1 66:11 73:11 87:6 88:20 96:7 97:10 100:20 102:10 112:17 118:13 119:6 142:12 discussing 28:24 29:6 33:17 52:12 53:22 62:21 68:24 69:4 70:14 77:2 77:22 89:17 92:4 93:9 102:24 106:20 108:9,18 110:4 discussion 94:11 discussions 46:10 DISTRICT 1:1,2 1:10 DIVISION 1:3 Diwadkar 76:14 doctor 4:6 5:2 12:7 12:14 17:10 20:17 20:22 22:4,9,13 22:16 27:12 28:17 34:9 36:3,9 37:12 38:16,21,24 39:9 41:6,9 42:13 45:5 47:18 48:21 49:14 53:9 54:7 55:14 57:11,14 59:16 64:12 65:7 70:11 75:4 76:22 78:14 78:20,22 84:1,23 88:12 89:7 90:13 92:3 97:21 104:2 105:19 107:11 109:20 110:7 111:8 114:14 116:9,24 118:23 121:10,14,20 122:10,16 125:5 125:14 126:13 127:5,20 128:13 128:19 129:8,16 130:4,24 131:5
---	---	---	--	---

132:2,5,11,15 133:12,17,22 134:5 135:6,11 136:13 138:1,5,17 139:21 140:11 141:3,18 142:12 143:2 144:2,5 doctors 30:1,6,18 58:3 72:12 73:8 73:15,22 112:15 113:1,18 114:4,16 114:16,24 115:11 115:12 117:11 118:23 119:15 120:21 121:5 124:6 133:22 document 1:8 38:17 58:15,22 124:5,11,16,21 125:3 documents 41:17 41:19,22 46:6,9 52:11 54:9,20 55:3,7,11 108:8 108:16 110:4 123:6 129:19 136:14 dogs 39:6 doing 7:7 26:17 32:22 34:24 45:12 45:17 46:17,24 76:8 146:8 doubt 103:23 Dr 28:4 133:3,6,7 drafting 91:8 130:8 drafts 116:16,20,21 draw 32:16 80:4 88:11 due 37:12 62:16 80:19 duly 4:3 145:5,8 dyspareunia 31:8 32:4 71:20 77:3 81:5 111:17 141:7	earlier 66:12 85:4 103:1 105:20 117:12 139:11 143:20 early 18:11 East 1:17 economic 46:1 educated 30:16 educating 27:13 education 17:13,14 82:11,15,20 104:20 effect 91:8 effective 28:4 effectiveness 42:23 efficacious 85:2,5 85:13 efficacy 42:15 43:6 43:21 44:19 48:23 50:15 51:23 56:22 137:11 effort 112:14 eight 20:16,18 100:5,11 107:20 108:6 either 13:3,4 132:15 133:2,22 138:6 elderly 24:21 Elevate 11:4,14 17:16 47:15 elicit 122:21 elicits 107:12 Email 2:6,12 employ 6:1,16 employed 124:6 employee 145:13 ended 121:16 endoscopic 88:23 ends 107:20 engineer 53:15,17 entail 25:11,12 entire 9:12 41:8 59:5,10 entirely 111:6 entitled 59:23 60:20 65:9,23	70:1 88:14 102:5 104:5 105:23 epidemiologists 42:19 epidemiology 47:19 equipment 61:18 erosion 31:7 74:6 74:12,17 75:2,8 77:9 103:7,8,17 104:18 129:9,13 129:19 erosions 32:3 141:24 142:1 errata 146:6,9,12 146:15 148:11 error 94:16,16 ESQ 2:3,9 essentially 123:18 establish 43:20 estimate 18:15,21 20:11,21 21:15,16 25:7,9,18 et 1:10 Ethicon 1:5,10 7:3 15:11,12 16:22,23 30:13 41:17 43:17 45:7,11,16 46:22 52:1 54:8,20 55:3 55:7 58:3 72:10 107:5 108:9 113:5 113:10,14,17,21 114:3,15,20,24 115:9 116:10 117:14,23 118:2,3 118:10,13,17,19 119:2,11,14,19 120:14 121:4 124:5,23 135:18 Ethicon's 52:6 107:8 110:3 117:2 119:22 120:7 137:6,19 evaluate 61:18 62:2 evaluating 53:23 80:8 event 22:17	events 23:7,8,13 66:4 113:17 everting 9:12 everybody 33:20 everybody's 24:7 evidence 38:9 48:16 52:7 53:22 56:16 62:4,11 63:19,20 64:6 72:4 84:3 85:4 90:9,9,17 92:4 95:2 98:5 99:24 100:21,23 101:17 102:11 107:21,23 142:19,23 evidenced 79:7 82:2 evidences 27:1 evidencing 78:9 81:11 exact 17:22 exactly 33:12 36:15 49:6 114:12 139:19 examination 3:4,5 4:4 97:3 121:12 142:10 examined 4:3 33:10 example 29:16 30:8 examples 68:2 exhibit 3:8,10,11 3:12,15,18,19,20 4:11,14,18,24 57:16 59:2,5 60:16,19 65:5,8 70:12 71:7,9 90:5 95:4,7,14 96:20 104:3 123:11,15 130:20 133:13,14 EXHIBITS 3:6 exist 5:20 37:6 58:21 74:7 75:3 78:12 79:14 108:16 existed 44:13,24 46:23 52:12 74:12	existence 79:7 84:3 84:10 108:9 exists 62:23 74:3,17 expected 66:23 expensive 45:21 experience 7:19 17:12 26:22 29:10 44:10 58:16 71:19 81:3 82:9,12,15 82:19,19 104:19 106:17 112:4,5 expert 42:8,10 47:19 48:7 49:24 53:16 58:9 59:10 133:3 143:11 experts 105:6 133:7,23 expires 145:22 148:20 explain 13:8 50:18 53:9 58:7 79:18 81:22 84:2 explant 63:2 explanted 3:17 62:15 64:3,7 65:10 67:23 107:23 explants 3:14 60:22 explosive 104:9 exposed 68:5 exposure 77:10 97:5 98:24 100:7 102:5,15,17,22 103:2 104:6,14 105:12 127:10 extensive 42:5 extent 48:11 external 17:17 extrapolate 19:8 88:3 extrusion 31:8 77:10 extrusions 32:4 141:24 142:1 eyes 28:17
E E 145:1,1 147:1				F

F 145:1	feel 17:16 36:10	130:14,19	fourth 1:17 68:20	50:10 57:7 60:18
fact 11:20 33:13	45:24 60:11 72:11	followed 80:17	frankly 133:15	64:9 65:7 88:7
47:11 56:11 58:15	72:14 84:24 85:1	follows 4:3	French 54:23 55:1	95:6 114:8 121:1
61:6 63:10 66:12	99:23 106:6	Ford 92:18	frequency 32:12,16	123:11,12 126:12
70:20 77:22 85:8	128:20	foregoing 145:9	113:6 138:18,23	136:24
85:12 94:19 99:13	felt 13:9 56:21	148:6	139:6	GOLKOW 1:22
101:4 105:12	fibrosis 37:8 68:11	foreign 109:14	frequently 87:4	good 26:1 28:8 29:4
122:22 142:22	69:6 109:21,24	foreign-body	front 61:23 83:10	34:24 45:24 87:18
143:9	110:2,4	107:13,18 108:7	133:13	GOODWIN 1:9
fail 146:18	field 105:6	108:10,21 109:3,9	Frost 1:16	gotcha 68:8 96:6,8
failed 28:19	filament 49:22	109:11	full 15:16,17 46:10	100:13
failure 28:5,6 87:5	File 1:5	forgot 105:21	48:3 66:5 68:22	gotten 20:1
120:2 127:6,21	final 117:1	form 20:14,20 21:2	78:19 79:3 93:12	graft 130:16
128:5,6,21	finalize 122:1	21:11 22:20 23:15	110:18	great 1:17 8:6 28:9
fair 8:16 13:24 14:6	financial 46:1	23:19 27:4,21	function 140:13	Greg 4:6
17:10 18:4 20:17	find 12:5	30:3,9,14,19 33:7	further 3:5 66:15	GREGORY 2:3
20:19 22:10,11,14	finding 97:11 99:12	34:7,18 35:6,22	142:10 144:3	groin 77:3
24:8,17 27:10,11	100:17	36:4,13,21 38:6		group 71:18 81:3
27:20 28:15,20	findings 95:11	39:4,23 40:2 43:2	G	87:24 101:4
29:21 30:20 31:12	96:13,17 101:11	43:8,23 44:22	gather 139:17	group's 101:1
32:10 33:6 34:22	101:12 103:24	45:3,15,18 46:12	gbentley@zonies...	groups 100:6
37:15 39:8 44:10	126:7 143:18,22	47:1 48:4,13,22	2:6	102:17
44:11,17 47:11	fine 26:17 31:16	52:4,9,21 62:13	general 1:11 3:8	Guelcher 132:13
48:2 52:16 56:18	33:22 37:16 39:20	63:1 67:6 69:20	4:8,15 23:22 88:4	133:7
57:1 62:12 69:9	91:14	72:6,13 73:19,24	112:9	guess 56:7
73:9 91:11 100:2	first 4:2 8:22 10:11	81:13 85:15 87:19	generally 23:21	guessing 29:18
112:10,24 113:2	25:3,4 34:17 62:2	89:11 90:10 98:1	geometry 50:2	Gynecare 7:2,9,22
138:5	72:20 78:19 79:1	99:9 100:4 107:2	give 14:18 21:12,15	8:19 9:5 10:4
fairly 19:23	93:12 98:22	108:14,24 109:5	21:16 27:17 29:10	11:8,20,21 12:12
familiar 61:1 65:14	110:18 111:11	109:18 112:1,19	31:13 48:2,10	12:13,21,23 49:16
70:24 71:11	117:24 118:20	113:3,8,24 114:6	68:2 120:21	Gynemesh 7:12,13
109:20 123:21	123:21 145:8	114:21 115:2,13	121:24	8:19 9:5,15 10:4
124:2 132:15,19	fissures 67:10	116:3,7,19 117:21	given 145:10 148:8	12:12,21 49:16
family 11:21 12:13	five 18:20 20:16,18	118:5,21 119:3,9	gives 108:5	53:11 54:1 92:4
Famous 121:19	five-year 130:19	119:16 120:11,15	giving 145:6	
fashion 47:23	fleshed 123:3	148:10	go 8:11 19:19 33:24	H
favorable 28:13,18	flexibility 66:18	formed 131:19	35:14 46:16 47:4	half 103:16
48:16 110:20	floating 69:18	forming 43:12	47:9 56:17 57:12	halfway 111:11
fax 1:23	floor 19:1 35:8,8	48:21 124:22	76:9 84:13 87:2	hand 4:13,20 60:18
FDA 22:17,22,24	58:15,16 62:4	formulating 130:8	95:17 105:4 107:9	65:7 95:6 124:10
42:6,18,22 43:13	88:7 111:12,23	131:2	126:15 141:1	145:17
43:17,19 44:14,18	112:2,3 123:1	forward 46:15	goes 11:15 36:22	handed 59:4
45:6 46:23,24	141:18,21	found 80:11 85:12	79:24 83:1	hands 28:8 85:3
47:3 52:18	focus 56:15	85:20 97:11	going 4:13,20,23	87:20
FDA's 42:14 43:4	follow 26:12	102:21 104:14,22	9:12 18:11 20:14	happen 68:3 97:13
43:10 52:23 73:1	follow-up 16:18	four 17:9 19:9,9,9	23:24 28:6 29:4	happened 33:12
feasible 56:4	75:19 130:11,12	26:14 110:20	37:10,13 50:1,6	47:2

happening 140:12 happens 38:14 40:4 happy 24:4,7 hard 25:7 32:24 33:3 45:19 harm 135:2 header 70:4 106:21 heal 71:17 81:1 health 43:14 120:5 heavier 12:17 49:17 50:24 help 40:18 128:21 128:22 helpful 90:8 117:19 118:23 119:14 hemorrhage 31:6 hereunto 145:16 high 28:19 51:1 120:1,2 high-risk 88:17 89:5 higher 25:24 57:2 76:2 97:4,6,11 98:4 99:7 104:14 104:23 126:10 128:20,23 142:23 highest 75:17 100:23 102:11 Highland 2:10 highly 42:19 hip 69:8 hold 47:18 holding 123:22 home 29:19 honed 59:11 honest 143:14 honestly 56:4 hope 30:21 72:17 73:16 hopeful 85:7 horrible 93:18 hour 24:6 57:7 hours 37:13 hundred 17:24 18:13 hymen 87:14 hypothetic 41:11	<hr/> I <hr/> Iakovlev 3:15 65:9 65:18 132:13 133:3,6,10,16 135:12 143:3 ideal 129:9,13 identification 4:11 4:18 59:2 60:16 65:5 71:7 95:4 123:15 identify 51:13,20 53:22 IFU 57:19 105:24 107:9 115:1,4,10 117:5 118:1,4,15 118:20 122:11,17 IFUs 16:1 106:24 116:12,16,21 117:1,11,12,13 118:11 ignore 48:16 iliococcygeus 13:18 impact 44:8,9 52:15 63:15 67:4 67:15 68:24 69:2 69:19,22,24 89:21 89:23 137:10 impacts 53:19,23 109:9 imperative 146:14 implant 18:17 31:12,22 36:19 54:3 66:13 97:14 107:16 110:5 implantation 38:12 38:14 66:8 80:19 108:6 140:9 implanted 20:7 22:4,7 26:13 38:5 38:10 109:9 116:2 137:16 implants 36:12 37:20 38:18 39:3 39:10 62:3,23 63:21 69:8 108:12 109:24	important 34:14,15 42:16 43:1,7,21 43:24 44:1,3 47:22 48:1,3,6 67:9 84:20 90:18 91:21 115:17,21 improved 130:18 include 20:13 22:23 90:18 91:22 94:24 97:12 included 142:16 includes 95:1 including 71:20 81:4 82:19 86:10 92:12 111:16 incontinence 97:5 97:7 98:24 111:13 incorporates 37:7 140:23 incorporation 37:8 increase 66:23 increased 35:1,10 35:15 increases 34:21 Increasing 77:15 index 3:1 77:12 indicate 51:14,21 84:17 indicated 66:7,17 indications 44:7 individual 24:12 individually 6:20 individuals 88:17 88:18 132:21 industry 47:3 inert 3:14 60:21 62:6 infection 31:6 68:6 68:6 141:14 inflammation 68:11 69:6 inflammatory 108:22 inform 28:12 45:1 information 27:18 32:17 47:4,5 73:9 73:23 85:8 113:6	113:22 114:3,16 114:20,24 115:9 115:11,12,16 116:5 117:15,24 118:2,2,3,6,14,17 118:20,22,24 119:14 120:13 121:4 124:11,16 124:23 125:17,18 informative 56:22 informed 27:18 29:8 32:23 115:21 115:22 116:6 informed-consent 28:24 30:22 32:13 ingredients 136:15 136:18 initial 16:19 26:10 initially 5:6 8:12 128:8 injury 31:6,7 32:3 32:3 97:6 innovations 87:4 inside 107:16 INSTRUCTIONS 146:1 insufficient 43:20 44:20 Intact 61:12 integrity 137:21 intend 58:2 intensity 109:9 intercourse 111:18 interest 145:14 internal 41:17 54:9 54:19,23 55:3,7 107:5,9 110:4 113:14 136:14 internally 52:1 119:19 interrupt 12:6 invasive 40:12,22 88:23 involved 15:18 involves 49:21 115:18 issue 24:22 28:10	56:22 89:18 issues 41:14 47:23 48:2 52:12 129:3 iterations 117:1 <hr/> J <hr/> Jimmy 1:9 joint 27:10 joints 68:10,11 69:5,7,22 70:7 JORDAN 2:9 jordan.walker@... 2:12 JOSEPH 1:9 journals 55:9 JUDGE 1:10 July 134:7 145:18 June 1:19 jury 58:3 143:21 justify 88:18 <hr/> K <hr/> KARRAM 1:13 3:3 4:1 145:7,11 148:15 keep 30:4 41:6 121:23 Key 98:20 kind 6:22 35:19 58:14,18 134:11 134:16 135:2 kit 10:11 12:24 14:5 18:10 kits 10:8,16,22,24 12:24 13:5 14:11 14:12 15:3 18:5 24:24 25:24 75:17 89:4 93:23 99:6 111:3 139:12,16 knew 133:11 knitted 51:1,3 know 11:14 14:20 17:22 19:7 22:12 33:11,13,13 38:23 40:21 41:12,12,14 41:15 45:6,9,11 45:13,14,17,20
---	---	--	--	---

46:3,5,7,18,21,21 46:22 47:2,2 52:1 52:18 53:18 55:10 58:19,20 60:10,12 60:13 72:12 76:13 84:12 91:7 103:6 106:12 107:3 108:4 109:8 115:23 116:18 117:5 119:18 124:9 128:9 135:21 138:13,14 139:3,5 142:15 knowledge 111:12 111:23 112:9,20 113:1 114:5,17 122:24 knowledgeable 30:7 known 23:9,9 69:5	left 61:12 77:1 86:9 leg/groin 111:18 legal 41:13 106:23 lengthier 88:23 let's 8:11 19:9 78:13 83:20 95:14 96:19 121:14,15 126:15 136:7 letter 115:1 level 56:15 100:21 102:11 113:1 114:4,17 142:18 142:23 levels 90:17 LIABILITY 1:6 life 34:1 130:19 life-altering 34:5,8 35:18,19,21 71:19 72:1,5,8 81:4,11 81:23 82:6,7 84:4 84:10,13 138:2 life-changing 33:5 33:24 life-threatening 33:14,23 lifelong 138:9,14 ligament 13:18,20 lighter 12:2,8 liked 44:21 46:8 52:13 54:22 55:6 108:15 likelihood 28:6 128:23 likewise 22:7 53:18 limited 23:3 71:16 80:24 97:17 111:16 LINE 147:4 list 3:10 4:21,24 41:16 54:9 55:22 58:23 61:6 62:10 65:16,18 71:5 83:1 122:24 listed 54:11 55:22 61:19 literature 16:2 17:12 27:1 29:9	29:12,15,19,22 30:2,5,7,17 32:18 32:20 33:16,19 37:4,23,24 38:3,9 38:17 39:2,7,9 42:22,24 43:11,20 44:9,19 45:2 47:22 49:4 50:14 51:7,14,18 54:12 55:4,5 60:10 62:5 70:16 73:12,18 78:9 81:9 82:10 82:14,18,21,22,23 83:8,16 86:6 99:18 103:21 104:19 109:24 112:4,18,21 113:11 129:18,24 131:1,13,18,23 134:8 135:1 137:22 138:22 139:6 literature's 55:8 litigation 1:6 4:7 89:10 133:8 134:2 143:10 little 12:2,17 50:24 91:4 live 15:20 16:3,5,9 16:12 34:1 LLC 1:17 2:4 LLP 2:10 log 41:6 long 26:12 107:15 140:9 long-lasting 33:23 long-term 130:5 138:6 longer 6:10 12:20 14:22 15:4 41:10 41:20 53:3 look 4:16 33:8 37:4 42:19 47:5 72:20 76:14 95:14 96:19 106:3 123:12 143:5 looked 56:7 58:24	60:11 61:3 84:7 85:19 99:24 100:18 101:7 102:13,21 104:13 105:17,20 110:23 130:5 140:8 looking 50:15 58:14 68:18 84:6 96:16 100:12 102:7 105:4,5 127:9,12,15,17 134:9 loss 49:8 59:24 60:2 66:17 low 87:3 lower 97:1 142:18	material 55:1 67:11 74:14,20 131:17 materials 6:7 122:11 math 18:6 matter 55:9 matters 46:13 52:24 143:12 MAUDE 22:22,24 23:4,7,12 maximum 33:2 MDL 1:5 mean 23:23 38:23 45:20 46:13 79:23 85:22 meaningful 134:11 134:16 means 50:1 85:22 97:17 measures 87:10 medical 11:3,5 17:12 29:8,11,15 29:19,22 30:17 32:18,20 33:11,16 35:24 37:22,24 38:3,8,16 39:2,9 43:11 44:9,19 45:2 47:22 78:9 81:8 82:10,14,17 82:21,22,23 83:8 83:16 86:5 88:22 99:18 103:21 104:19 109:23 110:19 112:4,18 112:21 113:11 124:23 129:18,23 131:18,23 134:8 134:24 137:21 138:22 139:6 medicine 5:3 40:19 medicolegal 143:12 meetings 70:16 mention 123:6 mentioned 31:11 mesh 6:19,20,22 7:11 8:6,22 9:2,6
L			M	
labeling 59:12 107:1,4,6 labs 124:4 lady 24:21 Landsheere 130:2 142:23 large 13:12 56:9 120:4 145:3 larger 10:1 29:2 lastly 68:8 101:19 late 136:3 137:1,1 latest 93:13,20 94:12 LAW 2:4 lawful 4:2 layer 66:16 lead 40:8,9,10,14 40:23 108:23 109:4,16 leading 109:3 124:8,19 130:18 132:10 133:4,9 learn 112:2 lecture 16:21 led 16:9			M.D 1:13 3:3 4:1 145:7,11 148:15 ma'am 144:6 macrophages 68:14 69:14 macroporous 11:17 50:22 Maher 3:19 93:14 93:20 94:6,20,21 95:7,11,15,20 130:12,13 majority 25:20 making 142:7 malignant 49:9 managed 23:9 33:22 manufacturers 14:13 mark 4:23 123:10 123:11 marked 4:11,13,18 57:15 59:2,5 60:16,19 65:5,8 70:12 71:7 95:4,7 95:15 123:15 market 45:12 46:11 53:4 marking 71:9 Master 1:5	

Michael Karram, M.D.

Page 158

9:7,13,15,21 10:6 10:7,16,22 11:7,8 11:15,17,18,20 12:18,19 14:5 18:5,10,16 31:7 31:12,15,17,21 32:2 36:10,11,12 36:14,19,20,22,23 37:5,8,19,21,23 38:1,4,9,11,13,15 38:17 39:2,12,18 39:21 40:1,4,10 40:23 46:16 49:3 49:10,10,13,15,17 50:19,20 51:1,3,9 51:9,11,18,22,23 52:7 53:10 54:4,5 55:15 58:17 59:17 60:2 62:19 66:8 66:23 67:3,23 68:1,5,7 69:17 71:16,21 74:4,6 74:12,17,20 75:2 75:6,7,8,17 76:6 76:15 77:5,9,17 77:18,22 78:9,12 79:7,14,20,21,23 80:9,13,15 81:1,5 86:12 87:5 88:15 88:16,17 89:4 92:16 93:23 97:1 97:5,17 98:24 99:3,6,8 100:6,7 102:5,15,16,17 103:2 104:5,8 107:12 108:5 109:8,11,14,24 110:21 111:14 125:21 126:8,10 127:10 128:14,17 130:16 131:3,14 131:20 133:8 134:2,9,15 135:17 138:16 139:12,16 139:22 140:3,9,10 140:13,18,21,23 141:2,23 143:13	mesh-based 20:4 20:11,19,24 28:7 76:3 111:3 mesh-related 66:7 meshes 3:17 7:6,9 7:19,22 8:5,8,12 8:14 10:3 65:10 68:12 69:12 meta-analyses 56:8 56:13,16 meta-analysis 82:23 127:5,21 132:6 134:9 135:7 methods 40:18 86:10 MICHAEL 1:13 3:3 4:1 145:7,10 148:15 microscopic 3:16 65:10 mid 11:18 midurethral 93:2,3 mind 110:9 minimal 33:2 minute 95:17 Mississippi 2:11 mistake 83:15 mitigate 128:22 modern 87:9 Monarc 11:14 monofilament 11:18 50:23 Monograph 3:20 123:7,22 months 26:16 80:8 80:16 Moore 1:15 145:4 145:21 move 46:15 64:9 70:8 80:20 114:8 115:5 multiple 32:10 34:13 36:1,5,6 40:24 41:2 116:15 117:1,3 multitude 135:7 muscle 13:18	N N 2:9 name 4:6 14:19 108:3 narrowing 111:18 native 6:5 8:18 14:7 25:12,19,20 26:1,8 28:3,5 29:4 31:14 74:7,13,15 74:17,18 75:3,18 85:1,5,13,20,23 86:10 88:4,5,6,10 89:8 97:3 99:1,14 102:14 120:4 125:21 126:8,11 127:6,22 128:4,15 129:1 138:23 139:7 142:2 necessarily 9:9 14:1 22:12 34:23 35:18 49:21 51:5 63:2 85:16,22 97:24 113:9 necessary 146:4 necrosis 68:10 69:6 need 8:7 31:8 32:5 43:5 57:8 73:8 86:2 115:4 needed 87:5 needs 107:9 neighborhood 17:23 18:7,12 20:15 21:4,19 neither 145:13 never 7:22 13:17 14:14,15 23:4 29:18 new 46:24 94:21 129:7 night 15:17 Nilsson 92:12 Nine 126:1 non-mesh 58:17 noninvasive 40:17 40:19 nonresponsive 37:2	37:11 64:10 80:21 115:6 nonsurgical 5:15 40:18 nonuse 77:4 normal 34:1 notary 145:5,22 148:22 note 72:23 noted 146:11 148:11 Notice 1:14 notices 43:13,15 notification 73:1,4 noting 73:22 novo 97:6 number 17:22 18:4 19:23 21:13,21,22 21:23 41:16 54:11 55:21 65:18 66:4 92:12 93:5 95:11 118:10 125:19 137:5 138:1 numbers 56:9	118:5,21 119:3,9 119:16 120:11,15 136:24 objection 122:14 122:19 123:5,24 124:8,14,19 125:1 127:3 128:16,24 129:21 131:10,16 132:1 134:1,6,12 134:17,22 135:4,9 135:19 136:10,20 136:22,23 137:13 137:23 138:8,11 139:1,9 140:5,15 140:20 141:5,12 141:16 142:5 objective 47:23 48:7,19 85:19 87:14 130:17 obligation 48:10 obliterative 6:4 8:18 24:5,17 observed 68:12 69:12,22 observing 16:15 obstructive 5:16 obviously 32:19 36:20 50:5 occasional 68:12 69:12,23 occur 31:10 32:6 60:8 66:12 74:15 77:3,17 112:6 141:20 occurred 67:17,22 108:22 occurrence 39:15 occurs 60:6 Off-the-record 83:21 offer 58:2 116:9 office 22:23,24 40:20 76:6,16 145:17 offices 1:16 official 145:17 Oh 12:9 20:15
---	--	--	---	---

Michael Karram, M.D.

Page 159

55:15 64:16 83:12 89:24 90:6 95:22 100:12 114:13 122:2 127:9,14 136:4 Ohio 1:18 145:2,6 145:22 okay 4:20,24 5:1,10 5:14,20,23 6:9,12 7:1 8:17,22 9:5,14 10:3,9,10,16,24 11:2,19 12:19,23 13:8 14:17,21 15:1,6,18,21,24 16:12,18,23 18:8 19:15 20:2,15,17 20:22 21:7 22:16 24:8,10 25:6,14 27:12,23 29:6,13 29:18 31:18,20 35:24 36:7,8,18 37:17 38:4 39:17 40:8,16 42:1 43:17 44:16 45:5 45:11 47:14 48:1 49:14 50:1,13 51:6,20 52:1,18 53:6,9 54:14 55:24 56:3,18,20 57:14,23 58:7,12 58:23 59:4,8,14 59:20 60:8,18 61:1,5,10,14,17 61:23 62:9,18 63:4,8,15,23 64:18,19,21 65:20 65:22 66:3,15,21 67:8 68:17,19 69:11,17 70:13,19 70:24 71:11,24 72:4,9,20 73:11 74:22,24 75:11,22 76:20,24 77:8,15 78:3,18 79:15 80:2,6 81:15,18 81:22 82:8 83:13 84:23 85:11 86:7	87:8,21 88:8,9 89:3,7 90:2,21 91:17,19,24 92:3 92:9,10,15,18 93:2,8 94:8,23 95:6,9,14 96:4,15 96:16,21 97:10,16 98:17,18 99:23 100:13,16 101:15 102:1,6,20,24 103:6 104:2,4,8 104:21 105:1,12 105:16,19,22 106:5,11,14 107:8 107:11,15,21 109:8 110:17,23 111:2,5,10,22 112:8,12,22,23 113:21 114:10 115:16 117:10,23 118:8,9 121:2,8,9 122:2,5 125:4,8 126:16 127:16,18 127:18 128:3 129:17 133:16 137:3 139:4,11 144:4 once 12:23 38:5,10 ones 56:13 130:10 ongoing 108:10 open 88:23 120:4 operate 19:7 operation 26:9 opine 122:10 opining 111:22 opinion 34:4 35:9 36:23 37:5,7,19 37:22 38:2,4,8,13 38:16 39:1 41:15 44:6 48:17 58:2 60:14 63:4,16 64:16 72:7 82:22 83:1,3,6 86:5 89:21 91:20 107:22 110:24 111:5 117:10 122:17 131:22	140:3,7 141:3 opinion's 83:7 opinions 17:11 42:13 43:12,22 44:1,3,8,9 45:1 46:20 48:21,23 52:15 54:23 58:8 70:14,15 72:9 82:13 84:20 89:18 89:23 90:22 92:1 106:15 116:9 117:8 124:22 130:8 131:2,19 137:11 143:11 opposed 7:6 140:18 options 5:10,15,20 5:24 6:1 order 41:23 42:2 organ 5:17 72:15 74:4 88:16 110:21 111:14 112:7 122:22 organizations 70:21 71:24 73:7 73:21 83:4 84:20 original 87:8 89:8 146:15 originals 122:1 outcome 28:14 74:3 87:10 outcomes 87:10 130:18 134:20 outdated 94:20 outside 35:7 outweigh 98:5 overall 75:19 102:15 103:8 104:8 oxidate 136:11 oxidizing 136:1,12	74:2 76:23 77:2 78:17,23 83:10 86:5,24 90:4,5 92:3,6,11 93:8,9 93:12,19 94:3,5 94:11,19 95:10,16 95:20,21,23 96:2 96:5,14,20 98:20 101:20 102:4 103:1,12 104:3 105:19 110:7 111:9 121:20 122:4 123:3,7,17 123:18,19 125:6 125:14 126:12,15 129:15 130:22,22 133:17 143:6 147:4 pages 148:6 paid 133:23 pain 31:8 32:4 40:8 40:9 41:3 71:20 77:2,3,16 81:4 109:4,7 111:17,17 111:19 141:3 para 79:10 paragraph 66:5,22 67:8 68:9,22 72:21 74:5 75:14 78:20 79:3,9 80:5 80:7,23 93:4,13 98:22 100:11 110:18 111:11 122:8 Parkway 2:10 partially 7:20 particle 49:8 59:24 60:2 particles 68:12 69:13,23 particularly 88:19 parties 145:14 passers 17:18 patient 9:23 14:2 24:3 26:13 27:9 27:13,17,23 28:12 28:18,18,23 29:7	30:23 32:14,22 33:1 56:9 57:19 67:4 85:23 105:24 106:3,7,15,20 107:1,4,6 115:22 117:19 118:24 119:4,8,12 120:8 124:12 128:10,18 129:3 patient's 33:11 patients 3:17 15:20 20:3,6 25:19 26:8 26:23 27:5,8 29:9 29:19 30:24 31:23 33:21,22 41:7 45:22 53:20 62:15 64:3,8 65:11 71:16,19 80:13 81:1,3 82:3,5 88:14 89:5 97:23 97:24 106:10 112:5 115:18 116:5 119:20,24 120:1,1,3,3 121:5 125:20 134:21 137:16 peer-reviewed 55:9 143:18 pelvic 1:5 3:13 5:17 18:24 19:1 31:8 32:4 35:2,3,8,8 58:15,16 60:21 62:3 72:15 74:4 77:2,3 88:7,15 110:21 111:12,14 111:17,23 112:2,3 112:6 122:22 123:1 141:3,18,21 pelvis 35:5,7,7 Pennsylvania 15:10 people 30:10 33:14 people's 85:3 percent 18:20 19:5 19:6 20:10,16,18 20:23 21:4,5,8 25:5 80:12,13,15
--	---	--	--	---

86:14 87:13,17 99:1,2,2,5,15 100:5,11 102:16 102:21 103:3,6,7 103:11 104:9,14 104:22 105:2,7,13 128:5,6 129:12,14 129:20 130:1,2,3 percentage 18:15 21:22 25:1,8,18 26:8,11 perform 18:16,22 34:24 41:7 43:18 45:7 72:24 performed 17:21 18:2 performing 9:3 32:13 72:14 Perigee 11:1 13:17 period 140:9 permanent 71:19 81:3 96:24 99:3,8 102:16 111:16 permanently 116:2 personal 44:10 82:8,18 personally 16:20 22:21 132:17 pessaries 5:16 ph 1:23 Phone 2:5,11 photos 61:18,20 62:14 phrase 35:19,20 physical 120:3 physicians 27:6 picture 48:3 pictures 61:11 piece 54:4 76:5 81:8 109:13 pieces 129:23 Pinnacle 14:15 place 30:11 33:12 140:19 145:10 placed 40:7 88:15 placement 74:4 80:9 88:18	plaintiff 1:14 2:2 89:12 plaintiffs 4:7 49:3 133:7,24 plan 28:11 plating 108:23 109:3,6,17 please 38:20 42:4 57:14 70:11 79:11 84:1 86:4 98:19 101:20 110:7 111:8 146:3,8 Plus 6:17,19 point 8:13,19 62:22 78:14 83:18 107:19 108:6 poll 112:15 polypropylene 3:12 3:16 6:24 7:6 11:17 49:22 51:4 59:17 60:20 62:6 62:16,16,19,23 63:21 65:9,24 68:12,13 69:12,13 70:2,6 108:12 132:3,12 135:12 135:22 136:1,2,8 136:11,19 143:12 population 88:4 porcine 6:7 pore 49:9,12 50:2 50:14,20,22 51:8 porosity 51:1 portion 15:19 position 3:18 70:21 71:1 77:6 78:4,5 79:8 82:2 83:5 90:8,16,16,23 91:2,12 98:6 110:20 119:23 positive 86:1 130:17 137:18 possible 27:18 31:8 32:5 58:20 98:3 122:20 Possibly 45:4 52:17 63:6 67:7 73:20	posterior 11:4 13:16 23:20 potential 49:9 67:10,15 69:2 138:9 potentially 109:16 111:15 PP 62:6 practice 6:6,12 7:10 18:14,24 19:5,6 20:2,10,18 20:23 21:8 23:4 134:19 practicing 5:2,11 preceptor 16:10 preclude 88:23 prefer 36:3 preference 7:5 13:3 13:4 23:17 preferred 13:14 preparing 44:23 present 77:11 106:14 presented 8:19 48:11 76:11 pretty 47:3 87:18 previous 28:14,19 129:2 previously 4:22 14:22 42:7 49:14 77:21 85:14 90:7 97:22 primary 97:18 119:8 prior 10:18,19 15:23,23 16:4 probably 9:13 13:14 17:5,6,9,23 18:3,11,12 21:3 21:19 24:18 25:4 30:10,16 40:6 46:21 65:16 79:16 128:18 problem 24:6 68:7 problems 26:17 31:9 32:6 33:9 49:3 71:17 81:2	81:11,24 111:19 procedure 6:21 7:7 9:2,6 17:1,4 21:10 21:18 23:23 24:5 24:6,17,18 26:3,4 26:10 27:3,19,20 28:1 29:1,7 30:12 31:9 32:5,23 33:6 33:10,11,18 34:21 34:23,24 40:5,12 43:19 44:6 45:8 76:16 77:12 103:18 116:1 119:1 124:13 125:21 138:24 procedures 5:18 6:13,15,20 17:21 18:2,9 19:9 25:9 27:14 32:10 36:6 56:11 72:24 88:24 97:13 139:17,19 139:20 process 11:12 28:24 30:22 32:14 46:9 processes 108:22 procentia 9:11 proctor 16:21 proctoring 30:12 product 10:6 12:17 13:10,14,23 14:1 17:16 20:8 22:4,8 25:11 26:13 27:14 28:7,8,13 29:23 42:5 45:24 54:8 86:8 128:14 products 1:6 10:7 11:7,21 12:14,20 15:2 18:2 20:4 46:16 49:2,3 53:3 53:6,24 55:16 58:18 81:12 84:5 84:11 134:10 135:18 Professional 1:15 profile 84:24 97:17 programs 124:4	prolapse 5:4,7,8,12 5:18 6:2,14 8:14 8:23 9:10,10 10:1 13:12 14:6,13 18:2,5,9,16,23 19:3,4,13,14 21:1 23:18 24:19 25:2 26:10 28:3,15 29:2 72:15 74:5 85:24 87:14 88:16 88:19 93:23 97:2 97:2,2,4 98:24 110:21 111:14 112:7 119:13 120:3 122:23 128:10 129:4 130:16 Prolene 7:15 11:20 11:22 12:13,19 49:15 50:19 51:9 51:9,22 53:7,10 53:11 54:1 59:17 62:18 131:6,9 134:9,10,15,20 135:2,18,22 136:9 136:15,18,19 Prolift 1:11 3:9,21 4:9,15 6:9 9:8,13 9:15,20 10:12,13 10:18,19,21 11:22 12:24 13:9,11,16 13:19 14:1,11,22 15:2,4 16:16,19 17:1,4,21 20:7 21:10,18 22:4,8 22:18 23:3 24:24 25:2,3 26:13,20 27:3,7,24 28:13 28:18 29:1,7,22 30:7,12,17 31:2 32:8,23 33:5,15 33:18 34:14 36:2 37:20 38:18 39:3 39:10 40:5 41:10 41:20 42:15,24 43:6,11,19 44:14 44:20 45:8,12,16
--	--	---	--	--

46:10 48:22,24 50:16 51:10,11,13 52:3,20 53:2,12 53:24 54:4,8 55:17 56:23 57:5 58:4 62:18 72:11 83:18 84:24 85:2 89:4 93:5,9 97:13 97:23 99:7 107:12 110:5 111:3 114:18 116:16 117:1,24 118:11 119:1,7,12,19,23 120:9 121:5 122:11,13,17,18 122:21 123:7 124:12,18 125:12 125:21 127:1,6,22 128:4,5,10,14,22 129:19 130:5 131:8,14,20 135:8 137:6,10,12,17,17 137:20 138:10,24 139:7,12 141:4,8 141:11,15 Prolift-specific 15:6 Prolift+M 8:1 properties 51:12 51:17,22 propounded 148:9 proprietary 11:12 prospective 82:24 prosthetic 68:9 69:5 provide 64:4,12 82:17 96:11 98:12 101:16 provided 54:19 66:6 116:10 124:5 124:23 143:11 provides 62:4 PS 7:13,14 8:19 9:6 9:15 10:4 12:12 12:21 49:16 92:4 public 43:14 145:5 145:22 148:22	publications 133:1 publicly 54:18 published 55:4,5,8 62:5 71:1 93:5 143:19 pulled 46:11 47:13 purposes 4:23 pursuant 1:14 145:12 put 15:11,12 36:23 70:16 110:20 115:4 117:24 118:3,20 120:14 120:20 121:4 <hr/> Q <hr/> qualified 42:19 quality 130:18 139:16 quantified 85:21 quantify 32:24 33:3 75:24 76:4 quantity 76:1 question 34:19 36:15,16 37:14,15 38:20 39:1,19,22 44:15 60:4 62:22 75:4 76:5 79:5 93:18 99:16 114:12 115:6 119:5 127:19 139:2 questions 28:10 73:1 121:11 125:9 128:8,11 129:9 130:24 137:5 138:1,17 139:22 143:2 144:3 148:8 quote 51:24 quoted 108:2 quoting 76:13 <hr/> R <hr/> R 1:9 145:1 147:1,1 randomized 45:21 46:16 56:8,13 82:23 86:9 87:12	105:6 125:19 128:4 132:8 134:14 135:7 143:24 range 29:16 rate 75:15,17 76:1 76:2 87:18 97:12 98:23 99:7,14 104:9,9,14,18,23 105:12 127:6,10 127:11,21 128:5 129:9,13,19 rates 29:16 86:12 87:3,5,11 97:1,4,6 125:10 ratify 51:11 rats 39:6 107:24 RCT 87:12 RCTs 102:7,10 105:17 re-ask 91:5 115:6 121:1 reach 99:18 117:6 reached 42:24 128:7 reaching 42:13 54:23 100:17 reaction 107:13,18 108:5,7,10,22 109:3,10,12,14 reacts 50:24 read 16:1,1 27:1 33:16,19 59:13 62:1,7 66:9,19 67:1,12 69:15 71:3,22 75:20 77:19 81:6 83:10 87:15 89:15 97:8 97:19 98:7 99:4 99:21 100:14 102:18 103:4 104:11 111:20 132:24 146:3 148:5 Reading 15:10 ready 57:12 real 60:13	really 21:12,14 29:4 33:13 46:13 46:19 53:13 55:9 69:23 Realtime 1:16 reanalyzed 87:9 reason 8:4 23:6 63:23 64:5 67:17 82:17 87:4 103:23 143:18,22 146:5 147:6,8,10,12,14 147:16,18,20,22 147:24 reasonable 114:2 114:15,20,23 115:3,8,14 117:17 117:18 121:4 reasons 76:15 84:23 123:2 recall 15:13 129:13 133:2 136:17 137:7 receipt 146:17 receive 15:6 recess 57:9 reconstructive 77:4 record's 12:7 records 33:11 recreating 129:7 recruit 45:22 recurrence 85:24 98:4 128:21,23 recurrences 120:2 recurrent 28:3 88:19 redirect 79:17 121:17 reduction 80:15 reevaluated 85:12 refer 37:23 reference 4:21 38:9 39:2,12,14 129:11 referenced 78:10 references 84:6,7,9 referencing 95:19 referral 22:8 referred 22:3,5	referring 39:7 84:9 91:14 116:20 127:12 141:23 reflect 72:4 reflected 125:23 136:14 137:21 reflects 58:24 regarding 4:9,15 29:22 30:17 32:23 42:14 43:6,11,18 44:8,10,19 45:2 48:21,23 49:5 50:14,20 51:8,23 52:3,7,20 54:8 55:7 58:4 62:23 70:20 84:3 86:6 92:4,15,24 93:23 106:15 109:24 113:6,22 114:5,17 115:17,24 118:1 118:14,18,24 121:5 128:9 131:19 132:3 137:11 138:23 139:6 regardless 33:2 77:4 regards 110:20 Registered 1:15 regulation 107:3 regulatory 42:8,10 58:9 59:10,11 106:23 reinforcement 3:13 60:20 62:4 129:6 related 20:3,11 21:9 23:10,13 31:21 33:15 34:14 36:2 37:20 38:17 39:3 51:22 73:1 84:11 108:10 113:7 143:12 RELATES 1:8 relating 135:8 relationship 55:17 139:15 relative 145:13
---	--	---	---	---

released 117:2 118:10 relevance 46:19 131:1 relevant 50:19 51:8 51:14 52:8 131:13 reliable 50:13 90:9 reliance 3:10 4:21 4:24 41:16 54:9 55:22 58:23 61:6 62:10 65:16,18 71:5 relied 81:9 83:3,5 124:22 126:5 rely 48:22 50:14 56:11 73:7 82:18 101:4 130:7 relying 49:4,7 107:21 128:15 remainder 25:8 remember 10:14 108:3 110:24 125:9 126:20 128:11 129:8 130:24 132:2,11 133:15 136:13 138:2,20 139:13 139:21 142:13 143:3 removal 40:10,24 remove 40:20 removed 76:6,15 reoperation 75:15 75:16 76:2,4,7,17 86:2 97:2,4,12 98:23 99:7,14 reoperations 76:16 repair 1:5 8:14 9:8 9:14,16 14:8 21:1 25:13,19,21 26:2 26:9,10 28:4,5 29:4,5 31:14 34:13 74:13,15,17 85:5,13,23 86:10 88:6,6,16 89:8 97:3 99:1,3,8,15 102:14 120:4,5	126:9,10,11 127:7 127:23 128:15,18 129:1 138:24 139:7 142:2 repairing 6:21 7:8 repairs 6:3,4,5,5,8 6:23 8:18 71:17 74:7,18 75:3,18 76:3 81:1 85:2 88:4,10 138:15,15 repeat 26:9 34:13 100:6 127:19 139:2 repeated 36:1 rephrase 37:16 64:20 74:23 91:18 139:3 report 3:8 4:15 17:10 44:23 47:21 52:16 55:14 56:1 56:6,21 57:4,15 59:21 64:4,12,15 64:22 70:12 78:3 78:8,11 79:6 81:18 82:13 84:19 85:9 86:22 90:4 90:19 91:2,22 92:3,6 95:10 96:17 98:12 101:15,21 104:3 105:2,20 106:5,15 106:19 110:8,16 111:5,9 121:21 122:6,10 123:3 125:7,15 126:13 129:12,15,18 130:8,21 reported 22:16,21 22:24 23:4,6 86:12 113:18 reporter 1:16 83:22 121:24 127:20 144:5 reports 77:16 89:9 89:15,17 133:3 represent 61:5 65:17 71:4	representing 4:7 reproducible 56:12 reputable 101:1 request 45:7 requested 43:17 46:24 require 9:13 required 100:6 103:2 requirement 59:12 requirements 106:23 107:1 reserved 88:16 89:5 Resource 3:20 123:7 respect 5:23 7:9 37:12 respects 145:12 response 73:4 responsibility 58:19 rest 82:13 result 33:5 67:20 77:18 86:1 137:18 145:15 Resulting 79:22 results 8:6 26:1 28:8 98:20 retention 111:19 retraction 38:13,15 38:17,19,23 39:2 39:12,18 77:17 retrospective 82:24 return 146:15 review 3:19 17:12 30:2 46:8 47:6 54:7,22 56:15 58:12 75:15 83:8 83:14 92:19 93:14 93:20,23 94:6,12 94:20 95:1,8,11 95:15 96:19 100:21 101:1 102:5,8 103:20,24 104:13,21 105:16 126:23 130:7	131:18 134:8 142:16,20,22 reviewed 42:22 46:4 54:17 55:2 55:17 58:9 59:10 91:21 106:24 107:5,8 108:8 109:23 110:3 116:12 117:6,9 124:21 126:3 132:24 134:24 137:22 reviewing 86:5 99:18 112:9 133:2 135:6 136:13 reviews 56:16 126:18 142:19 revised 87:11 revision 103:17 revisit 79:16 Ridgeland 2:11 right 5:2 8:11 19:20 20:13 21:12 24:2,14,21 25:11 25:16 31:2 32:2 35:5 36:20 40:23 41:17 42:8,11 45:2,9,13 48:7,19 49:23 50:8,11 53:4,17 54:13,15 56:1 57:5 58:24 59:22 61:9,13 62:19 67:19,20 68:17 70:1 73:13 73:18,21,23 74:1 74:8 75:5 76:7,8 77:6,13 78:11,15 79:2,4 82:16 83:14 88:2,2 91:9 92:16,23,24 93:2 93:3,21 94:4 96:12 99:6,24 100:18 101:6 108:19 121:18 123:13 126:19 136:6,21 rigorous 43:5,18	risk 28:19 35:1,10 35:13 74:6,7,12 74:14,16 75:2,2,7 88:18 98:4 99:2 102:15 120:1,2 128:20,23 risk-benefit 84:24 97:16 risks 23:9 27:8,13 30:23 31:5,5,7,11 31:13 32:13,17 34:9,21 98:5 115:23,23 122:12 122:18,20,23 124:17 rolls 40:6 RPR 145:4 RTCs 56:18 102:21 <hr/> S <hr/> sacrocolpopexies 6:4 sacrocolpopexy 25:15 sacrospinous 13:17 13:19 safer 128:18 safety 42:14,23 43:6,21 44:19 48:23 50:15 51:23 56:22 115:18 117:19 118:1,18 137:11 sanitary 24:22 save 59:15 saw 22:13 33:12 41:21 60:10 124:10 saying 49:3 67:21 67:22 69:21,21 74:16 76:2 84:8 99:6 140:17 says 60:7 61:12,13 62:2,14 83:12 86:16 99:11 143:16 scar 108:23 109:3,6
--	--	---	---	--

109:16 scarring 32:4 108:23 111:18 140:23 141:10 scientific 7:4 14:14 55:21 56:7,13 61:18 118:7 139:18 scientists 42:18 85:11 108:9 scope 123:24 124:8 Scott 132:13 seal 145:17 search 55:15 second 61:24 66:5 68:9 69:4 71:15 74:5 88:15 second-to-last 98:22 143:5 section 3:11 54:12 57:18,23 58:13 59:7,23 65:23 70:1,4,5 74:3 75:1 88:12 98:20 102:2 102:5 103:1 104:5 106:21 133:19 section's 105:23 sections 77:18 see 8:7 26:14,15,17 36:10 44:12 46:10 57:21 58:10 60:23 61:11,15,21,22,24 65:12 66:1 74:2 78:13 80:7 83:20 86:8 92:5,13 93:15 94:7 102:8 104:6 106:1 123:18 133:19 143:8 seeing 127:8 133:2 seek 22:8 seen 27:5 33:21 44:21 52:13 55:1 55:6 65:15 82:3,4 82:9 106:4,12 108:15 110:1 134:19,24 135:11	137:17 138:14 selection 119:4 124:12 sense 49:1 sentence 61:24 66:21 68:9 69:4 69:11 71:15 72:23 74:5 75:1,14 88:15 98:9,23 100:10 106:20 sequelae 71:20 72:1 81:4 serious 33:17,21 34:16,17 35:16,17 set 145:16 seven 130:14 seven-year 130:11 severe 33:2 68:6 80:11 severity 32:21,24 33:3 113:7 sexual 111:17 sexually 24:22 SGS 110:19 shape 140:22 share 114:3,15,20 114:24 115:9 she'd 28:9 sheet 146:7,9,12,15 148:11 short 57:11 short-term 138:6 shorter 75:19 show 29:16 62:14 71:3 80:18 98:15 125:19 showed 66:16 140:9,21 shown 132:2,11 shows 37:24 100:1 108:7 shrinkage 77:17 79:22,23 80:11,14 80:16,18,19 139:22 140:12 shrinks 140:3 sic 99:2	sides 48:10,11 sign 146:8 Signature 144:5 significance 60:2,5 60:7,9,12,14,15 63:12,16 65:24 70:2,6 125:22 128:7 significant 66:4 67:20 71:18 81:3 134:20 significantly 130:18 signing 146:10 similar 9:1 66:11 97:11 simply 81:15 single 106:20 sir 91:16 sit 51:21 63:24 79:18 81:22 82:16 84:1 119:18 143:21 situation 9:1 24:9 24:11 28:13 situations 9:20 13:9 14:4 six 26:15,15 107:20 108:6 sixteen 19:10 size 9:10 29:2,3 49:9,12 50:14,20 50:22 51:8 80:13 140:10,22 skimmed 89:16 slightly 139:3 slings 19:2 20:13 21:6 51:19 93:2 small 71:18 76:5 81:2 smaller 13:21 54:4 SNOW 2:10 So-and-So 28:4 societies 110:19 Soft 7:15 11:22 51:9,23 53:11 54:1 59:17	sold 18:10 somebody 28:2 67:23 76:5 sorry 6:18 7:14 12:6 21:21 22:1 32:1 44:15 47:8 51:9 65:2 68:15 70:4 74:21 76:10 83:12 89:24 91:18 96:2 100:10 101:22,24 103:10 114:8 115:5 116:20 120:17,19 125:13 127:9,12 127:14,15 sort 103:17 SOUTHERN 1:2 space 146:6 special 30:11 specific 7:11 9:6 29:11 32:8 110:1 112:8 122:18 specifically 23:14 27:24 31:19,22 32:2 33:8 39:1 55:16 79:10 122:8 122:12 130:10 143:23 specify 12:7 specimens 66:6 spend 21:8 SS 145:2 SSC 8:18 stage 29:3 stand 110:9 standard 47:3 104:17 105:11,13 standardization 88:9 139:12,16 standards 104:10 105:8,14 107:6,9 standpoint 46:1 120:4 start 6:6 58:17 66:5 93:19 104:8 started 10:3 12:23 25:3 47:12	starting 92:5 starts 58:18 state 51:1 66:15,22 69:11 71:14 75:15 84:10 98:23 102:14 103:2 110:18 111:12 145:2,3,6,22 146:5 stated 90:7 statement 3:18 14:3 71:1 75:5,9 76:11,18 78:4,5 78:10 79:8,10 81:16,19 82:2 83:5,6 84:14,16 89:4 90:8,16,16 91:12 93:17 statements 70:21 84:19 110:20 states 1:1 75:1 86:9 93:13 stating 73:8 102:20 statistical 128:7 stayed 19:23 29:21 stays 80:1 stiffening 66:23 stiffer 67:3 stipulations 145:12 stops 107:19 story 48:10,11 stratosphere 35:14 Street 1:17 2:4 stress 97:5,7 111:13 strike 37:1,11 64:9 70:8 80:20 90:11 114:9 115:5 126:15 striking 120:17 strong 13:19 structure 129:7 studies 42:14,16 43:5,18 45:7,13 45:17,21 46:23,24 47:6,11 51:11,13 51:20 52:2,19
--	--	--	--	--

Michael Karram, M.D.

Page 164

55:7,13 56:20 57:4 80:17 89:9 92:12 93:5 97:10 125:23 126:2,7 130:5 131:23 140:8,21 study 47:17 62:2,4 76:13,14 80:8 86:3,16,18,19,21 87:9,21 92:12,15 92:24 108:1,2,4,5 112:9 128:3,3 130:1,2 132:3 135:11 142:12,15 142:18,23,24 143:3 studying 39:9 stuff 54:19 subject 146:10 subjecting 34:12 subjective 85:19 87:11 130:17 Subpoena 1:14 Subscribed 148:18 subsection 58:24 subsequent 35:2 subsequently 10:5 12:24 substance 148:10 success 29:16 86:12 86:13 87:3,11,11 87:18 125:10 successful 28:14 suffer 6:13 21:9 suffered 5:3,7,11 6:2 21:17 22:18 33:4 39:18,21,24 suffering 18:23 20:3,6,19,24 27:2 119:13 suffers 41:3 SUFU 60:11 110:19 suggests 63:22 suitable 131:14 Suite 1:18 2:4,10 support 5:16 13:15 58:15 98:6,15	129:7 sure 12:9 24:20 26:21 30:10 33:9 42:21 47:20 55:19 56:3 71:6 78:16 106:19 110:10,11 142:8 surface 10:1 surgeon 58:16 87:20,22 88:2,7 Surgeon's 3:20 123:7,22 surgeons 72:14,24 87:24 111:12,24 112:2,3,9,17 123:1 surgeries 16:12,16 18:15,22 19:13,14 25:2,10 34:13 35:3,4,10,15 36:2 40:24 41:3 129:5 141:19 surgery 3:13 16:5,9 23:10 28:14,19 31:5 34:10 35:2 35:12,12 41:7 58:16 60:21 72:15 77:4 97:6,18 100:6 103:2,8 111:13 119:8 130:16 138:10 139:8,16 141:21 surgical 5:18,23 6:1,13 14:1,12 15:3 23:18 97:13 103:17 surrounding 68:13 69:13 survey 112:15 suture 11:15 sutures 142:3 sworn 4:3 145:8 148:18 symptoms 5:9 synthetic 6:19,22 7:9 8:12,14,22 10:3 18:10,16	31:7 51:19 62:3 74:4,14,20 128:14 128:17 129:6 130:16 SYSTEM 1:5 systematic 56:16 100:21 142:19 Systems 11:3,5 <hr/> T T 145:1,1 147:1 tailor 24:15 take 9:2 29:19 43:10 112:15 taken 1:14 57:9 145:11 takes 24:6 talk 31:16 90:14 110:9 talked 135:17 139:11 143:20 talking 11:16 27:7 43:14 69:8 70:7,9 72:1 75:7 90:23 91:1 141:22 taught 16:23 taut 77:18 teach 17:1,3 teaching 124:3 technique 80:19 techniques 40:19 TECHNOLOGI... 1:22 tell 14:19 27:23 31:1,4 49:6,6 143:21 temporary 111:16 Teresa 1:15 145:4 145:21 term 35:24 terminology 84:14 84:16 terms 126:8 129:12 131:13,14 132:18 140:12 142:1 testified 42:7 47:10 49:14 59:16 97:22	137:9 140:2 testifying 59:9 testimony 45:5 120:7 126:17 thank 14:9 22:1 59:14 75:13 76:20 121:10 142:9 144:2 Thanks 103:14 theoretically 139:20 thicker 66:16 thing 19:8 59:13 things 47:6 think 6:6 8:24 10:15 11:13,16 13:24 14:16 16:14 20:21 21:5 23:10 23:16 28:9 32:24 34:14,15,16 35:11 35:19,23 39:13 41:13,14,24 42:18 43:24 46:13 49:24 50:13,17,18 51:16 55:8 56:24 61:3 65:15 69:8,10 70:3,19 72:19 74:10 78:9,19 79:20,21 88:1 94:16 97:22 98:15 105:7,15 107:17 107:18,24 108:2 109:6 114:7 115:4 117:12 118:23 119:13 122:21 123:1,18 127:24 131:21 133:11 136:3 thinking 123:2 third 68:24 72:23 123:18,19 thirty 146:16 thought 14:4 23:16 31:24 41:12 52:2 52:18 85:14 96:14 three 5:20 16:14,15 16:15 17:9,23	18:13 19:8 21:4 68:20 80:8,16 86:9 87:12 three-year 102:8 tied 63:10 time 12:20 14:10 15:1,3 25:5 30:2 32:19 34:20 35:12 38:12 59:15,18 60:3 66:16,24 67:3 117:7 118:10 140:9 145:10 times 9:22 17:3 19:9,10 tissue 6:5 14:8 25:12,19,21 26:1 26:8 28:3,5 29:5 31:14 68:10,13 69:6,14 74:7,13 74:15,17,18 75:3 75:18 79:21 85:1 85:5,13,23 86:11 88:4,5,6,10 89:8 97:3 99:1,14 102:14 120:4 126:9,11 127:7,22 128:5,15 129:1,2 138:24 139:7 140:13,17,22,24 142:2 title 70:4 titled 74:3 133:19 today 4:8 5:21 6:9 6:12,22 7:10 14:21 18:14,18,21 23:17 25:22,24 41:9 42:11,12,13 45:6 51:21 59:9 64:1 79:18 81:22 82:16 84:1 119:6 119:18 143:21 today's 104:10 105:7,13 Todd 1:17 told 31:24 120:21 top 61:9 86:8 topic 141:1
--	--	---	--	--

total 9:7,8,16 18:4 21:22,23 75:16 76:1	tried 29:24 46:22 48:5 55:15 56:15 56:20	typically 26:12	unique 24:12 36:10 36:11 77:9 122:12 122:18 138:10 141:2,4,7,10,14 141:23	video 1:13 15:21 16:4 110:12
tough 30:4	trocarn 17:17	typing 94:16		videos 16:2
Tower 1:18	true 22:15 25:22,23 40:24 42:11,12 63:12 115:23	<hr/> U <hr/>	UNITED 1:1	viewed 28:17
tracks 23:13	truth 145:8,8,9	U.S 1:10	update 94:23 105:1	viewpoint 52:6,23
tract 31:6 32:3	try 37:14 136:7	ultimately 115:16 117:14 118:13	updated 94:24 118:11	viewpoints 43:4
traditional 6:3 8:17 127:7,22 128:6 138:15	Tuesday 1:18	ultralateral 86:11	Uphold 14:16	VIRGINIA 1:2
training 15:7,9,13 15:16,17,22 16:18 16:19 17:11 82:11 82:15,19 112:3	turn 38:24 57:14 59:20 61:8,23 65:20 70:11 74:2 76:22 86:4 90:4 94:3 95:16 98:19 101:19 104:2 105:19 110:7,14 111:8 123:17 126:12 129:15 133:17	ULTRAPRO 7:23	urinary 31:6 32:3 97:5,7 98:24 111:13,19	vivo 39:6
transcript 146:17 146:19	turning 93:8,8	ultrasound 80:8	urogynecology 19:1	vividly 138:4
transcription 148:7	TVM 54:23 55:1	ultrasounds 140:8	use 5:17 6:13,19,22 8:1,4 10:16,21,24 13:22 14:5,7 18:16 36:3 40:19 44:7 53:6 58:18 71:20 75:6 77:4 81:5 111:14 128:10,14	vivo,in 39:6
transvaginal 96:24 97:17 102:16 130:16	TVT 11:20 12:13 12:17,20 48:22 49:4,15 50:14 51:7,14,18,22 52:2,19 53:3,6,11 53:24 54:3 92:15 131:1,1,5,12 135:8	um-hmm 13:13 16:6,8 39:11 49:20 57:17 69:3 72:22 73:14 78:18 80:10 88:13 92:20 96:18 122:9 126:14 133:18	uses 54:3 62:19 84:14,16	Vladimir 3:15 65:8 132:13
transvaginally 88:15	twelve 19:10	unacceptable 105:10	usually 19:8 22:6 24:11,21	voiding 111:19
treat 5:6,11 6:1,13 8:23 14:6,13 18:5 18:16,22 20:2,6 20:18 22:5 23:24 24:18 25:2 26:8 28:15 36:2 93:23 103:18 128:10	two 13:5 15:15,16 15:16 17:23 18:13 19:7 21:4,5 26:14 37:13 51:5 61:11 68:20 126:17 132:16 133:22 139:19	undergo 26:9 27:19 29:1,7 36:1 81:1 116:1	utilizing 142:3	<hr/> W <hr/>
treated 21:17,24 22:9,17 39:17,20 39:24 53:21 82:5 125:20	TVT-O 4:22 70:20 131:1,5	undergoing 28:23 71:16 102:14 130:15	v 1:9	wait 95:17
treating 5:3 13:7 20:11,24 21:8 82:9	TVTs 92:24	undergone 39:10	vagina 76:6	Walker 2:9 3:4 12:6 19:17 20:14 20:20 21:2,11,21 22:1,20 23:15,19 27:4,21 30:3,9,14 30:19 31:2 33:7 34:7,18 35:6,22 36:4,13,21 38:6 39:4,23 40:2 43:2 43:8,23 44:22 45:3,15,18 46:12 47:1 48:4,13 52:4 52:9,21 57:7 59:15 62:13 63:1 67:6 69:20 72:6 72:13 73:19,24 78:14,17,19 81:13 85:15 87:19 89:11 90:10 96:3 98:1 99:9 100:4 103:10 103:14 107:2 108:14,24 109:5 109:18 112:1,19 113:3,8,24 114:6 114:21 115:2,13 116:3,7,19 117:21 118:5,21 119:3,9 119:16 120:11,15 121:13 122:3
treatment 24:15	type 5:8 7:7 11:18 42:20 50:23 68:7 94:15 112:6,14	understand 4:9 11:24 33:4 44:2 55:19 64:2 68:2 74:21 116:15,24 117:2	vaginal 9:12 35:4 62:3 71:17,21 74:4 75:17,18 77:16 80:9 81:1,5 86:12 87:5 88:16 111:18	
treatments 23:18	types 128:11 141:18	understanding 7:10 9:19 11:6,9 11:11,19 12:11 17:20 18:1,8 20:23 21:7 23:12 25:1 26:7,19 41:9 42:1 54:17 107:11 109:2 119:22 120:8,12	versus 9:15 27:20 126:8,11 139:20	
trial 42:5 82:24 86:9 87:12 128:4 132:8 134:14 143:24	typical 9:14	undertaken 112:14	vice 63:13	
trials 45:22 46:17 56:9,9,10,14 105:6 125:19 135:7		unfavorable 57:4		

Michael Karram, M.D.

Page 166

123:10,14,16 127:19 128:1 130:21,23 137:1,4 142:7 144:4 wall 86:10 want 19:8,12 27:17 31:16 37:1 41:13 45:23 48:15 83:10 128:9 141:1 wanted 36:10 warn 117:11 warned 58:3 72:10 warning 117:15 warnings 57:24 116:10 117:12 118:14 wasn't 36:15 40:7 85:5 87:22 96:16 114:12 watch 15:21 watched 15:23 16:4 way 48:2 115:10 134:11,16 136:6 Wazee 2:4 we'll 37:4 62:1 we're 4:8,23 26:4 57:11 68:16,18 71:9 88:7 137:1 141:22 144:4 we've 33:21 57:7 66:11 97:10 118:13 135:17 wealth 113:21 weave 12:3,4 49:15 49:18 50:5,19,20 53:7 weaving 11:12 Weber 86:17,18,21 87:21 89:7 week 19:7,9 weeks 26:14,15,15 107:20 108:6 weight 12:2,8,17 49:9,12 50:11,15 50:21 51:8 57:2 well-known 58:21 68:10	well-positioned 73:12 well-versed 73:12 73:17 went 8:17 13:17,18 13:19 22:13 85:12 85:18 weren't 8:12 85:2 WEST 1:2 WHEREOF 145:16 wish 24:20 withdraw 45:12,16 83:24 withdrawn 83:19 Witness 4:2 19:18 21:23 37:17 78:18 114:10 121:22 122:2 123:13 136:23 137:3 144:6 145:16 146:1 woman 21:17 22:7 22:17 34:12 39:17 39:20,24 41:3 102:14 109:4 woman's 107:16 women 5:3,6,11 6:1 6:13 18:23 20:18 20:24 21:9 22:3 27:2 33:4,9,17 34:4 36:1 39:10 80:8 82:9 87:13 98:4 100:6 102:16 102:22 103:3,7,7 103:16 130:15 word 135:12 words 121:19 work 26:10 working 112:3 143:9 wouldn't 29:11 35:15 44:9 48:15 48:19 50:2 75:23 woven 49:22 written 89:9 100:12	<hr/> X <hr/> <hr/> Y <hr/> yeah 8:24 17:15 19:18,21 20:13 23:16 31:4 44:5 44:11 45:9 46:7 47:9 55:20 56:12 68:23 94:18 100:12 108:20 110:15 136:6 143:16 year 19:12,15 26:16,20 27:2 104:22 yearly 26:18 years 17:7 25:4 66:8,13 77:12 130:14 Yep 68:21 <hr/> Z <hr/> ZONIES 2:4 zoomed-in 61:17 <hr/> 0 <hr/> 06/17/21 145:22 <hr/> 1 <hr/> 1 3:8 4:11,14 11:18 50:23 56:15 57:16 70:12 90:5 100:21 104:3 1,097 102:15 1.4.2 102:2,5 1.4.4 103:1,13 10 17:6 65:21 68:16 68:17,19 86:24 100 3:14 60:21 103:3 1020 2:10 109 3:11 58:13,24 11 90:5 92:3,6 133:17 12 102:16,21 103:6 105:13 121 3:4	1227 103:3 123 3:20 134 102:15 14 93:9 125:6,14 1400 2:10 142 3:5 15 17:6 93:12,19 94:11,19 95:23 126:15 16 95:20 96:2,14 101:20 102:2,4 103:13 126:12 129:15 130:22 17 130:22,22 18 94:3 95:10 96:3 96:4,5 99:5 110:7 110:14 182 19:17 19 102:7,13,21 104:3 105:17 1900 2:4 <hr/> 2 <hr/> 2 3:10 4:18,24 74:2 95:16 96:20 2.5 130:2 2:12-cv-02076 1:11 2:12-MD-02327 1:5 20 25:4 111:9 148:19 200 19:15,20 2001 86:9,19 2002 92:5 2004 83:9,12 2006 10:15 2007 10:15 2011 71:2 83:12 91:20,21 2012 137:19 2013 92:12 93:14 93:20 94:20 126:23 2015 92:21 134:7 2016 1:19 3:19 94:6 94:21 95:7,11 104:21 142:16,20	142:22 145:18 203 2:4 21 3:11 57:18 58:9 58:12 105:19 121:20 122:4 123:7 22 58:7 86:17 123:3 2327 1:5 250 18:5 265 61:9 27 59:21 78:17 79:1 28 1:19 <hr/> 3 <hr/> 3 3:11 59:2,5 76:23 80:1 104:9 105:2 105:7 129:14 3.2 130:1 30 21:19 25:5 86:13 146:16 301 1:17 3300 1:18 375 18:5 39 128:5 39157 2:11 <hr/> 4 <hr/> 4 3:8,10,12 60:16 60:19 86:5 40 21:20 45202 1:18 46 86:14 <hr/> 5 <hr/> 5 3:15 65:5,8 70:11 99:1,15 5.3 130:3 50 18:3 80:12,15 104:14,22 500 41:17 513 71:1 522 41:22 42:2 45:17 47:15 59 3:11 5th 145:17 <hr/> 6 <hr/>
---	--	--	--	---

Michael Karram, M.D.

Page 167

63:18 71:7,9 79:24**6:49 1:19****60 3:12****601-948-5711 2:11****65 3:15 128:6**

7

7 3:19 95:4,7,14**96:20 99:2,5****71 3:18****720-464-5300 2:5****75 18:3**

8

8 3:20 95:21 99:2**100:13 103:3,7,11****104:9 105:2,7****123:11,15 129:12****129:14,20****80 19:5,6****801 3:11 58:9,13****80202 2:5****84 6:6****877.370.3377 1:23****89 87:13,17**

9

9 68:19**9.3 80:13****9:30 144:12****90 19:6****917.591.5672 1:23****95 3:19**